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ABSTRACT 
Diabetes mellitus is a highly prevalent condition, afflicting an estimated 6% of 
the United States adult population . It is also a complex condition to manage. 
Dietary, exercise, and drug therapies are essential for reducing the risk of 
various neurologic and vascular diseases related to disease progression. 
Tight control of blood glucose as achieved through intensive pharmacologic 
therapy has been shown to decrease the risk of developing several types of 
diabetic complications. Success in achieving tight blood glucose control is 
contingent upon adherence to the prescribed hypoglycemic drug regimen , a 
behavior known to often be sub-optimal. 
The objectives of this study were a) to describe hypoglycemic drug utilization, 
and compare drug regimens prescribed and costs among age groups, 
insurance plans, and by gender; b) to assess adherence to prescribed 
hypoglycemic therapies, and to explore the association between 
nonadherence and change in the strength or type of hypoglycemic medication 
prescribed; and c) to identify the frequency of nonadherence among patients 
who are prescribed monotherapy with a sulfonylurea or metformin, as 
compared to the frequency of nonadherence in patients who are prescribed 
dual therapy with both medications. 
Analyses were performed using retail pharmacy data. The data provided 
included over one-quarter-million dispensings to 5056 diabetic patients. From 
this population , 2901 patients that received at least 2 dispensings for a 
hypoglycemic medication during a 12-month period were selected for study. 
Sulfonylureas were the mainstay of treatment for those receiving oral therapy: 
82% of patients received a sulfonylurea as monotherapy or in combination 
with another hypoglycemic medication. The most frequently observed drug 
regimen was sulfonylurea monotherapy (40.3%); followed by insulin use only 
(24.9%); dual therapy with sulfonylurea plus metformin (13.9%); and 
metformin monotherapy (6.96%). Differences in the drug regimen utilized 
were found among age groups and between genders. Most notably, 
sulfonylurea monotherapy was prescribed most frequently for patients 65 
years of age and older (age 65 years or older: 48.4%; age 50-64: 43.6%; age 
under 50: 30.8%, p < 0.0001 ). The 12-month cost of hypoglycemic medication 
dispensed was lowest among patients 65 years of age or older. 
The medication possession ratio (MPR) was used as an estimate of 
adherence. Possession of medication was found to be associated with a 
change in the strength or type of hypoglycemic medication dispensed. 
Sulfonylurea users who failed to possess medication for at least 80% of days 
during a four-month period were 41.7% more likely to receive a dispensing for 
a different strength of medication in subsequent months, as compared with 
those possessing medication for at least 80% of days (OR 1.42, 95% Cl 1.02 -
1.96). Additionally, among patients receiving either monotherapy with a 
sulfonylurea or metformin, those possessing medication for at least 80% of 
days were 36.4% more likely than those possessing at least enough 
medication for 80% of days to receive a dispensing for a different strength of 
medication (OR 1.36, 95% Cl 1.019 - 1.83), or for a different strength or type 
of hypoglycemic medication (OR 1.39, 95% Cl 1.03 - 1.87). This finding was 
not statistically significant in the smaller sample of patients receiving 
monotherapy with metformin. 
Medication possession was also found to be associated with the number of 
hypoglycemic drugs prescribed. Patients who were prescribed a regimen of 
dual therapy with a sulfonylurea plus metformin were found to be less likely to 
possess medication for 80% or 90% of days, as compared with those 
prescribed monotherapy with either a sulfonylurea or metformin. In 
multivariate analyses controlling for age and the total number of dispensings, 
patients receiving dual therapy were more than 3 times more likely to fail to 
possess medication for at least eighty percent of days (OR 3.14, 95% Cl 2.42 
- 4.08), or 90% of days (OR 3.20, 95% Cl 2.49 - 4.11 ). 
The findings of this pharmacoepidemiologic research provide insight into the 
drug utilization patterns of diabetic patients. Among patients in this study, the 
type of drug regimen prescribed differed in frequency among age groups and 
between genders. The strength and type of hypoglycemic medication utilized 
was found to change frequently, particularly among patients that were 
classified as nonadherent. Overall, a substantial percentage of patients were 
found to be nonadherent with hypoglycemic drug therapy. Patients least 
frequently adherent to drug therapy included those under 65 years of age and 
those prescribed dual therapy with a sulfonylurea plus metformin. Presuming 
that lack of medication possession results in poor glucose control, patients 
who do not possess medication are at increased risk for diabetic 
complications. 
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Hypoglycemic Drug Utilization in a Diabetic Population: A 
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ABSTRACT 
Background For most diabetic patients, pharmacologic therapy is an 
essential component of disease management. Several classes of 
hypoglycemic medications are available for prescribing , with no single class of 
hypoglycemic drugs has been proven superior in reducing diabetic 
complications. 
Objective To describe hypoglycemic drug utilization patterns among 
diabetic patients ; and to determine if such patterns differ by patient 
characteristics. 
Methods Cross-sectional descriptive study of hypoglycemic medication 
dispensings to 2901 diabetic patients. Drug utilization was classified into 
categories representing 10 various hypoglycemic drug regimens. The 
frequency of drug regimen utilization was compared by age group, insurance 
plan , and between genders. The total cost of hypoglycemic dispensings 
during a 12-month period was also determined, and compared within each age 
group and insurance plan , and between genders. 
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Results The most frequent hypoglycemic drug regimen utilized was 
monotherapy with a sulfonylurea (n = 1168; 40 .26%). Use of insulin and no 
oral hypoglycemic medication was the second most frequently utilized regimen 
(n = 723; 24.92%). Dual therapy with both a sulfonylurea and metformin was 
utilized by 13.93% of patients (n = 404). No other regimen was observed at a 
frequency greater than 5 percent. A substantial percentage of patients 
received a dispensing for troglitazone (16.04% of all patients over 40 years of 
age), mostly in combination with other medications. Patients 65 years of age 
and older more frequently received dispensings for a sulfonylurea only (age 65 
years or older: 48.4%; age 50-64: 43.6%; age under 50: 30.8%, p < 0.0001 ), 
but not for dispensings for a sulfonylurea and metformin (age 65 years or 
older: 14.4%; age 50-64: 15.2%; age under 50: 15.6%, p < 0.8275). Older 
patients also less frequently received dispensings for only metformin (age 65 
years or older: 4.8%; age 50-64: 7.9%; age under 50: 7.2%, p < 0.0.476), and 
for troglitazone (age 65 years or older: 10.28%; age 50-64: 17.6%; age under 
40-49: 20.3%, p < 0.0001 ). Female patients more frequently received 
dispensings for only insulin (28.1 % versus 22.2%, p = 0002). Male patients 
received only a sulfonylurea more frequently than female patients (44.1 % 
versus 35.8%, p< 0.0001 ). The hypoglycemic drug regimen utilized did not 
differ significantly by insurance plan for the most frequently utilized regimens 
and between the two main insurers included in this study. The 12-month cost 
of hypoglycemic drug utilization was lowest among patients 65 years of age or 
3 
older (age 65 years or older: $470.38; age 50-64: $593.23; age under 50 : 
$580.80, Pr> F less than 0.0001 ). 
Conclusions We found sulfonylureas to be the mainstay of treatment 
for the majority of patients receiving oral therapy. Patients 65 years of age 
and older were less frequently dispended troglitazone, or metformin in mono-
therapy, and were most frequently prescribed sulfonylureas as the only 
hypoglycemic medication. For patients 65 years of age or older, the 12-month 
cost of hypoglycemic medications dispensed was roughly 20% less than the 
average hypoglycemic drug utilization cost for younger diabetic patients. 
Differences in drug utilization among senior patients may reflect differences in 
co-morbidities that influence drug selection, differences in insurance coverage 
and associated out-of-pocket costs, or perhaps reluctance of prescribers to 
utilize newer therapies in older diabetic patients. Further research is needed 
to determine if older patients are less frequently prescribed newer therapies, 
and if diabetes control and progression is impacted. 
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INTRODUCTION 
Diabetes mellitus has been identified as an epidemic throughout the world (1-
15). Approximately 16 million Americans are afflicted with the condition, a 
prevalence rate that exceeds 6% of the United States population (16). The 
number of Americans living with diabetes has increased steadily. Based upon 
data from the US National Health Interview Surveys, the prevalence of 
diabetes has grown in a near-linear manner, rising from under 1 % in 1958 to 
approximately 7% in 1993 (17). Recently, Mokdad et al reported that the 
prevalence rate of diabetes increased 33% from 1990 to1998 (4.9 to 6.5%) 
(18). The number of Americans living with diabetes is expected to double by 
2020, and the disease is expected to become more prevalent in younger age 
groups (19). 
Positive family history (20-22), older age (23-26), and obesity (27-29) are 
associated with an increased risk of developing diabetes. The rise in diabetes 
prevalence reflects the growing number of older adults in the US population, 
and is compounded by an increased rate of the disease in this population (17). 
An increasing prevalence of obesity among Americans of all adult ages has 
also contributed to the rise in diabetes prevalence (30). Diabetes has a major 
impact on the health of those afflicted with the condition. Diabetes is the 
seventh leading cause of death among U.S. citizens (31 ), and contributes 
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significantly to other leading causes of death such as cardiovascular disease 
(32 , 33), stroke (34), and kidney failure (35-37). 
Type 2 diabetes, formerly termed adult-onset or non-insulin dependent 
diabetes mellitus, accounts for roughly 90% of all cases of diabetes (17). 
Patients with type 2 diabetes mellitus generally develop the condition after the 
age of thirty (20), and are usually managed with oral hypoglycemic 
medications when dietary therapy and exercise fail to control blood glucose 
levels. Sulfonylureas, discovered in 1942 by Janborn (38), have long been the 
mainstay of type 2 diabetes treatment. During the past several years newer 
oral therapies have become available, which exert a hypoglycemic effect 
through differing biological mechanisms. These agents have been approved 
for use in combination with other medications (39-45) or, for some drugs, for 
use as mono-therapy (40, 43 - 45). 
The choice of oral hypoglycemic medication may reflect patient characteristics. 
For example, metformin has been shown to be particularly efficacious in 
patients with obesity (46), and sulfonylureas may cause rash in some patients 
(47). However, despite the several classes of hypoglycemic medications to 
choose from, specific guidelines or algorithms for selection of drug therapy in 
type 2 diabetic patients are lacking. For example, the American Diabetes 
Association 's 2001 Clinical Practice Recommendations (48) include specific 
goals of pharmacologic therapy; including reduction of glycated hemoglobin 
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(HbA 1 c) to below 7%. However, the choice of hypoglycemic agent is left to 
the prescriber. Thus , the choice of anti-diabetic agent utilized can be largely 
determined by prescriber preferences and experiences. Further, despite the 
availability of numerous studies assessing the glycemic control achieved with 
various hypoglycemic drugs, there is scant comparative data describing 
primary outcomes among diabetic patients prescribed alternative 
hypoglycemic drug classes. 
We examined hypoglycemic drug utilization in a large diabetic population , 
using data obtained from retail pharmacies during a 24-month period. We 
determined the frequency of dispensing of medications, and the characteristics 
of patients receiving dispensings for specific hypoglycemic agents. Changes 
in hypoglycemic drug regimen during a 12-month period were determined, 
including the number of patients switching to a different drug or combination of 
drugs. The average cost of hypoglycemic medications dispensed during a 12-
month period was calculated, and compared between age groups, gender, 
and insurance types . 
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METHODS 
Data source and study population 
Consumer Value Stores (CVS). Inc provided data from 198 retail pharmacies 
throughout Pennsylvania . The data included all pharmacy claims for 5056 
diabetic patients from April, 1997 - May, 1999. The total number of pharmacy 
dispensings for these patients during the 2-year period was 288, 171. 
All patients were enrolled in a comprehensive diabetes management program 
through one of two health insurance plans. Pharmacy services for these 
patients were provided by CVS pharmacies. and patients were not reimbursed 
for prescriptions filled by other pharmacies. Thus, the data represents 
patients' util ization of hypoglycemic drugs, though some patients may have 
filled prescriptions elsewhere using a different third party plan for drug 
reimbursement, or by paying cash. 
To create a standard basis of comparison, we included only patients who were 
dispensed at least 2 prescriptions over a time period spanning at least 12 
months. This was accomplished by determining the number of days between 
the first and last dispensing of any hypoglycemic medication during the two-
year period for which data was available. Of the 5056 patients in the 
population, 2901 patients (57.4%) met this criteria . For these patients. a 
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sample was created that included only the first 12-months of hypoglycemic 
drug dispensings. This sample was used for all analyses. 
Hypoglycemic medications were categorized by therapeutic class, or by 
generic name if the drug was the only available product of its class. The 
following categories were created: insulin , sulfonylurea , metformin, alpha-
glucosidase inhibitor, meglitinide, glimepramide, and troglitazone (Rezulin®), 
the first available drug from the thiazoladinedionne class. The study period 
preceded the withdrawal of troglitazone from the U.S. market, and also 
preceded the introduction of two newer thiazoladinedionne agents to the US 
market: pioglitazone (Actos®) and rosiglitazone (Avandia®). 
Patients were categorized as receiving one of ten hypoglycemic drug 
regimens, based upon the class(es) of hypoglycemic agent prescribed during 
the first 90 days of the 12-month period. These drug regimens are presented 
in Figure 1. For comparison , we also categorized drug regimens based upon 
hypoglycemic agents dispensed during the last 90 days of the 12-month 
period. 
For all patients, we determined the age , gender, and insurance plan 
associated with prescription dispensings. Age was categorized into three 
groups: less than 50; 50-65; and 65 years or older. To enhance the focus on 
drug regimens used by type 2 diabetics, some analyses were performed 
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restricting the population to those 40 years of age or older, to exclude patients 
likely to be type 1 diabetics. The two major insurers included in this study 
were classified as health plan A and health plan B. Patients were categorized 
as enrollees of health plan A or health plan B if any prescription dispensed 
during the 12-month period was associated with a reimbursement claim to 
either of these insurers. In instances where both insurances were used during 
the 12 month period , the insurance type associated with first hypoglycemic 
drug dispensing was used. A smaller number of patients used other 
insurances for their prescription drug coverage. These patients were included 
in a third category consisting of all 'other insurances'. A fourth category 
included patients that paid cash for their hypoglycemic medication 
prescriptions during the 12-month period . 
For dispensings of sulfonylureas, we also categorized agents as first 
generation sulfonylureas (chlorpropamide, tolazamide, and tolbutamide) or 
second-generation sulfonylureas (glyburide or glipizide), and into groups of 
brand name and generic products. The use of these agents among different 
age categories was determined. 
We calculated the total cost of all hypoglycemic medication dispensed during 
the 12-month period , and compared this cost between genders, age 
categories, and insurance types. Cost was calculated as the average 
wholesale price (AWP) of medication dispensed minus 10 percent. Generally, 
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drug purchasers pay AWP minus a discount rate for drugs, which can be 
influenced by factors such as the quantity of medication purchased (49). We 
considered AWP-10% to be a relatively conservative estimate of the cost of 
drug dispensed, representing the highest amount a drug purchaser would 
typically pay (50-52). 
Statistical analyses 
Descriptive statistics were used to determine and present gender, age 
category, and insurance type. Drug regimens utilized and changes in drug 
regimen were presented as frequencies and percentages. Non-parametric 
(chi-square) analyses were used to determine if the frequency of drug regimen 
utilized differed in statistical significance by the gender, age category, and 
insurance type of subjects. Chi-square tests were also to determine 
differences in dispensing of brand name products and first generation 
sulfonylureas among age groups, gender, and insurance types; and to 
determine differences in the frequency of troglitazone dispensing in the three 
age groups. 
Analysis of variance procedures using Tu key's test were used to determine if 
differences in 12-month hypoglycemic drug utilization costs among age groups 
and insurance types were statistically significantly different. We used the 
student's t-test for independent samples to determine if hypoglycemic drug 
spending differed by gender. 
11 
Statistical analyses were performed using SAS for windows version 8.01 . 
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RESULTS 
Descriptive statistics 
A total of 2901 patients received hypoglycemic drugs spanning at least a 12-
month time period . Of these patients, 1002 (34 .54%) were under 50 years of 
age; 1259 (43.4%) were between 50 and 65 years of age; and 640 (22.06%) 
were 65 years old or older. Slightly more patients were male (n = 1552; 
53 .5%). One-third of patients (n =967) were insured by health plan A, and 
53.84% of patients (n = 1562) were enrollees in health plan 8 . A smaller 
percentage of patients (8.62%) used other insurance plans for their 
prescription coverage, and 4.21 % of patients paid for their prescriptions by 
cash . Nearly one-third of the population were insulin users (n = 890; 30.86%). 
These statistics are presented in table 1. 
Drug regimen prescribed 
Patients were categorized as receiving one of nine potential drug regimens. A 
tenth regimen category represented miscellaneous combination therapies not 
captured by the first nine regimen categories. The number and percentage of 
patients receiving each regimen during the first 90 days of the 12-month 
period is presented in Table 2a. A comparison of the frequency and percent 
utilization of drug regimens identified using the first and last 90-days of the 12-
month period is presented in Table 2b. 
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Based upon dispensings during the first 90 days of the 12-month period , the 
most frequently prescribed hypoglycemic drug regimen was mono-therapy 
with a sulfonylurea (n = 1168; 40.26%). The 723 patients receiving insulin as 
their only hypoglycemic medication accounted for next most frequently 
observed regimen (24.92%). Combination therapy with sulfonylurea and 
metformin was the only other regimen observed in more than 10% of patients 
(13.93%; n = 404 ). Metformin mono-therapy was the fourth most frequently 
observed hypoglycemic regimen (6 .96%; n =202). The prevalence of the 
other five prescribed regimens ranged from 1.17 to 3.14%. Less than 2 
percent of patients received a combination of drugs that was not characterized 
by any of drug regimen categories 1-9. 
Drug regimen classification based upon the last 90 days of the 12-month 
period produced similar results , though some differences were observed . The 
order of the top four frequently utilized regimens was the same for drug 
regimens classified using the first and last 90 days. However, the percent of 
patients utilizing other regimens differed notably. The percentage of patients 
receiving a sulfonylurea plus another oral agent other than metformin (regimen 
6) more than doubled (6.17% versus 2.65%). Correspondingly, the 
percentage of patients receiving sulfonylurea mono-therapy during the last 90 
days of the 12-month period declined from 40.26% to 31.51 %. Also, during 
the last 90-days , a greater number of patients received a regimen other than 
one of the 9 identified regimen categories (6.27% versus 1.72%). Utilization of 
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the other less frequently observed regimens remained similar: the difference in 
percentage observed ranged from 0.14% - 1.14%. 
We determined the number of patients remaining on the same regimen during 
the two 90-day periods. For patients not utilizing the same hypoglycemic drug 
regimen in each 90-day period , we identified which regimen patients switched 
to. These results are presented in Tables 3a (frequencies) and 3b 
(percentages). Insulin-only users as identified during the first 90-day period 
were most likely to be classified as utilizing the same regimen in each 90-day 
period (82%). The regimens with the lowest percentage of patients utilizing the 
same hypoglycemic regimen in each 90-day period were regimen 2 (insulin + 
troglitazone (56%)) and regimen 3 (insulin+ non-troglitazone agent (30%)), 
though the total number of patients receiving these regimens was small. 
Three-quarters of patients receiving a sulfonylurea. glimepramide, or 
metformin mono-therapy utilized these same regimens in each 90-day period. 
Patients receiving mono-therapy with a sulfonylurea, glimepramide, or 
metformin remained on the same regimen more frequently than patients 
receiving combination therapy of a sulfonylurea plus another oral agent 
(remained on mono-therapy with either sulfonylurea, glimepramide, or 
metformin: 74-75%; remained on sulfonylurea plus metformin: 70%, or 
remained on sulfonylurea plus non-metformin oral agent: 65%). Half of 
patients categorized as receiving mono-therapy with troglitazone during the 
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first 90-days of the 12-month period were utilizing this regimen during the last 
90-day period . Of the patients categorized as utilizing an uncategorized 
combination of hypoglycemic agents (regimen 10) during the first 90-day 
period , 68% remained in this category when examining the last 90 days of 
drug dispensings. A greater number of patients utilized an uncategorized drug 
regimen during the last 90 days as compared to the first 90 days of the 12-
month period (232 versus 50). 
As compared with male patients, females were more frequently dispensed 
prescriptions for insulin (28.12% versus 22.2%; p = 0.0002) and dispensings 
for insulin and troglitazone (3.9% versus 2.5%; p = 0.0386). Diabetic males 
were more frequently prescribed sulfonylureas as mono-therapy (44.1 % 
versus 35.8%; p < 0.0001 ). There was no statistically significant difference in 
the percentage of male and female patients that received combination therapy 
that included a sulfonylurea. The percentage of male and female patients 
receiving mono-therapy with metformin, troglitazone, or glimepramide also did 
not differ significantly. These findings are summarized in Table 4. 
Table 5a presents regimen categories stratified by age group. A higher 
percentage of patients under 50 years of age received insulin as their only 
hypoglycemic agent, as compared to patients aged 50-64 or 65 or older 
(36.9% versus 18.4% and 19.1% respectively, p < 0.0001). Conversely, the 
percentage of patients that received only a sulfonylurea was significantly less 
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for patients under 50 years of age as compared to patients aged 50-64 or 65 
or older (30.8% versus 43.6% and 48.4%, p < 0.0001 ). 
To focus on drug prescribing in type 2 diabetic patients, we identified drug 
regimens prescribed for patients over 40 years of age (Table 5b). When 
patients under 40 years of age were excluded from the analysis, the 
percentage of patients using insulin as their sole hypoglycemic agent was no 
longer statistically significantly different among age groups. However, 
subjects in the 40-49 age group were more frequent users of insulin plus 
troglitazone combination therapy (5.0% versus 3.3% and 1.4%; p = 0.0013), 
though there was a relatively small number or total patients receiving this 
regimen (91 /2901 ; 3.14%). The youngest age group remained the least 
frequent users of a sulfonylurea mono-therapy regimen (39.6% versus 43.6% 
and 48.4%; p = 0.0067). Diabetics 40-49 years of age were also more likely 
to be prescribed metformin compared to patients over 65 years of age (9.1 % 
versus 4.8%; p = 0.0107). 
We also examined the relation between insurance type and drug regimen 
utilized. Table 6 presents percentages of patients receiving each drug 
regimen , stratified by four categories of payment: Plan A, Plan B, other 
insurance, and cash payment. There was no statically significant difference in 
the percentage of patients utilizing regimens of insulin only, insulin plus an oral 
agent, sulfonylurea mono-therapy, or sulfonylurea plus a non-metformin oral 
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agent. Patients not utilizing insurance (paying cash) were less frequently 
dispensed regimens that included metformin (metformin mono-therapy: cash 
2.5%, plan A: 6.5%, plan B: 4.0%, other insurance types: 8.4%; p = 0.0107; 
metformin plus sulfonylurea: cash 9.8%, plan A 11.8%, plan B 15.8%, all other 
insurance types: 12.8%; p = 0.0187. Also, a lesser percentage of Plan B 
patients received mono-therapy with glimepramide (plan A: 4.3%, plan B: 
1.3%, all other insurances: 2.8%, cash: 5.7%; p< 0.001) 
The percentage of patients receiving a brand name sulfonylurea did not differ 
in statistical significance among age groups or gender (Table 7). Patients with 
insurance plan A received brand name products more frequently that patients 
enrolled in plan B (64.0% versus 41 .8%; p < 0.001 ). The percentage of brand 
name sulfonylureas dispensed was highest among patients paying cash for 
their prescription (64.6%), although the frequency was only slightly higher than 
that found for plan A (64.0%). Of patients with insurance other than plan A or 
plan B, 55.2% of sulfonylurea-using patients received brand name products. 
Of the 1575 patients receiving a sulfonylurea, 17 (1 .08%) received a first 
generation product. The frequency of first-generation sulfonylurea utilization 
did not differ in statistical significance among age groups, gender, or insurance 
type. 
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Patients 40-49 years of age were most frequently dispensed troglitazone 
(20.3%), while those 65 years of age or older were least frequently prescribed 
this drug (10 .1 %). The difference in frequency of troglitazone utilization 
between these age groups was statistically significant (p < 0.0001 ). 
Table 9 presents the average cost of all hypoglycemic medications dispensed 
during the 12-month period for each age category, gender, and insurance 
type. The average 12-month cost of hypoglycemic medication utilized by 
patients 65 years of age and older was significantly less than the cost of 
hypoglycemic medications utilized by younger patients (age 65 and older: 
$470.37, age 50-65: $593.23, age under 50: $580.80; Pr> F: < 0.0001 ). The 
average 12-month hypoglycemic drug utilization cost did not differ significantly 
between men and women. Average costs were similar among insurance 
types, but not among patients paying cash. (plan A: $521.63, plan B: $587.82, 
all other insurances: $523.01, cash: $385.37). 
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DISCUSSION 
Pharmacy data is a useful and often available information source for 
pharmacoepidemiologic investigations of drug utilization patterns. Pharmacy 
data can be used to identify trends in prescribing patterns (53), assess the 
impact of regulatory changes (54), and to determine drug expenditures (55). 
Though the lack of information related to patient diagnoses can be limiting 
(56), pharmacy data can be superior to the medical record for determining if 
and when prescriptions are actually filled by patients; an action necessary for 
adherence to therapy. Pharmacy data is an excellent source for describing 
drug use in populations, and for comparing patterns of use between 
populations. 
In this study, pharmacy data was used to describe the utilization of 
hypoglycemic drugs in a population of diabetic patients. We created nine 
categories of drug regimens utilized, based upon the types of hypoglycemic 
drugs dispensed to patients. We compared the frequency of regimen 
utilization among age groups, gender, and payment type. Identification of 
regimen utilized was based upon hypoglycemic drugs dispensed during the 
first 90 days of a 12-month period , and was compared with the frequency of 
regimens utilized in the last 90-days of the 12-month period. We identified 
which patients changed medication regimen , and which different regimen was 
utilized. 
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Frequency of regimen category utilized 
Sulfonylureas, a staple of therapy for type 2 diabetes for several decades, 
were the most frequently prescribed oral hypoglycemic agent in this 
population. Factors contributing to the popularity of these agents include a 
long history of use (38), relatively low expense (57), high tolerability (58), and 
prescriber familiarity. Metformin was also prescribed frequently in this 
population, either as mono-therapy or in combination with other oral agents, 
usually a sulfonylurea. Several oral hypoglycemic agents became available 
just before or during the study period: troglitazone, acarbose, repaglinide, and 
glimepramide. Despite the availability of these newer agents, the majority of 
patients receiving oral hypoglycemic therapy were receiving a sulfonylurea , 
metformin, or both together. However, the impact of the new 
thiazoladinedionne drug class was apparent. Troglitazone, the first 
thiazoladinedionne available in the US market, was the only 
thiazoladinedionne available for prescribing during the study period. 
Consistent with its approved indications, troglitazone was utilized as mono-
therapy or in combination with insulin or oral hypoglycemic agents. 
Troglitazone was discontinued in 1999 after awareness of an association with 
hepatic failure and death among patients prescribed this agent (59-62). The 
increased risk for liver toxicity in those treated with troglitazone was 
recognized while the drug was available for prescribing (63), potentially 
explaining why troglitazone was prescribed less frequently for older patients in 
this population (Table 7). 
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Despite the effective treatment of diabetes with sulfonylurea, metformin, or 
insulin , glycemic control is known to become poorer as diabetes progresses 
(64-66). Failure of sulfonylurea mono-therapy to control blood glucose levels 
generally occurs within 5 years (67 , 68). In this population, patients changed 
medication regimens with high frequency; perhaps reflecting increased 
medication needs to achieve blood glucose control. Though it was the most 
frequently observed oral hypoglycemic regimen , mono-therapy with a 
sulfonylurea was the regimen having the largest percentage change during the 
12-month observation period (sulfonylurea mono-therapy in first 90 days: 
40.26%; in last 90 days: 31.51 %). Slightly greater than 10% of patients 
utilizing sulfonylurea mono-therapy added metformin to their regimen during 
the 12-month period {Table 3a). Another 5% of patients added an agent other 
than metformin, and 6% of these patients changed therapy to a combination 
regimen that did not include a sulfonylurea. These findings suggest that many 
type 2 diabetic patients do not remain stable on their medication regimens, 
and that medication requirements increase over time. Indeed, 26.68% of 
patients (774/2127) were categorized as utilizing a different drug regimen 
during the last and first 90 day periods of the 12-month period. The finding 
that one of four patients changed regimen during the 12-month study period is 
consistent with what is known about diabetes: the condition progresses, it can 
be unstable, and medication needs increase over time (20). 
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As compared to util ization based upon the first 90 days of the 12-month 
period, the utilization of sulfonylurea mono-therapy was less, and the 
utilization of combination therapies was greater during the last 90-days of the 
12-month period . The decrease in sulfonylurea mono-therapy and increase in 
use of oral combination therapies may be related to several factors . First, it is 
possible that the increase in utilization of combination regimens is partly the 
resu lt of increased medication needs associated with disease progression 
over time. Second , the increased use of combination therapy may reflect the 
availability of newer hypoglycemic agents approved for use in combination 
therapies during the 12-month period, such as repaglinide, glimepramide, 
acarbose, and troglitazone. A third possible influencing factor is the increased 
awareness and popularity of combination therapy as a means to achieve 
improved glycemic control. 
Of patients categorized as users of insulin as their sole hypoglycemic 
medication during the first 90 days of the 12-month period, 5% added 
troglitazone to their regimen during the following 9 months. Another 5% of 
insulin users added an oral agent other than troglitazone to their regimen . 
Differences in hypoglycemic drug utilization between the two 90 day periods 
may be partly attributed to patient behavior, and may not necessarily represent 
changes in hypoglycemic drugs prescribed. Non-adherence to prescribed 
drug regimens is a recognized problem (69-71 ), and may have caused 
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misclassification of regimens, since patients must have filled a prescription to 
be identified as being prescribed the drug. It is also possible that patients may 
have received medication from another pharmacy, though the data includes all 
designated pharmacies for patients in health plans A and B. A third possible 
factor contributing to misclassification of regimens is the possibility that 
patients received several month-supply of medication shortly before the 90-
day categorization period . Such stockpiling would be most likely among cash 
paying subjects, since health plans A and B allowed only a one-month supply 
of medication per dispensing. A frequency analysis of days supply dispensed 
confirmed that one or two month supplies of medications were dispensed to a 
great majority of patients. 
Frequency of drug regimen utilization by gender, age group, and 
insurance type 
We compared the frequency of drug regimen utilization among female and 
male subjects. Women were more frequently prescribed insulin as a sole 
hypoglycemic therapy (p = 0.0002), and women were more frequently 
dispensed insulin in combination with troglitazone (p = 0.0386). This finding, 
in addition to the less frequent utilization of sulfonylurea mono-therapy 
regimens, may indicate a greater frequency of type I diabetes among female 
subjects in this population. However, there was no statistically significant 
difference in the utilization of other oral hypoglycemic drug regimens between 
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men and women. Additionally, the frequency of metformin use did not differ in 
statistical significance among men and women. In sum, women were more 
frequently dispensed insulin and less frequently dispensed only sulfonylureas; 
yet the frequency of utilization of other oral regimens did not differ significantly. 
This observation is not readily explainable. 
Those in the under-50 age group were the most frequent users of insulin, likely 
due to a higher prevalence of type 1 diabetics in this age strata. There was no 
significant difference in the frequency of insulin-only therapy among age 
categories when patients under 40 years of age were removed from the 
analysis. This finding suggested that the proportion of type 1 diabetics in each 
age group was similar when including only patients 40 years of age or older. 
Thus, when comparing drug regimens utilized among age groups, differences 
in the regimen utilized was presumed not to reflect differences in the 
proportion of type 1 and type 2 diabetics. 
We found differences in the frequency of drug regimen utilized by patients 65 
years of age or older. First, though there was no statistically significant 
difference in insulin prescribing among age groups, seniors were less 
frequently prescribed troglitazone in combination with insulin. Though 
removed from the US market in 2000 due to risk of life-threatening hepatic 
injury, troglitazone, the first available thiazoladinedionne, was recommended 
as a useful agent in the management of diabetes (72-74). Prescribers may 
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have avoided prescribing troglitazone in older patients due to concern that 
older patients may be at greater risk for troglitazone-induced hepatic toxicity. 
Though prescription drug coverage was available to older patients in this 
population, it is also possible that prescribers avoided prescribing this product 
in older patients due to financial considerations. The retail price for a 30-day 
supply of troglitazone exceeded the average one-month cost of a generic 
sulfonylurea, a regimen utilized with increased frequency among older 
subjects. Since the cost of the dispensing to the patient (co-payment) was 
not available, the influence of cost on drug regimen utilization cannot be 
directly assessed. However, it is interesting that seniors were most frequently 
prescribed mono-therapy with a sulfonylurea, the oldest and most inexpensive 
oral hypoglycemic drug regimen available. Additionally, seniors utilized 
metformin as mono-therapy less frequently, but were not less frequent users 
of regimens of sulfonylurea plus metformin. Thus metformin was used more 
frequently as an adjunct to sulfonylurea therapy in seniors. Contrastingly, 
younger patients were prescribed mono-therapy with metformin more 
frequently than older patients (p = 0.0107). Metformin has been shown to be 
particularly useful in obese diabetic patients (65). The less frequent use of 
metformin mono-therapy among seniors may reflect a lower prevalence of 
obesity among those 65 years of age and older in this population . 
We also examined the frequency of drug regimen prescribed for each insurer 
type. We did not find the frequency of drug regimens prescribed to differ 
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significantly between the two main insurance plans included in this study. One 
exception was the use of glimepramide as mono-therapy, which was less 
frequently prescribed for patients insured by plan B. However, only a small 
percentage of patients were prescribed this drug as mono-therapy (2.6%; 
76/2901 ). Of the patients that paid cash for their prescription , one-half were 
prescribed sulfonylurea mono-therapy. 
Additional analyses 
We found a low prevalence of first generation sulfonylurea utilization (1 .1 %; 
17/1168), and older persons were not more frequently dispensed these 
agents. The infrequent use of these products reflects an awareness of the 
increased potential for hypoglycemia associated with chlorpropamide (58), and 
the lower likelihood for adverse effects such as hyponatremia and disulfiram-
type reactions (75-77). Use of first-generation sulfonylureas did not differ by 
age group or by gender. We did not expect to find a difference in dispensings 
for brand-name sulfonylurea products among age groups or by gender. 
However, although patients covered by health plan B utilized brand name 
sulfonylureas less frequently, the average 12-month cost of hypoglycemic 
drugs dispensed to patients in plan B was the highest of all insurance types. 
Thus, it appears that factors other than dispensing of generic products were 
important determinants of drug utilization costs; and may include factors such 
as the frequency of use of combination therapies, disease severity, or a more 
frequent use of newer drugs for which generic products are not available. 
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Average total 12-month cost of hypoglycemic drugs dispensed 
A major finding of this research was that of all age groups, expenditures for 
hypoglycemic medications were lowest among patients age 65 or older. The 
mean 12-month expenditure of $470.38 for seniors differed by more than $100 
compared with patients aged 50-64 ($593.23) and less than 50 years of age 
($580.80). This finding is consistent with other observations in this study. 
First, seniors were less frequently prescribed troglitazone in combination with 
other medications, and were less frequent users of metformin as mono-
therapy. Both troglitazone and metformin are higher priced products. Second, 
seniors were more frequently prescribed mono-therapy with sulfonylureas, a 
drug class available as generic products that are less expensive than 
metformin or troglitazone. Though seniors were less frequently prescribed 
brand name sulfonylurea products (Table 8), the relative difference among 
groups was small and did not differ in statistical significance. Thus, though the 
proportion of patients in each age category prescribed generic sulfonylureas 
was similar, more seniors received generic sulfonylureas as their only 
hypoglycemic agent. 
Study limitations 
Several limitations of this study can be described. First, this study categorizes 
drug regimen prescribed based upon medications dispensed during a 90-day 
period. It is possible that medications were prescribed by the physician but not 
dispensed by the pharmacy during the 90 day period. For example, 
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medications received as samples or through special programs were not 
identified. Further, it may be argued that drugs dispensed during the 90 day 
period may not accurately reflect hypoglycemic drug utilization during a 12-
month period. We felt that using the first and last 90 days of the 12-month 
period to identify the regimen afforded the opportunity to compare regimens 
utilized at the start and end of the study period . Using a 12-month period to 
categorize regimens would have resulted in identification of a large number of 
miscellaneous regimens: Patients switching regimens during the year would 
have been considered users of all hypoglycemic drug types dispensed during 
the 12-month period. Another limitation relates to the use of other 
pharmacies. Prescriptions filled by non-designated pharmacies would not have 
been captured in this sampling , potentially resulting in the false indication of a 
drug regimen change (i.e. change from combination therapy to mono-therapy). 
It is also important to note that drug expenditures were calculated using AWP-
10%. We selected this figure mainly to provide a common metric for 
assessing costs of hypoglycemic drug utilization. The dollar totals do not 
include the cost of syringes or blood glucose monitoring devices or supplies, 
or medications used for reasons and conditions other than blood glucose 
control. 
Though various insurance types are represented , a majority of study patients 
were enrolled in a diabetes management program through one of two health 
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plans. Generalizability to other populations is impaired by a lack of knowledge 
of race and socio-economic status, and the absence of diagnostic information 
such as diabetes type and co-morbidities. 
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CONCLUSION 
Retail pharmacy data were used to describe hypoglycemic drug utilization and 
associated costs in a large population of ambulatory diabetic patients. Several 
important findings are reported here. First, sulfonylureas continue to be the 
mainstay of treatment in patients with type 2 diabetes. Second, many patients 
changed medication regimens during a 12-month period, not including 
changes in medication dosage. Third , patients 65 years of age and older were 
less frequently prescribed troglitazone, or metformin in mono-therapy, and 
were most frequently prescribed sulfonylureas as their only hypoglycemic 
agent. The difference in hypoglycemic drug type utilization among seniors 
was reflected in the average 12-month cost of hypoglycemic medications 
dispensed. For seniors, this cost was roughly 20% less than average 
hypoglycemic drug utilization costs for middle-aged and younger-aged diabetic 
patients. 
Perhaps the recent attention directed towards tight glycemic control and 
enhanced control of post-prandial blood glucose will generate an increase in 
the use of combination drug therapies that includes newer hypoglycemic 
agents . However, though glycemic control may be enhanced through the use 
of some of the newer agents, there is no evidence to suggest that 
sulfonylureas are less effective than newer agents at preventing death and 
disability due to diabetes. In this population, sulfonylureas were by far the 
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most frequently used agents, particularly in older patients. Older patients were 
also less frequently dispensed prescriptions for troglitazone, and metformin in 
combination with a sulfonylurea. These findings may or may not suggest a 
difference in the standard of care delivered to seniors, but we believe it 
indicates a difference in the type of care received . 
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Figure 1. Drug Regimen Categories 
Regimen 
1 Insulin only 
2 Insulin + troglitazone 
3 Insulin + non-troglitazone agent 
4 Sulfonylurea mono-therapy 
5 Sulfonylurea + metformin 
6 Sulfonylurea + non-metformin agent 
7 Troglitazone mono-therapy 
8 Glimepramide mono-therapy 
9 Metformin mono-therapy 
10 Other regimen not classified above 
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Table 1. Population Characteristics 
N % 
Total population 2901 
Age 
Under 50 1002 34.5 
50-64 1259 43.4 
65 and older 640 22.1 
Gender 
Female 1349 46.5 
Male 1552 53 .5 
Insurance type 
Plan A 967 33.3 
Plan B 1562 53.8 
Other insurer 250 8.6 
Cash 122 4.2 
Insulin use 890 30.7 
Oral hypoglycemic use 2010 69.3 
34 
Table 2a. Frequency and Percentage of Drug Regimens Utilized, Based 
Upon Dispensings During First 90 Days of the 12-Month Period 
Regimen n % 
1 Insulin only 723 24.92 
2 Insulin + Troglitazone 91 3.14 
3 Insulin + non-troglitazone agent 76 2.62 
4 Sulfonylurea mono-therapy 1168 40 .26 
5 Sulfonylurea + metformin 404 13.93 
6 Sulfonylurea + non-metformin agent 77 2.65 
7 Troglitazone mono-therapy 34 1.17 
8 Glimepramide mono-therapy 76 2 .62 
9 Metformin mono-therapy 202 6.96 
10 Other regimen not classified above fill ill 
TOTAL 2901 100.00 
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Table 2b. Comparison of Drug Regimen Utilization During First and Last 
90 Days of the 12-Month Period. 
First 90 Last 90 Change 
Regimen days days 
n % n % n % 
Insulin only 723 24.92 641 22.10 -82 2.83 
2 Insulin + Troglitazone 91 3.14 110 3.79 +19 0.65 
3 Insul in + non-troglitazone 76 2.62 87 3.76 +11 1.14 
4 Sulfonylurea mono-therapy 1168 40.26 914 31 .51 -254 8.76 
5 Sulfonylurea + metformin 404 13.93 426 14.68 +22 0.76 
6 Sulfonylurea + non-metformin 77 2.65 179 6.17 +102 3.52 
7 Troglitazone mono-therapy 34 1.17 48 1.65 +14 0.48 
8 Glimepramide mono-therapy 76 2.62 66 2.28 -10 0.34 
9 Metformin mono-therapy 202 6.96 198 6.83 -4 0.14 
10 Other regimen not classified 50 1.72 232 8.00 +182 6.27 
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Table 3a. Frequency of Change in Hypoglycemic Drug Regimen Utilized During 12-Month Period 
Patients remaining on same drug regimen or switching to 
different regimen during 12-month period 
REGIMEN CATEGORY: LAST 90 DAYS 
Insulin Sulton- Su If on- Sulfon- Troglit- Glimep Mellor- Other 
Insulin+ +non- ylurea ylurea ylurea+ azone -ramide min regimen 
Insulin Troglit- troglit- mono- +met- non met mono- mono- mono- not 
only a zone a zone therapy form in -form in therapy therapy therapy classified 
REGIMEN CATEGORY: 
FIRST 90 DAYS N 1 2 3 4 5 6 7 8 9 10 
1 Insulin only 723 593 39 35 2 1 2 4 0 4 43 
w 2 Insulin+ 
-.J 
Troglitazone 91 15 51 11 0 0 2 3 1 0 8 
3 Insulin+ non-
troglitazone 76 19 13 23 7 2 8 0 1 0 3 
4 Sulfonylurea 
mono-therapy 1168 4 3 7 869 121 58 11 2 24 69 
5 Sulfonylurea + 
metformin 404 5 0 7 19 282 49 4 0 14 24 
6 Sulfonylurea + 
non-metformin 77 2 0 0 9 3 50 1 2 1 9 
7 Troglitazone 
mono-therapy 34 1 2 2 1 0 4 17 · o 0 7 
8 Glimepramide 
mono-therapy 76 0 0 0 1 0 2 1 57 2 13 
9 Metformin 
mono-therapy 202 1 0 1 5 14 1 5 2 151 22 
10 Other not 
classified 50 1 2 1 1 3 3 2 1 2 34 
Total 2901 641 110 87 914 426 179 48 66 198 232 
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Table 3b. Percent of Change in Hypoglycemic Drug Regimen Utilized During 12-Month Period 
Patients remaining on same drug regimen or switching to 
different regimen during 12-month period 
REGIMEN CATEGORY: LAST 90 DAYS 
Insulin Insulin Sulfonyl- Sulfonyl- Sulfonyl- Troglit- Glimep Metfor- Other 
+ + non- urea urea+ urea+non azone -ramide min regimen 
Insulin Troglit- troglit- mono- met- metfor- mono- mono- mono- not 
only azone a zone therapy form in min therapy therapy therapy classified 
REGIMEN CATEGORY: 
FIRST 90 DAYS N 1 2 3 4 5 6 7 8 9 10 
1 Insulin only 723 82% 5% 5% 0% 0% 0% 1% 0% 1% 6% 
w 2 Insulin+ 00 
Troglitazone 91 16% 56% 12% 0% 0% 2% 3% 1% 0% 9% 
3 Insulin+ non-
trogl itazone 76 25% 17% 30% 9% 3% 11 % 0% 1% 0% 4% 
4 Sulfonylurea 
mono-therapy 1168 0% 0% 1% 74% 10% 5% 1% 0% 2% 6% 
5 Sulfonylurea + 
metformin 404 1% 0% 2% 5% 70% 12% 1% 0% 3% 6% 
6 Sulfonylurea + 
non-metformin 77 3% 0% 0% 12% 4% 65% 1% 3% 1% 12% 
7 Troglitazone 
mono-therapy 34 3% 6% 6% 3% 0% 12% 50% 0% 0% 21 % 
8 Glimepramide 
mono-therapy 76 0% 0% 0% 1% 0% 3% 1% 75% 3% 17% 
9 Metformin 
mono-therapy 202 0% 0% 0% 2% 7% 0% 2% 1% 75% 11 % 
10 Other not 
classified 50 2% 4% 2% 2% 6% 6% 4% 2% 4% 68% 
Table 4. Percentage of Patients Prescribed Each Drug Regimen; 
Stratified By Gender 
REGIMEN CATEGORY N Female Male 
Insulin only 723 28.1% 22.2% p = 0.0002 
2 Insulin 
+ Troglitazone 91 3.9% 2.5% p = 0.0386 
3 Insulin + non-
troglitazone agent 76 2.4% 2.8% p = 0.4362 
4 Sulfonylurea 
mono-therapy 1168 35.8% 44.1% p < 0.0001 
5 Sulfonylurea 
+ metformin 404 14.0% 13.9% p = 0.9029 
6 Sulfonylurea + 
non-metformin 77 2.5% 2.8% p = 0.6758 
7 Troglitazone 
mono-therapy 34 1.2% 1.2% p = 0.9477 
8 Glimepramide 
mono-therapy 76 3.1% 2.2% p=0.1207 
9 Metformin 
mono-therapy 202 7.5% 6.5% p = 0.3013 
10 Other regimen §Q 1.5% 1.8% 
Total 2901 100% 100% 
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Table 5a. Percentage of Patients Prescribed Each Drug Regimen; Stratified By 
Age 
AGE 
Under 65 or 
REGIMEN CATEGORY N 50 50-64 older 
Insulin only 723 36.9% 18.4% 19.1% p < 0.0001 
2 Insulin 
+ Troglitazone 91 4.1% 3.3% 1.4% p = 0.0092 
3 Insulin + non-
troglitazone agent 76 2.4% 2.5% 3.1% p = 0.6478 
4 Sulfonylurea 
mono-therapy 1168 30.8% 43.6% 48.4% p < 0.0001 
5 Sulfonylurea 
+ metformin 404 12.1% 15.2% 14.4% p=0.1004 
6 Sulfonylurea + 
non-metformin 77 1.8% 3.4% 2.5% p = 0.0568 
7 Troglitazone 
mono-therapy 34 1.1% 1.4% 1.0% p = 0.7058 
8 Glimepramide 
mono-therapy 76 2.1% 2.7% 3.3% p = 0.3315 
9 Mettormin 
mono-therapy 202 7.2% 7.9% 4.8% p = 0.0476 
10 Other regimen §Q 1.5% 1.9% 2.0% 
2901 
Total 100% 100% 100% 
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Table 5b. Percentage of Patients Prescribed Each Drug Regimen; 
Stratified By Age, Patients Under 40 Years of Age Excluded 
AGE 
REGIMEN CATEGORY n 40-49 50-64 65 or older 
Insulin only 723 20.1% 18.4% 19.1% p = 0.6506 
2 Insulin 
+ Troglitazone 91 5.0% 3.3% 1.4% p = 0.0013 
3 Insulin + non-
troglitazone agent 76 2.8% 2.5% 3.1% p = 0.7627 
4 Sulfonylurea 
mono-therapy 1168 39.6% 43.6% 48.4% p = 0.0067 
5 Sulfonylurea 
+ metformin 404 15.6% 15.2% 14.4% p = 0.8275 
6 Sulfonylurea + 
non-metformin 77 2.4% 3.4% 2.5% p = 0.3715 
7 Troglitazone 
mono-therapy 34 1.0% 1.4% 1.0% p = 0.6493 
8 Glimepramide 
mono-therapy 76 2.8% 2.7% 3.3% p = 0.7612 
9 Metformin 
mono-therapy 202 9.1% 7.9% 4.8% p = 0.0107 
10 Other regimen 50 1.6% 1.9% 2.0% 
Total 2901 100% 100% 100% 
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Table 6. Percentage of Patients Prescribed Each Drug Regimen; Stratified By Insurance Type 
Other 
REGIMEN CATEGORY N Plan A Plan B Insurance Cash 
Insulin only 723 24.1% 25.3% 27.2% 22.1% p = 0.6444 
2 Insulin + Troglitazone 91 3.8% 3.1% 2.0% 0 
3 Insulin +non-
troglitazone agent 76 3.4% 2.1% 2.8% 3.3% p = 0.2019 
4 Sulfonylurea mono-
therapy 1168 39.3% 40.6% 37.2% 50.1% p=0.1010 
... 
N 5 Sulfonylurea 
+ metformin 404 11 .8% 15.8% 12.8% 9.8% p = 0.0187 
6 Sulfonylurea + non-
metformin 77 3.4% 2.1% 2.8% 3.3% p = 0.2477 
7 Troglitazone mono-
therapy 34 0.8% 1.2% 2.4% 0.8% 
8 Glimepramide mono-
therapy 76 4.3% 1.3% 2.8% 5.7% p < 0.001 
9 Metformin 
mono-therapy 202 6.5% 4.0% 8.4% 2.5% p = 0.0107 
10 Other regimen 50 2.6% 4.5% 1.6% 2.4% 
Total 2901 100% 100% 100% 100% 
• X2 not reported due to cells with less than 5 subjects 
Table 7. Prescriptions for Brand Name Sulfonylurea Products and Age, 
Gender, and Insurance Type 
Percentage of Patients 
Dispensed Brand Name 
n Product 
Age 
under 50 430 54.2% 
50-64 740 50.1% 
65 and older 402 48.3% p = 0.2079 
Gender 
Female 672 48.4% 
Male 900 52.6% p = 0.1000 
Insurance Type 
Plan A 316 64.0% 
Plan B 368 41.8% 
Other Insurance 69 55.2% 
Cash 45 64.6% p < 0.001 
Table 8. Troglitazone Prescribing and Age Category 
Age 
40-49 
50-64 
65 + 
Total 
*p < 0.0001 
N 
616 
1259 
640 
2515 
Number 
prescribed 
troglitazone 
125 
222 
65 
412 
43 
% prescribed 
Troglitazone* 
20.3% 
17.6% 
10.2% 
16.4% 
Table 9. Prescriptions for Hypoglycemic Drugs: 12-Month Expenditure 
12-month expenditure 
n (mean) Pr> F 
Age 
under 50 1002 $580.80 
50-64 1259 $593.23 
65 and older 640 $470.38 < 0.0001 • 
Gender 
Female 1349 $538.83 
Male 1552 $531 .72 0.1172b 
Insurance Type 
Plan A 967 $521 .63 
Plan B 1562 $587.82 
Other Insurance 250 $526.01 
Cash 122 $385.37 0.0002• 
a. Analysis of Variance, Tukey's test 
b. Student's I-test for independent samples 
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Changes in Oral Hypoglycemic Therapy: Influence of Nonadherence as 
Determined by Medication Possession 
ABSTRACT 
Background Recent large trials have provided evidence that intensive 
therapy for achieving tight glycemic control can reduce the risk of several 
types of diabetic complications. Tight glucose control necessarily presumes 
strict adherence to the prescribed hypoglycemic regimen. However, 
adherence to prescribed drug therapy for chronic diseases is known to be sub-
optimal. 
Objective To determine if nonadherence, as determined by medication 
possession , is associated with changes in hypoglycemic drug prescribing; 
either as a change in medication strength or a change in type of hypoglycemic 
medication dispensed . 
Methods . A retrospective cohort study examining retail pharmacy 
dispensings of sulfonylureas and metformin. The medication possession ratio 
(MPR) was used to assess adherence, with patients that did not receive a 
sufficient quantity of medication to cover eight of ten days in the period (MPR 
< 8: 10) classified as nonadherent. Outcomes assessed were change in 
strength of hypoglycemic medication dispensed and change in type of 
hypoglycemic medication dispensed. Multivariate logistic regression was used 
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to estimate the influence of medication possession on these outcomes, 
controlling for the potential confounding factors age, gender, insurance type, 
and the total number of all pharmacy dispensings. 
Results For patients receiving dispensings only for a sulfonylurea , those 
failing to possess medication for eight of ten days (MPR < 8: 10) were 41.7% 
more likely to receive a dispensing for a different strength of medication in 
subsequent months (OR 1.42, 95% Cl 1.02 - 1.96). Such patients were also 
47.1 % more likely to receive a dispensing for a different strength or different 
type of hypoglycemic medication (OR 1.47, 95% Cl 1.05 - 2.06). For the 
smaller sub-population of users of only metformin (n = 166), a statistically 
significant increase in the likelihood of either a change in strength or type of 
hypoglycemic drug dispensed was not found for those having an MPR less 
than 8: 10. However, for the combined sample of patients receiving either 
monotherapy with a sulfonylurea or metformin, those having an MPR less than 
8:10 were 36.4% more likely to receive a dispensing for a different strength of 
medication (OR 1.36, 95% Cl 1.019 - 1.83), or for a different strength or type 
of hypoglycemic medication (OR 1.39, 95% Cl 1.027 - 1.87). 
Conclusions Glycemic control would expectedly be poorer 
among patients failing to possess prescribed hypoglycemic medication. In this 
study, patients failing to refill prescriptions when due were more likely to 
receive a dispensing for a different strength or type of hypoglycemic 
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medication in subsequent months. This finding suggests that for patients that 
do not tightly adhere to therapy, providers may respond to poor glucose 
control by increasing the amount of medication prescribed. This response 
may precipitate dangerous hypoglycemic reactions, and fails to address the 
root cause of poor glycemic control for such patients, potentially resulting in 
diabetic complications that could have been prevented. 
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INTRODUCTION 
Patients with diabetes are at risk for numerous adverse health outcomes. 
Beyond consequences immediately related to blood glucose regulation, such 
as hypoglycemia or ketoacidosis (1 ), diabetes increases risk for 'macro' 
vascular diseases such as myocardial infarction and stroke (2). Diabetics are 
also more likely to develop hypertension and dyslipidemia (3), which are risk 
factors for developing these outcomes. In addition to macrovascular diseases, 
diabetes also increases the risk of developing diseases resulting from damage 
to the smaller blood vessels, such as retinopathy, neuropathy, and 
nephropathy (4). The quality of life in patients with diabetes often diminishes 
over time as diabetic complications become disabling (5). 
Appropriate management of diabetes can reduce and delay the sequelae of 
this disease. Therapeutic interventions have been proven effective in 
controlling blood glucose levels (6) and in the longer-term, preventing some 
types of diabetes complications (7-9). Dietary changes and routine exercise 
are fundamental interventions. Often , however, normalization of blood glucose 
control can only be achieved through drug treatment (10). 
In addition to resolving blood glucose instability in many patients , drug therapy 
has been demonstrated to confer the added benefit of preventing some types 
of diabetes complications. Results from two large trials have provided 
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evidence that drug therapy can reduce the incidence of micro-vascular 
disease in patients that are aggressively managed. 
Researchers in the Diabetes Control and Complications Trial (DCCT) (9) 
compared standard care with intensive drug treatment and monitoring 
regimens in 1,441 type 1 diabetics during a ten-year period . In this study, the 
risk of developing retinopathy, nephropathy, and neuropathy was reduced by 
76%, 50%, and 60% respectively among diabetics receiving the intense 
treatment. This finding led researchers to conclude that intensive drug therapy 
"delays the onset and slows the progression" of these diseases. 
The United Kingdom Prospective Diabetes Study (UKPDS) (7) investigated 
whether intensive drug therapy reduced the incidence of diabetic 
complications in type 2 diabetes. In this study, 3867 patients with newly 
diagnosed disease were followed during a 10-year period . As in the DCCT, 
researchers attempted to determine if intense treatment and monitoring would 
reduce the incidence of diabetic complications. The results of the UKPDS 
provided compelling evidence that drug therapy can reduce the incidence of 
certain types of complications in patients with type 2 disease. Compared with 
patients treated with conventional care, the risk for developing microvascular 
complications in patients receiving intensive therapy was reduced by 25%. 
Further, the risk of developing retinopathy was reduced by 21 %, while the risk 
of developing microalbuminurea was reduced by 34%. The incidence of 
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myocardial infarction was also lesser in the group treated intensively, though 
the 16% difference observed between groups failed to achieve statistical 
significance (p = 0.052). 
These two trials provided strong evidence that tight control of blood glucose 
can prevent the microvascular complications in patients with diabetes, and 
may reduce the risk for macrovascular complications such as myocardial 
infarction. Since the publication of these trials, standards for the treatment of 
diabetes have incorporated tight blood glucose control as an objective of 
therapy. Thus, drug treatment is aimed at maintaining normal blood glucose 
throughout the day to obtain the benefits described in these trials. 
Patient adherence to prescribed drug regimens is implicit to a strategy of tight 
blood glucose control. When medications are not taken according to 
instructions, optimal control of blood glucose will clearly be compromised . 
This may be the case for many diabetic patients. Patient adherence with 
prescribed medication regimens for chronic diseases is known to be sub-
optimal (11-13) (14), and patients with diabetes in particular are known to have 
difficulty adhering to prescribed dietary, exercise, and drug therapies (15, 16). 
Further complicating matters is the progressive nature of diabetes, as patients 
generally experience a worsening of glycemic contro l over time. Therefore, 
not only is adherence important in reducing the risk of diabetic complications, 
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it is a fundamental component of active participation in therapy that continually 
requires assessment of medication needs for sustaining glucose control. 
Thus, both disease progression and poor adherence can cause inadequate 
blood glucose control, and it is important to distinguish between the two. The 
patient who is poorly controlled because his disease has progressed 
potentially requires a different intervention than the patient who is poorly 
controlled due to poor adherence. Increasing the dose of medication for the 
patient in the latter scenario may result in a dangerous hypoglycemic reaction. 
Our working hypothesis was that patients that do not adhere to prescribed 
drug regimens are more likely to be poorly controlled; and such poor control 
will be manifested as a change in medication dose or a change in medication 
prescribed . To investigate this hypothesis, we assessed adherence with 
sulfonylurea or metformin therapy using pharmacy claims data. We 
determined whether patients that were nonadherent to prescribed therapy 
were more likely to receive a change in dose or change in hypoglycemic drug 
dispensed during subsequent months. 
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METHODS 
Identification of the study samples 
We conducted a retrospective cohort study using prescription dispensing 
information. Consumer Value Stores, Inc (CVS) provided pharmacy utilization 
data used in this study. The data included over one-quarter million 
dispensings to 5056 diabetic patients between April 1997 and May 1999. 
Most patients included in this population were enrollees of one of two area 
health plans, and participants in a special managed care program in diabetes 
through these plans. Patients were restricted to designated CVS pharmacies 
for pharmacy services. The data provided represented pharmacy utilization by 
patients enrolled in these two health plans from the designated pharmacies . 
The restriction to designated pharmacies was an advantageous feature, 
potentially resulting in a more complete representation of pharmacy utilization. 
Of the patients included in the total population, we identified those that 
received any hypoglycemic medication during a 12-month observation period. 
From this population, we identified patients receiving mono-therapy with a 
sulfonylurea or mono-therapy with metformin during the first four months of 
this 12-month period . Patients who received two or more different types of 
hypoglycemic medication during this four-month period were excluded. Thus, 
two samples were created: patients receiving monotherapy with sulfonylurea 
and patients receiving monotherapy with metformin. 
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Patients who did not receive the same strength of medication and same 
number of tablets per day for all dispensings during the four-month period 
were excluded from study. Thus, the two samples represented patients 
receiving dispensings for either only a sulfonylurea or only metformin at the 
same dose during the four-month period, and receiving at least one dispensing 
of a hypoglycemic medication during the following eight months. 
Determining change in dose or medication regimen 
We assessed the influence of adherence for two main outcomes: change in 
dose of sulfonylurea or metformin; or change in hypoglycemic drug dispensed . 
To determine change in dose, we compared the initial strength of medication 
with additional subsequent dispensings during the following eight months. 
Also, we identified patients receiving an increased quantity of the same 
strength of medication (e .g. two tablets daily instead of one). To identify such 
patients, we compared the number of tablets in the daily dose for all 
dispensings. By dividing the quantity supplied by the days supply of 
medication received, we were able to determine the number of tables 
prescribed per day. Patients who received a different strength of a same 
medication, or who were prescribed a different number of tablets per day 
during the eight months following the four-month period were classified as 
havi ng a change in dose of sulfonylurea or metformin. 
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In addition to change in medication dose, we identified patients who received 
a dispensing for a different type of hypoglycemic drug in the months following 
the initial four-month period . The two outcomes were also used to create a 
combined outcome of receiving a dispensing for either a different strength or 
type of hypoglycemic medication. 
Calculating the medication possession ratio 
We used the medication possession ratio (MPR) as the measure of adherence 
with prescribed hypoglycemic drug therapy. The MPR describes the number 
of days that a patient was in possession of medication (17). To calculate the 
MPR, we determined the total days supply of medication received for all 
dispensings preceding the last dispensing of the four-month period . A ratio 
was created using the days supply of medication received and the number of 
days between the first and last dispensing during the four-month period . For 
example, the MPR for a patient that received three dispensings of 30 tablets 
each (90 tablets) during a period of 113 days would be 90: 113, or roughly 
8:10. For the purposes of this research , medication possession for at least 
80% of days (MPR <::8:10) was considered to be adherent. Other researchers 
have used this threshold in studies of adherence to therapies for other chronic 
conditions, such as hormone-replacement therapy (18); hypertension (19 , 20); 
and depression (21 ). Patients who received only one dispensing during the 
four-month period but who received medication in following months were 
classified as non-adherent. 
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A limitation of the MPR as used to assess adherence is the potential for 
misclassification, since a patient may possess but not consume a medication. 
Possession of medication has however, been considered a useful 'first-order' 
measure of adherence (22), since patients must first possess medication 
before they can adhere to therapy 
Potential confounding variables 
We also examined the effect of four other factors on change in dose of 
hypoglycemic medication or change in type of hypoglycemic medication 
prescribed. One such factor, the number of medications prescribed , was 
thought to potentially be an important influence on medication possession and 
change in hypoglycemic therapy. To approximate the number of medications 
prescribed , we identified the total number of dispensings for any class of 
medication during the four-month period; including medications for conditions 
other than diabetes. Three categories of this variable were created: less than 
5 dispensings, 5-15 dispensings, or more than 15 dispensings. We also 
assessed the effect of patient age, and categorized this variable using 
categories of less than 50 years of age, 50-65 years, and greater than 65 
years of age. Stratifications for the total number of prescriptions dispensed 
and patient age were based upon assessment of parametric form , as 
described in the following section . 
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The type of insurance used for prescription reimbursement was also included 
as a potential confounder. We categorized insurance type as health plan A, 
health plan B, or a third category that included all other insurance types and 
cash. We also included gender as an additional potential confounding 
variable. 
Based on the methodology for variable identification described above and as 
presented in figure 2, we determined the relative risk of a change in 
medication dose, change in class of hypoglycemic medication prescribed, or a 
combined outcome of either for patients having a medication possession ratio 
less than 8:10, as compared to those having an MPR ~8:10. Additionally, we 
assessed the influence of four other variables : the total number of 
prescriptions dispensed, age category, insurance type, and gender; attempting 
to control for the effect of these variables where necessary. 
Statistical methods 
Univariate statistics were used to describe the frequency and percent of 
monotherapy with a sulfonylurea or metformin. For each of the two samples, 
we categorized patients by gender, age, insurance type, and the total number 
of prescriptions dispensed. These characteristics were also presented as 
frequencies and percentages. We also determined the frequency and percent 
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of subjects having an MPR greater than 8:10 and 9:10. For all analyses 
involving the MPR, we used the lower threshold of :?:8: 10. 
We assessed the parametric form of the two continuous variables: age and 
total number of prescriptions dispensed. This was accompl ished by logistically 
modeling quartiles of the frequency distribution to assess linearity. For each 
independent variable, models were created for each quartile of the variable's 
frequency distribution and each dependent variable. The resulting parameter 
estimates were exponentiated and plotted to determine if a linear trend was 
present. Non-linear relationships suggested the need for stratification of each 
continuous variable for inclusion in multivariate logistic models. 
Bivariate analyses were used to assess the relationship between the MPR and 
other independent variables, and between independent and dependent 
variables. Chi square analyses were used to assess the relation between the 
medication possession ratio and the potential confounding variables. We also 
used chi-square analyses to examine the relation between all independent 
variables and the outcomes of change in dose and change in medication 
dispensed. For each independent variable, bivariate logistic regression was 
used to determine the relation between variable and change in dose and 
change in medication dispensed. These results were presented as an odds 
ratio with 95% confidence intervals. 
64 
Multivariate statistics were used to identify the presence of collinearity 
between independent variables, to determine the presence of interactions 
between independent variables, and to assess the influence of the MPR on 
outcome variables when other potential confounding variables were included. 
Collinearity diagnostics were performed using the PROC REG procedure for 
multiple regression as suggested by Allison (23). Collinearity was assessed 
for all independent variables in separate models with dependent variables 
change in dose, change in medication dispensed, and the combined outcome 
of change in either. Presence of collinearity was determined using thresholds 
for condition index and proportion of variance shared as described by 
Tabachnick and Fidell (24). 
Test for interaction between variables was performed using the chunk test for 
multivariate logistic models as described by Kleinbaum (25). For this 
procedure, we calculated the difference in the -21og statistic between full and 
reduced models. Full models included all possible interaction and single 
terms: Reduced models included single terms (variables) only. The difference 
in -21og statistic between full and reduced models was tested for significance 
using the Chi-square distribution, with degrees of freedom equal to the 
difference in terms between the two models. A difference in -21og value that 
was less than the X2 statistic indicated that an interaction was not present. 
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Final multivariate logistic models contained only variables with significant 
terms, or a significant strata . Initial models contained all independent 
variables. Least significant terms were removed in order (backward 
elimination), observing the effect of change in the parameter estimate beta 
and confidence interval for each variable eliminated . Terms were excluded 
from the model if they were non-significant contributors and if their removal 
resulted in small or no change in the parameter estimate for the MPR. In 
models where it was not a significant influence on the outcome variable, the 
MPR variable was removed from the model , and the influence of other 
significant terms was assessed. 
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RESULTS 
Table 1 presents the gender, age category, insurance type, and total number 
of prescriptions dispensed for patients in the sulfonylurea and metformin 
samples. Nearly six times as many patients received sulfonylurea 
monotherapy than metformin monotherapy (967 versus 166). Also, a greater 
percentage of males received sulfonylurea monotherapy, yet the percent of 
males and females that received monotherapy with metformin was similar. 
The age stratifications presented reflect the parametric form of this variable. 
Nearly half of all patients in both samples were between 50-65 years of age. 
A notable disparity was the higher percentage of patients in youngest age 
strata among metformin users, as compared with subjects in the sulfonylurea 
sample. Conversely, the sulfonylurea sample included a greater percentage 
of patients 65 years of age or older as compared with the metformin sample. 
In both the sulfonylurea and metformin samples , nearly 90% of patients were 
covered by one of the two predominant insurance plans. The remainder of 
patients used other insurance plans for prescription payment, or paid cash. 
Percentages of categories of insurance type were similar for the sulfonylurea 
and metformin samples. 
More than half of patients were categorized as receiving a total of 5-15 
prescriptions during the four-month period, a strata that represented the 
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second and third quartiles of the distribution of this variable . We chose to 
combine these quartiles due to a similar relationship between each quartile 
and the outcome variables. However, the first and fourth quartile of the 
frequency distribution of this variable differed from the second and third 
quartile in relation to the dependent variables, necessitating the three levels 
created . 
Table 2 presents the results of univariate analysis of the medication 
possession ratio. The percentage of patients possessing medication for at 
least 80% of days during the time period was 77.2% and 71 .1 % for the 
sulfonylurea and metformin samples respectively. The percentage of patients 
possessing medication for at least 90% of days was 66.8% for the sulfonylurea 
monotherapy sample , and 56.6% for those dispensed only metformin. The 
average percentage of days medication was possessed was similar (91 % for 
patients receiving only sulfonylurea; 86.6% for patients receiving only 
metformin). This percentage is highly skewed, with some patients receiving 
quantities of medication that were greater than the quantity required to cover 
100% of days between dispensings. 
Table 3 presents the relation between the potential confounding variables and 
the medication possession ratio. The percentage of patients having an MPR < 
8:10 did not differ significantly by gender or insurance type among patients 
receiving either dispensings for a sulfonylurea or metformin. Among 
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sulfonylurea users, patients in the youngest age category were more 
frequently identified as having an MPR less than 8:10 (age under 50: 33.19%; 
age 50-64 : 19.46%; Age 65+: 15.59%; p < 0.01 ). Similar percentage 
distributions were observed for metformin users, though the ability to detect a 
statistically significant difference was likely influenced by the smaller number 
of patients in this sample. Patients receiving less than five total dispensings 
during the first four months of the 12-month period were also more frequently 
categorized as having an MPR less than 8:10. Subjects receiving greater than 
15 dispensings were least frequently categorized as having an MPR < 8: 10. 
These differences were statistically significant among patients in the 
sulfonylurea sample (p < 0.01 ). 
Tables 4a and 4b present the comparisons of proportions of patients having 
an MPR < 8:1 O and the potential confounding variables with change of dose, 
change in medication dispensed, or the combined outcome of either. More 
than twice as many patients were identified as having a change in dose of 
hypoglycemic medication as compared with a change in type of drug 
dispensed (Sulfonylurea sample: change in dose: 58 .53%, change in regimen : 
26.78%, Metformin sample: change in dose: 48.19%; change in drug 
dispensed: 18.07%). 
Males and females in the sulfonylurea group were roughly equally likely to 
experience a change in dose or change in drug dispensed, though the 
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percentage of metformin patients that experienced a change in drug was non-
significantly higher among males (change in dose: sulfonylurea, males versus 
females: 59.01 % v 59.35%; change in dose: metformin, males versus females: 
53.75% v 48.84%. change in drug: sulfonylurea, males versus females: 
25.70% v 28.35%; change in drug: metformin, males versus females: 22.35% 
v 13.58%). In both the sulfonylurea and metformin samples, younger patients 
were more frequently identified as having a change in dose or drug dispensed 
(change in sulfonylurea dose, age less than 50 versus age 65 years or older: 
65.94% v 52.36%; change in metformin dose, age less than 50 versus age 65 
years or older: 54.55% v 40.00%; change in drug among sulfonylurea users, 
age less than 50 versus age 65 years or older: 29.26% v 17.57%; change in 
drug among metformin users, age less than 50 versus age 65 years or older: 
23.64% v 20.00%). These differences were only statistically significant in the 
sulfonylurea sample (p < 0.01 ). No statistically significant differences were 
observed between changes in medication dose or regimen and health plan or 
number of prescription dispensings. Patients in both samples having an MPR 
of less than 8:10 experienced a dose change more frequently (sulfonylurea: 
MPR < 8:10: 25.62%; MPR ~8:10 : 18.70%, metformin: MPR < 8:10: 32.50%, 
MPR ~8 : 10: 25.58%) This difference between values for MPR < 8:10 and 
MPR ~8:10 was nearly equal for both the sulfonylurea and metformin groups. 
However, the difference between groups was only statistically significant in the 
sulfonylurea group (p < 0.05), likely reflecting the fewer number of patients in 
the metformin sample. The proportion of patients having an MPR < 8:10 did 
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not differ significantly among those with a change in hypoglycemic drug 
dispensed for each sample (sulfonylurea: MPR < 8:10: 23.55%; MPR ~8 : 10: 
22.46%, metformin: MPR < 8:10: 30.00%, MPR ~8:10: 28.68). 
Bivariate and multivariate logistic regression models were also used to 
examine the relation between independent and dependent variables. These 
results are presented for the sulfonylurea and metformin samples, in analyses 
of the relation between each variable and the outcomes of change in 
medication dose (tables 5a, 5b) or change in drug dispensed (tables 6a, 6b). 
For the sulfonylurea sample, patients experiencing a change of dose were 
50% more likely to be categorized as having an MPR < 8:10 (OR 1.50; 95% Cl 
1.09- 2.05, p = 0.0118). The MPR was not statistically significantly 
associated with a change in medication dispensed among sulfonylurea users, 
or with a change of dose or medication dispensed among metformin users. 
Sulfonylurea patients 65 years of age and older were 43% less likely to 
experience a dose change (OR 0.57 , 95% Cl 0.40 - 0.81, p = 0.0018). Male 
gender, insurance type, and the total number of dispensings were not found to 
be significant influences on change in dose or of change in drug dispensed in 
either sample. 
71 
Multivariate results 
We assessed the influence of the MPR on three outcomes: change in dose, 
change in drug dispensed , and the combined outcome of change in dose or 
drug dispensed. We examined the effect of MPR on these outcomes for three 
populations: patients dispensed sulfonylureas , patients dispensed metformin, 
and a combined sample of patients dispensed either monotherapy with a 
sulfonylurea or monotherapy with metformin. In sum, nine multivariate models 
were created to assess these relationships. 
For each of these nine models , we assessed collinearity and interaction 
between variables. Collinearity between independent variables was not 
detected at condition indices above the threshold of 30. However, collinearity 
diagnostics indicated a high degree of shared variance between the number of 
prescriptions dispensed and age. Interaction between the MPR and other 
independent variables was assessed using the chunk test described by 
Kleinbaum. We did not detect a significant interaction between any 
combination of independent variables, as determined by comparing the 
difference in -21og statistic between full and reduced models with a chi-square 
value. These results are presented in table 7. 
Tables 8a-c, 9a-c, and 1 Oa-c present the multivariate results of the nine 
models . In these tables we have presented the resu lts of models that include 
all independent variables in the logistic regression , followed by a final model 
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containing only significant terms. For models having no significant terms, only 
the model containing all independent variables is presented. 
Tables 8a , 8b, and 8c present the multivariate results from the sulfonylurea 
sample for outcomes of change in dose, change in medication dispensed, and 
the combined outcome of change in dose, respectively. Table 8a presents the 
results for the outcome of change in dose. In a model containing all 
independent variables, the risk associated with a dose change was 42% 
greater among those having an MPR < 8:10 . We removed from this model the 
non-significant terms gender, insurance type, and total number of dispensings. 
The resulting final model included only age and MPR < 8:10. Based on this 
model, patients that were 65 years of age or older were significantly less likely 
to experience a change in dose of sulfonylurea (OR 0.60; 95% Cl 0.41 - 0.85). 
Age was also a significant influence in models for the outcome of change in 
medication dispensed in the sulfonylurea sample. Patients 65 years of age or 
older were less likely to be included among those with a change in type of 
medication dispensed (OR 0.51; 95% Cl 0.34 - 0.78). Neither the MPR nor 
any other independent variable was significantly associated with a change in 
drug dispensed in the sulfonylurea sample. 
Outcomes were combined to create a category of patients that included 
patients having either a change in dose or change in medication dispensed. 
For this combined outcome, the MPR and older age were both associated with 
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the risk of change in dose or medication dispensed; with MPR < 8:10 
increasing the risk of this outcome by 50% (OR 1.50; 95% Cl 1.08 - 2.08) and 
an age of 65 years or greater decreasing the risk of this outcome by 38% (OR 
0.62; 95% Cl 0.43 - 0.89). 
Based upon the results of the multivariate logistic models for the metformin 
sample (Tables 9a-c), none of the independent variables was a significant 
influence of change in dose, change in medication dispensed, or the combined 
outcome of either. The lack of significant predictors in the metformin sample 
was potentially a result of sample size. We created a third sample of patients 
by combining the sulfonylurea and metformin populations. As in the models 
for the sulfonylurea sample, the MPR and age 65 years or older were 
significant influences of change in medication dose in the sample of combined 
patients (MPR < 8:10: OR 1.38; 95% Cl 1.04 - 1.84 , Age 65 or older OR 0.62 , 
95% Cl 0.45 - 0.87). The oldest age group was the only variable with 
statistically significant influence in the model for change in medication 
dispensed in the combined sample (OR 0.55; 95% Cl 0.38 - 0.81 ). Last, 
using a population that included both the sulfonylurea and metformin samples, 
the MPR and older age were significantly associated with the combined 
outcome of change in dose or change in medication dispensed. The results of 
models using the combined sample of patients are presented in tables 1 Oa-c. 
74 
DISCUSSION 
Adherence to prescribed drug regimens is a common problem in patients with 
chronic diseases. Adherence to prescribed drug regimens in patients with 
diabetes is particularly important, since tight control of blood glucose has been 
demonstrated to reduce the incidence of many types of diabetes 
complications. Nevertheless, non-adherence to hypoglycemic therapy has 
been identified as a major barrier to effective management of diabetes. Lack 
of adherence with prescribed hypoglycemic medications has been correlated 
with diminished blood glucose control (26-28), which in turn can result in 
adverse health outcomes, both in the long and short-term. 
Much research has been conducted investigating the cause for lack of 
adherence to drug therapy. Immediate barriers to adherence include the cost 
of medication, access to medication, and the complexity of the drug regimen . 
Beyond these barriers, determinants of adherence are more complex, and 
include physiologic, cognitive, behavioral , and environmental factors (29). For 
example, the health belief model has been reported to predict adherence to 
drug therapy (30). 
According to the health belief model, adherence will be improved when 
patients perceive their disease to pose a threat to their health, and believe that 
prescribed medications will be effective in decreasing the risk of morbidity. In 
one study, knowledge about hypoglycemic medications among diabetic 
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patients in the UK was found to be poor, with only 35% of patients recalling 
receiving any information about their hypoglycemic medication (31 ). One in 
five patients surveyed in this study reported missing at least one dose of their 
hypoglycemic medication per week. The lack of knowledge of hypoglycemic 
drug therapy was perhaps a contributing factor resulting in the poor adherence 
rates observed , according to the principles of the health belief model. 
Other explanatory paradigms for predicting and understanding the behavior of 
adherence include self-efficacy theory (32), the transtheoretical (stages of 
change) model (33), and social learning theory (34). Each of these involves 
patients taking active control of the disease management process, including 
understanding the need for adherence to recommended therapies. 
Lack of adherence to hypoglycemic medications is a recognized , though 
perhaps under-appreciated problem. For example, Ward found that 
physicians may tend to over-estimate patients' adherence to prescribed 
medications (35). Yet the evidence continues to accumulate. Numerous 
studies of various methodology have demonstrated that drug treatments for 
chronic conditions are often not taken as prescribed (36, 37). Clearly this is an 
area of pharmacotherapy that deserves heightened focus . 
In this study, we attempted to demonstrate that lack of adherence to 
prescribed hypoglycemic medication increases the likelihood that prescribed 
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therapies will change. We assumed that a change in medication dosage or a 
change drug type was an action in response to poor blood glucose control. 
Appropriate interventions for patients who are non-adherent to therapy would 
logically involve efforts intended to improve adherence. Increasing the 
amount of medication prescribed to a non-adherent diabetic patient is a 
potentially inappropriate intervention. Such a response may also be 
dangerous, resulting in increased risk of hypoglycemia (38) and longer-term 
complications resulting from continued poor glucose control. 
In this study, the medication possession ratio was used to assess adherence. 
Also included in analyses were four other factors that were considered to be 
possibly associated with the MPR or related to the outcomes of change in 
medication dose or change in type of hypoglycemic medication dispensed . 
The age and gender of the patient were two of these factors. According to 
various studies, the relation between adherence and these two factors is 
unclear. For example, some studies have shown age and gender to be 
influences on adherence (39-40), though others have not (41-42). In one 
study of adherence with sulfonylurea therapy, age and gender were found to 
be statistically significant influences on drug regimen adherence (43) . In our 
study, we also included insurance type as a potential factor of influence. 
Though we had no knowledge of details regarding co-payment structures or 
formulary systems, we thought that attributes of the benefit design may have 
had an impact on adherence or change in dose or type of drug dispensed. The 
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total number of medications dispensed was the fourth of the other 
independent variables included in our study. We included this factor based 
upon research suggesting that adherence may be associated with the number 
of medications prescribed. 
As determined by the medication possession ratio, adherence to drug therapy 
was poor among patients in both the sulfonylurea and metformin samples. 
Only 77% of patients in the sulfonylurea sample possessed enough mediation 
to cover at least 8 of 10 days during the four-month period . The percentage of 
patients receiving enough of their sulfonylurea medication to cover 9 of 10 
days in the period was 67%. In the metformin sample, a lower percentage of 
patients possessed medication for each threshold. Of these patients, 71 % 
received enough metformin to cover at least 8of10 days in the period, and 
57% of patients possessed medication for 9 of 1 O days. In summary, roughly 
one in four patients dispensed sulfonylureas did not possess enough 
medication to cover eighty percent of days during the four month period; and 
approximately one in three did not receive enough medication for ninety 
percent of days. Those receiving metformin monotherapy were less frequently 
in possession of medication. 
The finding that patients do not regularly obtain hypoglycemic medication is 
not unexpected. In their investigation of compliance with sulfonylureas during 
a two-year time period, Venturini et al (44) reported a mean compliance rate of 
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83%: On average, patients did not possess medication for nearly one in five 
days. In a study using Medicaid pharmacy data, Sclar et al (43) found 
adherence with sulfonylurea therapy to be very low, with only 39% of patients 
receiving at least a six-month supply of medication during a period of 12 or 
more months. 
Of the four potential confounding variables used in this study, only age and the 
total number of dispensings were significantly associated with the MPR. The 
percentage of patients having an MPR < 8:10 did not differ statistically 
significantly by gender or insurance type. Patients 65 years of age and older 
were more frequently in possession of medication for greater than 80% of 
days; patients under 50 years of age were least frequently is possession of 
medication for at least 80% of days. This difference was not statistically 
significant in the metformin sample, though sample size may have affected the 
ability to detect a significant difference. The finding that older patients were 
more frequently categorized as adherent may perhaps be explained as a 
greater concern among older patients for the protection of health, with a 
corresponding adherence with prescribed medications. 
It was interesting that a greater number of prescriptions dispensed was more 
frequently associated with possession of medication for at least 80% of days. 
This finding may also be related to concerns for maintaining heath. Patients 
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receiving more medications are presumably less healthy, and perhaps more 
likely to take medications as prescribed. 
Multivariate analyses: Change in dose of hypoglycemic medication 
A change in dose of sulfonylurea or metformin was more than twice as 
frequently observed than a change in type of hypoglycemic medication 
dispensed. Diabetes is a progressive disorder, and even patients that adhere 
to therapy will require increased amounts of medication over time. In both the 
sulfonylurea and metformin samples, the youngest of the three age groups 
most frequently changed dose or type of drug dispensed, and the oldest age 
group least frequently experienced a change dose or type of drug dispensed. 
A possible explanation for the less frequent changes in drug dose among in 
older patients is that perhaps these patients are receiving a maximum dose of 
medication, a result of having diabetes for a longer duration. Betz-Brown et al. 
found that prescribers may tend to continue sulfonylurea therapies despite 
evidence that these agents are failing (45). The less frequent change in type of 
drug prescribed among older patients may be the result of avoidance of newer 
medications in older patients. For instance, troglitazone may have been 
avoided in older patients due to concerns of increased risk of hepatic toxicity in 
such patients . Another possible explanation for the more frequent changes in 
dose or type of drug dispensed in younger diabetics is increased attention to 
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achieving tight glucose control in younger patients, since these patients have a 
greater number of years in which to develop diabetic complications. 
Both in bivariate and multivariate analyses that included other potential 
confounding variables, an MPR < 8:10 was found to be an influence on the 
outcomes of change of sulfonylurea dose. An MPR < 8: 1 O increased the risk 
of experiencing a change in dose by 50% in a bivariate model , and by 43% 
when controlling for patient age. Of patients in the metformin sample, those 
having an MPR < 8:10 were 40% more likely to experience a change in 
medication dose. However, this finding was not statistically significant, 
perhaps due to the smaller number of patients in this sample. Using a 
population that included patients from both the sulfonylurea and metformin 
samples, multivariate analyses demonstrated that an MPR < 8:10 was 
associated with an increased risk for experiencing a change in medication 
dose (OR 1.36; 95% Cl 1.02 - 1.83). 
Of all patients included in this study, those who did not possess enough 
medication to be adherent for at least 80% of days were 36% more likely to be 
prescribed an increased amount of medication. This percentage increased to 
43% in analyses that included only those prescribed sulfonylurea 
monotherapy. The implications of this finding are uncertain. However, it is 
likely that the prescribing of a greater amount of sulfonylurea drug may place 
poorly adherent patients at an increased risk for hypoglycemic events. 
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Perhaps most importantly, a change in dose of hypoglycemic medication 
cannot be expected to induce an improvement in blood glucose control in 
patients that are non-adherent. Such patients may likely continue to be poorly 
controlled, and be at greater risk for diabetic complications. 
Multivariate analyses: Change in type of hypoglycemic medication 
dispensed 
Among patients in the sulfonylurea sample, only age was found to be 
significantly associated with experiencing a change in medication dispensed. 
Patients 65 years of age and older were 48% less likely to receive a different 
type of hypoglycemic medication than those under 50 years of age. In the 
metformin sample, age was not a significant influence on experiencing a 
change in type of drug dispensed. We examined the effect of age in a 
population that included patients from both the sulfonylurea and metformin 
samples. In this population , older age was again found to be an influence on 
change in type of drug dispensed. Patients 65 years of age or older were 45% 
less likely to experience a change in type of medication dispensed. The lesser 
frequency of change in type of medication dispensed among older patients 
may reflect an increased prevalence of co-morbidities within this age group. 
For example, many patients experiencing secondary failure of sulfonylurea 
therapy can regain blood glucose control through the addition of metformin. 
However, metformin is contraindicated in patients with heart failure or renal 
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disease. Additionally, patients with hepatic dysfunction would not be 
appropriate candidates for troglitazone therapy; which was commonly 
prescribed during the study period . 
For the combined population that included those in the sulfonylurea and 
metformin samples, we also conducted multivariate analyses assessing the 
influence of the MPR on the combined outcome of either a change in dose or 
change in type of medication dispensed. In these models, an MPR < 8:10 was 
found to be of significant influence, increasing the risk of the combined 
outcome by 41 % in a model that controlled for age. However, this result 
should be interpreted with caution . Though an MPR < 8:10 increased risk for 
a change in dose or change in type of drug dispensed, a direct influence of the 
MPR on change in type of drug dispensed was not detected in separate 
analyses. Thus, the influence of the MPR on the combined outcome appears 
to be largely due to the relation between the MPR and the outcome of change 
in dose. 
We did not find gender, insurance type, or the total number of prescriptions 
dispensed to be associated with change in dose, change in drug dispensed, or 
a combined outcome of either change in dose or change in drug dispensed. 
Thus, we did not include these factors in final multivariate logistic models. 
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This study was conducted solely through the use of pharmacy claims data. 
Such data is useful for assessing adherence with drug therapy (46), though 
the use of multiple pharmacies may contribute to misclassification when 
dispensings of medication are not captured. An advantageous feature of these 
data was that patients were assigned to the pharmacies from which the data 
was generated . Thus , misclassification of non-adherence may have been 
minimized since patients were not reimbursed for prescriptions dispensed by 
other pharmacies. The large number of records available for review is also a 
strength of this study. We identified 967 patients receiving therapy with a 
sulfonylurea which were eligible for inclusion for study. Though the number of 
patients receiving metformin monotherapy was less, we felt it useful to include 
this population for comparison with the sulfonylurea group, since this drug is 
also frequently prescribed. 
There were several important limitations to this study. Perhaps most 
importantly, this study evaluated a small number of potential influences of a 
change in dose or change in type of hypoglycemic medication dispensed. The 
factor of interest was medication possession , which has been used by various 
researchers to classify adherence. However, medication possession is only 
one of several potential determinants of medication adherence. Patients may 
possess medications yet take them incorrectly or sporadically. Certainly 
however, patients must possess medication in order to take them as 
prescribed. Thus, the medication possession ratio represents a potentially 
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useful 'first order' measure of medication adherence. However, the impact of 
various behavioral, clinical , social , and demographic factors on adherence was 
not assessed . 
The method used for determination of the medication possession ratio may 
have also been a limitation. We chose to limit the sample to patients that had 
received at least 12 months of hypoglycemic therapy. To allow sufficient time 
to determine if a dose of medication changed or a new type of drug was 
prescribed following a period of stability, we used only a four-month period to 
calculate the MPR. It is possible that a longer period would have resulted in a 
different percent of patients classified as having an MPR < 8:1 O; and such 
difference may have generated different results. Adherence assessments in 
diabetes have used longer periods than we have used in this study (22, 43, 
44). Additionally, a minimum MPR threshold of 8:10 may have been to low for 
classifying adherence in this population. A higher threshold may have been 
more appropriate in consideration of the degree of adherence necessary to 
achieve tight glycemic control. 
Also, we may have been incorrect in our assumption that a change in dose or 
a change in type of medication dispensed reflected unstable glucose control. 
For instance, some patients identified as experiencing a change in dose of 
hypoglycemic medication may have been new diabetics being titrated to their 
medication. Also, factors such as allergies or intolerances may have been a 
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cause for change in medication type dispensed, and not necessarily poor 
blood glucose control. However, it seems improbable that new diabetics 
accounted for the majority of the 59% of patients in the sulfonylurea sample 
and the 48% of patients in the metformin sample that were identified as having 
a change in dose. Likewise, allergy or intolerance to a medication would 
presumably not account for the majority of the 27% of sulfonylurea users that 
were dispensed a different type of hypoglycemic medication, especially given 
the high degree of tolerance ascribed to sulfonylureas (47). However, 
metformin may cause side effects such as abdominal discomfort and diarrhea 
in as many as 30% of patients (48). It is possible that a proportion of 
metformin users who received a different type hypoglycemic medication were 
intolerant of metformin, and not necessarily poorly controlled. However, the 
number of such patients is likely to be small , since metformin intolerance 
usually appears early in therapy. Study patients received at least four months 
of therapy without a change in dose or drug. 
The lack of availability of other data sources was also limiting. Medical data 
would have been useful for categorizing disease severity and duration, and for 
identifying relevant co-morbidities. For example, medical information would 
have been of use in determining if duration of disease was a contributing 
factor to the difference in frequency of dose change and change in type of 
drug dispensed among age groups. Laboratory data would have been useful 
in determining blood glucose control and its correlation with adherence to drug 
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therapy. Such information could have been used to validate the conceptual 
model presented in Figure 1. Last, information regarding prescription co-
payment would have been of use, given evidence that acquisition costs affect 
medication purchase. 
Despite these limitations, we feel that this study provides evidence to support 
the hypothesis that poor adherence leads to greater instability; in this case 
manifested as a change in medication dosage, or in the combined outcome of 
change in medication dose or type of medication dispensed. 
Lack of adherence to prescribed drug therapy is an acknowledged problem. 
This problem can be complicated by a patient's lack of awareness of an 
adherence problem, or a lack of truthfulness in describing medication-taking 
behavior to the physician (49). The result of poor adherence with therapies for 
controlling blood glucose can have adverse consequences. Prescribers that 
increase the amount of medication prescribed to a poorly adherent diabetic 
patient may cause great risk of inducing dangerous hypoglycemic reactions. 
Further, the incidence of microvascular, and perhaps macrovascular 
complications will be increased in patients with adherence problems and 
corresponding poor glucose control. 
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CONCLUSION 
Non-adherence with prescribed sulfonylurea regimens, as measured by 
possession of medication less than 80 percent of days, increases the 
likelihood that prescribed hypoglycemic therapy will be changed by 43 to 50%. 
Such change in therapy, presumably a response to poor blood glucose 
control , fails to address the underlying cause of poor glucose control, and may 
potentially cause dangerous hypoglycemic reactions. Increased awareness of 
non-adherence with prescribed medications as a cause of inadequate blood 
glucose control is necessary. Further, interventions aimed at improving 
adherence should be increasingly examined as a potential effective means to 
improve diabetes care. 
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Figure 1. Conceptual Model: Non-adherence, Poor Glucose Control , and 
Drug Therapy 
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Figure 2. Research Methodology: Identification of Users of Sulfonylurea 
or Metformin Mono-therapy and Determination of Non-adherence 
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Determine the number of days between the first and last dispensing of sulfonylurea 
or metformin during the 120-day period (A). 
Determine the days supply of medication received for all dispensings 
preceding the last dispensing of the 120-day period (B) 
Calculate the Medication Possession Ratio (MPR): 
MPR= B: A 
Research questions: 
Is MPR < 8:10 associated with a dose change in the 8 months following first 120 days? 
Is MPR < 8:10 associated with a medication change in the 8 months following first 120 days? 
Is MPR < 8:10 associated with a dose change or a medication change in the 8 months following first 120 
days? 
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Table 1. Univariate Analyses: Patients Receiving Sulfonylurea or 
Metformin Mono-Therapy 
Sulfonylurea (N = 967) Metformin (N = 166) 
n % n % 
Gender 
Male 572 59.2 85 51.2 
Female 395 40.8 81 48 .8 
Age 
under50 229 23 .7 55 33.1 
50-64 442 45.7 81 48.8 
65 or older 296 30.6 30 18.1 
Insurance 
Plan A 315 32.6 53 32.0 
Plan B 527 54.5 95 57.2 
Other 125 12.9 18 10.8 
Number of Rx 
Dispensed 
under5 151 15.6 31 18.7 
5-15 550 56.9 95 57.2 
over15 266 27 .5 40 24.1 
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Table 2. Medication Possession Among Patients Dispensed Only a 
Sulfonylurea or Only Metformin 
Medication 
Possession 
Ratio (MPR) 
~8:10 
~9:10 
Mean MPR 
Sulfonylurea (N = 967) 
n 
747 
646 
% 
77.2 
66.8 
91.0 
92 
Metformin (N = 166) 
n 
118 
94 
% 
71 .1 
56 .6 
86.6 
Table 3: Bivariate Analyses: Medication Possession Ratio (MPR) and 
Gender, Age Category, Insurance Type, and Number of Prescriptions 
Dispensed 
All subjects 
Gender 
Male 
Female 
Age 
Under 50 
50-64 
65 or older 
Insurance 
Plan A 
Plan B 
Other 
Number of Rx dispensed 
<5 
5-15 
> 15 
. p < 0.05, x2 
•• p < 0.01, x, 
MPR < 8:10 
Sulfonylurea users 
n = 967 
% 
22.75 
22.72 
22.78 
33.19** 
19.46** 
19.59** 
24.80 
20.95 
23.34 
41 .72** 
22.00·· 
13.53** 
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MPR < 8:10 
Metformin users 
n = 166 
% 
28.92 
29.41 
28.40 
36.36 
27.16 
20.00 
33.33 
32.08 
26.32 
45.16 
26.32 
22.50 
Table 4a. Bivariate Analyses of Proportions: Sulfonylurea Sample 
Change of 
Change of Change of Drug 
Dose Drug or Dose 
% % % 
All subjects 
(N = 967) 58.53 26.78 62.67 
Gender 
Male 59.01 25.70 62.59 
Female 59.35 28.35 62.78 
Age 
Under 50 65.94** 29.26 .. 69.43* 
50-64 58 .82 31 .67 .. 62 .90 
65 or older 52.36 .. 17.57 .. 57.09* 
Insurance 
Plan A 62.40 24.00 68 .00 
Plan B 55.87 24.13 59.05 
Other 59.20 29.03 63.57 
Number of Rx 
dispensed 
<5 64.24 29.80 69 .54 
5-15 56.36 25.27 60.18 
>15 59.77 28.20 63.91 
Medication 
Possession 
Ratio 
< 8:10 25.62* 23.55 70.45 .. 
< 9:10 18.70* 22.46 60 .37 .. 
. p < 0.05 
•• p < 0.01 
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Table 4b. Bivariate Analyses of Proportions: Metformin 
n = 166 Change 
Change of Change of of Drug 
Dose Drug or Dose 
% % % 
All subjects 
(N = 166) 48.19 18.07 51 .81 
Gender 
Male 53.75 22.35 55.29 
Female 48.84 13.58 48 .15 
Age 
Under 50 54.55 23.64 58 .18 
50-64 46.91 13.58 49.38 
65 or older 40.00 20.00 46.67 
Insurance 
Plan A 38.89 11 .11 38.89 
Plan B 50.94 18.87 56.60 
Other 48.42 18.95 51 .58 
Number of Rx 
dispensed 
<5 58.06 16.13 61.29 
5-15 45.26 17.89 47 .37 
>15 47.50 20.00 55.00 
Medication 
Possession 
Ratio 
< 8:10 32 .50 30 .00 56 .25 
< 9:10 25.58 28.68 50.00 
No significant differences among proportions 
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Table Sa. Bivariate Logistic Regression Analysis, Sulfonylurea Sample: 
Dose Change 
[), OR Cl low Cl high Pr > X2 
MPR < 8:10 .404 1.497 1.094 2.049 .0118 
Age 
Under 50* 1.0 
50-65 -.304 .738 .529 1.029 .0733 
65 + -.566 .568 .398 .811 .0018 
Male gender -.141 .986 .760 1.293 .9154 
Number of 
dispensings 
<5 1.0 
5-15 -.330 .719 .495 1.044 .8310 
> 15 -.190 .827 .547 1.251 .3684 
Insurance 
Plan A 1.0 
Plan B .137 1.146 .864 1.520 .3436 
Other insurance .271 1.314 .857 2.004 .2119 
96 
Table Sb. Bivariate Analyses of Metformin Sample: Change in Dose 
r., OR Cl low Cl high Pr > X2 
MPR< .80 .337 1.401 .714 2.747 .3268 
Age 
Under 50* 
50-65 -.306 .736 .370 1.464 .3828 
65 + -.588 .556 .225 1.370 .2020 
Male gender .197 1.218 .662 2.240 .5271 
Number of 
Dispensings 
<5 1.0 
5-15 -.516 .597 .263 1.356 .2178 
> 15 -.426 .653 .254 1.682 .3778 
Insurance 
Plan A 1.0 
Plan B -.101 .904 .462 1.771 .7686 
Other insurance -.490 .613 .206 1.823 .3785 
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Table 6a. Bivariate Analyses of Sulfonylurea Sample: Change in Drug 
Dispensed 
I). OR Cl low Cl high Pr> X2 
MPR < 8:10 0.062 1.064 .759 1.490 .7192 
Age 
Under 50* 1.0 
50-65 .114 1.121 .791 1.588 .5206 
65 + -.663 .515 .341 .779 .0017 
Male gender -.135 .874 .655 1.166 .3596 
Number of 
dispensings 
<5 
5-15 -.227 .797 .535 1.186 .2632 
> 15 -.078 .925 .596 1.435 .7278 
Insurance 
Plan A 1.0 
Plan B .252 1.286 .935 1.771 .1221 
Other insurance -.007 .993 .612 1.613 .9776 
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Table 6b. Bivariate Analyses of Metformin Sample: Change in Drug 
Dispensed 
f), OR Cl low Cl high Pr > 
xz 
MPR < 8:10 .064 1.066 .449 2.531 .8849 
Age 
Under 50* 1.0 
50-65 -.678 .508 .209 1.236 .1352 
65 + -.214 .808 .272 2.401 .7009 
Male gender .605 1.832 .811 4.139 .1 455 
Number of 
dispensings 
<5 1.0 
5-15 .125 1.133 .380 3.376 .8222 
> 15 .262 1.300 .379 4.454 .6762 
Insurance 
Plan A 1.0 
Plan B .005 1.005 .426 2.372 .9906 
Other insurance -.622 0.538 .106 2.724 .4534 
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Table 7: Chunk Test for Interactions 
-21og statistic -21og x2 dr=1: 
DV difference 14.07 
Dose Change EV + V's• 1288.97 
v ·s• 1293.35 4.38 NS 
SFU Drug Change EV + V's• 1094.38 
V's• 1099.1 0 4.73 NS 
Dose or EV+ V's• 1252.29 
Drug Change V's• 1256.71 4.42 NS 
Dose Change EV + V's• 213.28 
v·s· 223.98 10.70 NS 
MET Drug Change EV + V's• 145.23 
V's• 150.50 5.27 NS 
Dose or EV + V's• 213.54 
Drug Change V's• 221.79 8.24 NS 
Dose Change EV+ V's• 1520.58 
V's• 1529.19 8.62 NS 
SFU Drug Change EV+ v·s· 1260.95 
or 
MET v·s• 1267.154 6.20 NS 
Dose or EV + V's• 1487.08 
Drug Change V's only• 1494.36 7.28 NS 
SFU = sulfonylurea sample 
MET = metformin sample 
• EV= Interaction terms; V =Lower order terms (independent variables) 
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Table Ba. Multivariate Logistic Models of Sulfonylurea Sample: Change in 
Dose 
All Independent Variables 
Beta OR se Cl low Cl High Pr >X2 
MPR < 8:10 0.3485 1.4169 0.1655 1.0244 1.9599 0.0353 
Age 
under50 1.0 
50-64 -0.2529 0.7765 0.1735 0.5527 1.0911 0.1449 
65+ -0.5283 0.5896 0.1855 0.4099 0.8481 0.0044 
Male Gender -0.0039 0.9961 0.1356 0.7636 1.2994 0.977 
Insurance 
Plan A 1.0 
Plan B 0.1121 1.1186 0.1457 0.8407 1.4884 0.4416 
Other 0.2584 1.2949 0.2196 0.8420 1.9914 0.2393 
Total 
Dispensings 
0-4 1.0 
5-15 -0.2086 0.8117 0.1960 0.5528 1.1919 0.2871 
16+ 0.0055 1.0056 0.2214 0.6516 1.5519 0.9801 
Final Model 
Beta OR se Cl low Cl High Pr>X2 
MPR < 8:10 0.3569 1.4289 0.1622 1.0398 1.9637 0.0277 
Age 
under50 1.0 
50-64 -0 .2575 0.7730 0.1713 0.5525 1.0814 0.1328 
65+ -0.5212 0.5938 0.1831 0.4148 0.8502 0.0044 
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Table 8b. Multivariate Logistic Models of Sulfonylurea Sample: Change 
in Drug Dispensed 
All Independent Variables 
Beta OR se Cl low Cl High Pr> X2 
MPR < 8:10 0.0236 1.0239 0.1793 0.7205 1.4550 0.8953 
Age 
under50 1.0 
50-64 0.1256 1.1 338 0.1821 0.7935 1.6201 0.4904 
65+ -0.6453 0.5245 0.2148 0.3443 0.7991 0.0027 
Male Gender -0.1077 0.8979 0.1507 0.6683 1.2064 0.4748 
Insurance 
Plan A 1.0 
Plan B 0.2372 1.2677 0.1653 0.9169 1.7528 0.1513 
Other 0.0161 1.0162 0.251 0.6214 1.6621 0.9489 
Dispensings 
0-4 1.0 
5-15 -0.2264 0.7974 0.2101 0.5282 1.2037 0.2811 
16+ -0.0562 0.9454 0.2377 0.5933 1.5064 0.8131 
Final Model 
Beta OR se Cl low Cl High Pr >X2 
Age 
under50 1.0 
50-64 0.1141 1.1209 0.1776 0.7914 1.5876 0.5206 
65+ -0.6631 0.5153 0.2108 0.3409 0.7789 0.0017 
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Table Sc. Multivariate Logistic Models of Sulfonylurea Sample: Change in 
Dose or Change in Drug Dispensed 
All Independent Variables 
Beta OR se Cl low Cl High Pr> X2 
MPR < 8:10 0.3861 1.4712 0.171 1.0523 2.0570 0.0239 
Age 
under50 1.0 
50-64 -0.2256 0.7980 0.1781 0.5629 1.1314 0.2052 
65+ -0.4852 0.6156 0.1896 0.4245 0.8926 0.0105 
Male Gender 0.0036 1.0035 0.1382 0.7654 1.3158 0.9796 
Insurance 
Plan A 1.0 
Plan B 0.1694 1.1846 0.1478 0.8867 1.5826 0.2516 
Other 0.3732 1.4524 0.2263 0.9321 2.2631 0.0991 
Dispensings 
0-4 1.0 
5-15 -0 .2851 0.7520 0.2028 0.5054 1.1191 0.1598 
16+ -0.0520 0.9493 0.2286 0.6065 1.4860 0.8199 
Final Model 
Beta OR se Cl low Cl High Pr> X2 
MPR 0.4046 1.4987 0.1674 1.0795 2.0807 0.0157 
Age 
under50 1.0 
50-64 -0.2406 0.7862 0.1757 0.5571 1.1093 0.171 
65+ -0.4846 0.6159 0.187 0.4269 0.8886 0.0095 
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Table 9a. Multivariate Logistic Models of Metformin Sample: Change in 
Dose 
All Independent Variables 
Beta OR se Cl low Cl High Pr> X2 
MPR < 8:10 0.2252 1.2526 0.3564 0.6229 2.5187 0.5274 
Age 
under50 1.0 
50-64 -0.3241 0.7232 0.3604 0.3568 1.4656 0.3685 
65+ -0 .6631 0.5153 0.4976 0.1943 1.3664 0.1827 
Male Gender 0.1763 1.1928 0.3232 0.6331 2.2474 0.5853 
Insurance 
Plan A 1.0 
Plan B -0.0468 0.9543 0.3593 0.4719 1.9298 0.8964 
Other -0 .738 0.4781 0.5839 0.1522 1.5015 0.2063 
Dispensings 
0-4 1.0 
5-15 -0 .6359 0.5295 0.4617 0.2142 1.3087 0.1684 
16+ -0 .3006 0.7404 0.513 0.2709 2.0236 0.5578 
No significant terms 
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Table 9b. Multivariate Logistic Models of Metformin Sample: Change in Drug 
Dispensed 
All Independent Variables 
Beta OR se Cl low Cl High Pr > X2 
MPR < 8:10 0.0461 1 0471 0.46 19 0.4234 2.5891 0.9206 
Age 
under50 1.0 
50-64 -0.7268 0.4835 0.4639 0.1947 1.2001 0.1172 
65+ -0.2083 0.8120 0.6069 0.2471 2.6677 0.7314 
Male Gender 0.6746 1.9632 0.4251 0.8533 4.5168 0. 1125 
Dispensings 
0-4 1.0 
5-15 0.2825 1.3264 0.5784 0.4269 4.1213 0.6252 
16+ 0.4662 1.5939 0.665 0.4329 5.8685 0.4833 
No significant terms 
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Table 9c. Multivariate Logistic Models of Metformin Sample: Change in 
Dose or Change in Drug Dispensed 
All Independent Va riables 
Beta OR se Cl low Cl High Pr > X2 
MPR < 8:10 0.1441 1.155 0.3608 0.5695 2.3426 0.6895 
Age 
under50 1.0 
50-64 -0.4277 0.652007 0.3659 0.3183 1.3357 0.2425 
65+ -0.6356 0.529618 0.4999 0.1988 1.4109 0.2036 
Male Gender 0.3149 1.370122 0.3258 0.7235 2.5947 0.3336 
Insurance 
Plan A 1.0 
Plan B -0.1544 0.856929 0.3634 0.4204 1.7469 0.6709 
Other -1.0509 0.349623 0.5875 0.1105 1.1058 0.0737 
Dispensings 
0-4 1.0 
5-15 -0 .0706 0.931835 0.4704 0.3706 2.3429 0.1326 
16+ -0 .1438 0.866061 0.5227 0.3109 2.4126 0.7832 
No significant terms 
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Table 10a. Multivariate Logistic Models of Population of Combined 
Sulfonylurea and Metformin Samples: Change in Dose 
All Independent Variables 
Beta OR se Cl low Cl High Pr >X2 
MPR < 8:10 0.3102 1.3637 0.1489 1.0185 1.8258 0.0372 
Age 
under50 1.0 
50-64 -0 .2368 0.7891 0.1549 0.5825 1.0691 0.1264 
65+ -0.4821 0.6175 0.1697 0.4428 0.8611 0.0045 
Male Gender 0.0356 1.0362 0.1236 0.8133 1.3203 0.7736 
Insurance 
Plan A 1.0 
Plan B 0.0838 1.0874 0.134 0.8362 1.4140 0.5319 
Other 0.1523 1.1645 0.2024 0.7832 1.7315 0.4517 
Dispensings 
0-4 1.0 
5-15 -0.2505 0.7784 0.1779 0.5493 1.1032 0.1591 
16+ -0.0311 0.9694 0.2017 0.6528 1.4394 0.8776 
Final Model 
Beta OR se Cl low Cl High Pr>X2 
MPR < 8:10 0.3239 1.3825 0.146 1.0385 1.8405 0.0265 
Age 
under50 1.0 
50-64 -0.2421 0.7850 0.1531 0.5815 1.0597 0.1139 
65+ -0.4717 0.6239 0.1672 0.4496 0.8659 0.0048 
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Table 10b. Multivariate Logistic Models of Population of Combined 
Sulfonylurea and Metformin Samples: Change in Drug Dispensed 
All Independent Variables 
Beta OR se Cl low Cl High Pr> X2 
MPR < 8:10 0.0077 1.0077 0.1654 0.7287 1.3936 0.9628 
Age 
under50 1.0 
50-64 0.0351 1.0356 0.1672 0.7462 1.4372 0.8341 
65+ -0 .5959 0.5511 0.2001 0.3723 0.8157 0.0029 
Male Gender -0 .0111 0.9890 0.1406 0.7508 1.3027 0.9373 
Insurance 
Plan A 1.0 
Plan B 0.2098 1.2334 0.154 0.9121 1.6680 0.1732 
Other -0 .0385 0.9622 0.238 0.6035 1.5342 0.8714 
Dispensings 
0-4 1.0 
5-15 -0.1818 0.8338 0.1958 0.5680 1.2238 0.3531 
16+ 0.0279 1.0283 0.2216 0.6660 1.5876 0.9001 
Final Model 
Beta OR se Cl low Cl High Pr> X2 
Age 
under50 1.0 
50-64 0.0345 1.0351 0.1634 0.7514 1.4258 0.8329 
65+ -0 .5945 0.5518 0.1959 0.3759 0.8101 0.0024 
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Table 10c. Multivariate Logistic Models of Population of Combined 
Sulfonylurea and Metformin Samples: Change in Dose or Change in Drug 
Dispensed 
All Independent Variables 
Beta OR se Cl low Cl High Pr>X2 
MPR < 8:10 0.3255 1.3847 0.1526 1.0268 1.8675 0.0329 
Age 
under50 1.0 
50-64 -0 .2277 0.7964 0.1583 0.5839 1.0861 0.1504 
65+ -0.4374 0.6457 0.1727 0.4603 0.9058 0.0113 
Male Gender 0.0575 1.0592 0.1255 0.8282 1.3546 0.6468 
Insurance 
Plan A 1.0 
Plan B 0.1185 1.1258 0.1357 0.8629 1.4688 0.3829 
Other 0.2116 1.2357 0.2067 0.8240 1.8529 0.3058 
Dispens ings 
0-4 1.0 
5-15 -0 .3211 0.7254 0.183 0.5068 1.0384 0.0793 
16+ -0 .0563 0.9453 0.2072 0.6298 1.4188 0.7858 
Final Model 
Beta OR se Cl low Cl High Pr> X2 
MPR < 8:10 0.3444 1.4111 0.1496 1.0525 1.8920 0.0213 
Age 
under50 1.0 
50-64 -0.2377 0.7884 0.1564 0.5803 1.0713 0.1285 
65+ -0.4275 0.6521 0.1701 0.4672 0.9102 0.0120 
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Adherence to Hypoglycemic Therapy Among Patients Prescribed 
Monotherapy with a Sulfonylurea or Metformin, and Dual Therapy With 
Both Agents 
ABSTRACT 
Background Adherence to prescribed drug therapies for chronic 
conditions is known to be poor. Lack of optimal adherence to drug therapies 
for diabetes is particularly problematic, since poor glucose control has been 
associated with an increased risk of certain types of diabetic complications. 
Objective To determine if diabetic patients prescribed dual therapy with 
both a sulfonylurea and metformin as separate prescriptions are more likely to 
be nonadherent than patients receiving monotherapy with either agent. 
Methods A cross-sectional study examining retail pharmacy dispensings 
to diabetic patients receiving oral hypoglycemic therapy. Patients receiving 
monotherapy with either a sulfonylurea or metformin and patients receiving 
dual therapy with both drugs were identified. The medication possession ratio 
(MPR) was used to assess adherence , as the days supply of all hypoglycemic 
medication dispensed to the number of days between first and last 
dispensings. The influence of the type of therapy prescribed (dual or 
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monotherapy) on medication possession was assessed . Other factors 
investigated as potential influences of medication possession included age, 
gender, insurance plan associated with the dispensing, the total number of 
dispensings, and dispensings for selected anti-depressant medications. 
Multivariate logistic regression was used estimate the likelihood of 
nonadherence among those receiving dual therapy, and controlling for 
potential confounding variables. 
Results Overall, 71 % of patients possessed medication for at least 80% 
of days during the assessment period, and 59% of patients possessed 
medication for at least 90% of days. Patients who received only dispensings 
for a sulfonylurea were most frequently in possession of medication (MPR ;;;:: 
8:10: 77%, MPR ;;::9:10: 67%). Patients who received dispensings only for 
metformin were less frequently in possession of medication for at least 80% 
and 90% of days (MPR ;;::8 :10: 71%, MPR ;;::9: 10: 67%). Medication 
possession was lowest among patients receiving dispensings for both a 
sulfonylurea and metformin, with 57% of such patients possessing medication 
for at least 80% of days, and 43% of such patients possessing medication for 
at least 90% of days. Using multivariate logistic models controlling for the 
effects of age and the number of dispensings, we determined that patients 
receiving dual therapy with a sulfonylurea and metformin were more than 3 
times more likely to fail to possess medication for at least 80% of days (OR 
3.14, 95% Cl 2.42 - 4.08) or 90% of days (OR 3.20, 95% Cl 2.49 - 4.11 ). 
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Conclusions As determined using the medication possession ratio , 
adherence to oral hypoglycemic drug therapies was frequently sub-optimal. 
Patients that possessed medication for less than 80% of days were likely not 
achieving tight control of blood glucose. Adherence was poorest among those 
receiving the combination of a sulfonylurea plus metformin. 
The success of intensive therapy in tightly controlling the blood glucose level is 
contingent upon patient behavior. Though perhaps difficult to predict, 
adherence can be assessed. Diabetes management strategies should include 
the assessment of adherence with prescribed hypoglycemic drug regimens, 
and the application of interventions designed to improve adherence. 
Additionally, the complexity of the drug reg imen should be considered as a 
potential barrier to optimal adherence. 
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INTRODUCTION 
Non-adherence to prescribed drug regimens is a primary cause of sub-optimal 
health outcomes. Despite the efforts of prescribers and pharmacists, as 
many as one-half of patients or more will not achieve the full benefit of 
prescribed medications due to problems with adhering to therapy (1, 2). 
Various types of interventions intended to improve adherence rates have been 
studied. However, research has not uncovered any specific intervention that 
effectively improves adherence to the degree where the full benefit of therapy 
is realized (3-5). The utility of such interventions ultimately depends upon the 
ability of health care providers to identify non-adherence with treatment 
regimens and , most importantly, depends upon characteristics of individual 
patients (6). 
Further complicating the picture, despite greater than two decades of study 
regarding adherence with prescribed therapies, researchers have been mostly 
unable to consistently demonstrate associations between the behavior of 
adherence and various potential predictive factors (7). For example , some 
researchers have reported an association between adherence with prescribed 
therapies and age (8, 9), gender (9, 10), and race (11, 12), though others have 
not (13 , 14). Beyond such patient-specific factors , researchers have 
attempted to understand and describe the underlying psychological 
determinants of adherence. Models borrowed from the psychological sciences 
have been used to characterize and predict the behavior of adherence with 
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some success. For example, the health belief (15), self-efficacy (16), and 
stages-of-change models (17) have all been shown to be useful in explaining 
adherence to drug therapy. 
Factors specific to the drug regimen prescribed have also been examined as 
potential influences of adherence to therapy. Regimens having increased 
complexity and greater behavioral demand have been shown to be associated 
with decreased adherence (18, 19). The number of drugs prescribed and 
number of required daily dosages have been shown to be associated with 
adherence, with the probability of non-adherence increasing in patients 
prescribed multiple medications and receiving divided daily doses (20, 21 ). 
This phenomenon has been perhaps best demonstrated in studies of patients 
treated for hypertension (22-24) and human immunodeficiency virus infection 
(25). The cost of and access to medications may also be important barriers to 
adherence for some patients. 
Adherence to drug therapies prescribed for diabetes is particularly important. 
Hypoglycemic therapy is essential for preventing acute complications resulting 
from elevated blood glucose, such as the nonketotic hyperosmolar state. 
Additionally, tight control of blood glucose has been demonstrated to reduce 
the incidence of several types of chronic diabetic complications (26-28). For 
the majority of diabetic patients, such tight control of blood sugar can only be 
achieved through rigid adherence to the prescribed hypoglycemic drug 
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regimen. Poor adherence to prescribed drug regimens would expectedly 
result in sub-optimal blood glucose control, as demonstrated by Kavanagh et 
al (29). In the longer term, patients that do not adhere to hypoglycemic drug 
regimens are at increased risk for developing complications such as blindness, 
neuropathy, and kidney disease. 
In this study, we sought to determine if the complexity of the drug regimen was 
an influence of adherence to therapy. Specifically, we hypothesized that 
diabetic patients would be less likely to adhere to regimens that utilized two 
drugs as compared with regimens consisting of a single hypoglycemic agent. 
To test this hypothesis, we used pharmacy data to assess hypoglycemic drug 
utilization among patients receiving dispensings for a sulfonylurea, metformin, 
or both of these agents together but as separate tablets. 
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METHODS 
Population 
We conducted a cross-sectional study using data provided by Consumer 
Value Stores, Inc (CVS). The data included over one-quarter million 
dispensings to 5056 diabetic patients between April 1997 and May 1999. 
Most patients included in this population were enrollees of one of two area 
health plans, and were participants in a special managed care program in 
diabetes. Patients were restricted to designated CVS pharmacies for their 
pharmacy services, and all dispensings from these pharmacies were included 
in the data provided for research . The restriction of patients to these 
designated pharmacies was deemed an advantageous feature, potentially 
resulting in a more complete representation of pharmacy utilization and thus 
reducing the likelihood of misclassification of non-adherence. 
From the population of all patients included in the sample provided, we 
identified those that received a dispensing for any hypoglycemic medication 
during a 12-month period. Patients that did not receive dispensings for any 
class of hypoglycemic medication were not included in the sample. The 
hypoglycemic medication dispensed did not need to be the same throughout 
all 12 months. From those identified as receiving at least one hypoglycemic 
drug during a 12-month period , we selected patients that received either a 
sulfonylurea or metformin, or both during the first four months of this 12-month 
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period. Patients who received a hypoglycemic drug other than a sulfonylurea 
or metformin during this four-month period were excluded from the sample. 
Thus, the final sample included only patients that received dispensings for a 
sulfonylurea and/or metformin during a four-month period, and received some 
type of hypoglycemic medication throughout a 12-month period. Patients were 
classified by type of hypoglycemic drug regimen prescribed: either mono-
therapy with sulfonylurea or metformin, or dual therapy using both drugs. 
Calculating the medication possession ratio 
We used the medication possession ratio (MPR) as the measure of adherence 
with prescribed hypoglycemic drug therapy, defined as the number of days 
that a patient was in possession of medication. The use of the medication 
possession ratio for assessing adherence is described by Fairman and 
Motheral (30). 
To calculate the MPR, we determined the total days supply of medication 
received for all dispensings preceding the last dispensing of the four-month 
period . A ratio was created using the days supply of medication received and 
the number of days between the first and last dispensing during this four-
month period . For example, the MPR for a patient that received three 
dispensings of 30 tablets each (90 tablets) during a period of 113 days would 
be 90: 113, or roughly 8: 10. Patients who received only one dispensing during 
122 
the four-month period but who received medication in subsequent months 
were classified as non-adherent. There were 19 such patients (1 .1 %). 
We assessed adherence using MPR thresholds of 8:10 and 9:10. Non-
adherence was defined as failing to possess medication for at least 80% or 
90% of days in the period . For example, the patient that received 90 tablets in 
113 days would be classified as adherent using the 8:10 threshold , but 
classified as non-adherent using the 9:10 threshold . Results based upon 
these two MPR thresholds were presented separately. For patients dispensed 
both sulfonylurea and metformin as dual therapy, non-adherence was defined 
as failing to possess either medication for a number of days sufficient to cover 
eight of ten or nine of ten days in the period . Thus, patients prescribed both 
drugs must have adhered to both medications to be classified as adherent. 
The MPR threshold of 8: 10 has been used in previous studies. Some 
researchers have used a ratio of 8:10 , or 80% of days covered, in studies of 
adherence to other chronic therapies such as hormone-replacement therapy 
(31 ); hypertension (24, 32); and depression (33). Additionally, we also used 
second MPR threshold of 9:10 to define adherence based on estimates of 
what might be required to achieve tight glycemic control. 
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Potential confounding variables 
In addition to the type of hypoglycemic drug regimen prescribed , we assessed 
the influence of five other potential confounding factors that were derivable 
from the pharmacy data provided. Three of these variables , age, gender, and 
insurance type, were obtainable from the patient profile. We stratified age into 
three categories: < 50, 50-64, and 65 years of age or older; representing 
younger, middle-aged, and senior patients. Insurance type was also 
categorized into three types. Of all insurances associated with prescription 
refills, two area health plans accounted for nearly 90% of all dispensings. 
These two insurance types were classified as health plan A and health plan B. 
A third category of insurance type included patients whose prescription 
coverage was an insurance type other than health plan A or B, or patients that 
paid cash for all dispensings. In cases where more than one insurance type 
(or cash) was identified, the insurance type associated with the first non-cash 
dispensing was used . 
We also sought to examine the effect of the number of medications 
prescribed , hypothesizing that a greater number of prescriptions would be 
associated with a greater likelihood of non-adherence to therapy. For this 
variable, we determined the total number of dispensings during the four-month 
period , including medications for conditions other than diabetes. 
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DiMatteo et al found depression to be a risk factor for non-adherence with 
prescribed drug therapies (34). Thus, we also decided to include a fifth 
potential confounding variable representing patients who had received an anti-
depressant medication. We decided not to include patients receiving an 
tricyclic anti-depressant in our categorization method, since the popularity of 
these agents for use in depression is declining (35, 36) and these agents are 
used for conditions other than depression (37-41 ). Patients were considered 
to have depression if they received at least one dispensing for a medication 
presented in table1. 
Statistical methods 
Univariate statistics were used to determine the frequency and percentage of 
patients that received dispensings for a sulfonylurea, metformin, or both. The 
frequency and percentage of patients having a medication possession ratio 
percentage of at least 8:10 and 9:10 was determined, overall and for each 
type of regimen prescribed. The frequency and percentage of the potential 
confounding variables described above was also determined for each of the 
regimen types and overall. 
For initial evaluation, the total number of dispensings was categorized into 
three groups: less than 5 dispensings, 5-15 dispensings, and greater than 15 
dispensings. These three groupings reflected quartiles of the frequency 
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distribution for this variable, with the category of 5-15 dispensing representing 
a combination of the inner quartiles. 
For inclusion in logistic models, categories of the continuous variables age and 
total number of prescriptions dispensed were based upon association with 
medication possession, the dependent variable. Parametric form was 
assessed by plotting quartiles of the frequency distribution for these 
continuous variables with MPR thresholds of 8:10 and 9:10. The resulting 
strata for age and the dichotomization of the total number of dispensings 
reflect the results of this assessment. 
Chi-square analyses were used to assess bivariate relationships between 
proportions for all independent variables and the medication possession ratio. 
Bivariate logistic models were also constructed, with separate models 
assessed for each independent variable and the medication possession ratio. 
For the dependent variable of medication possession , ratio thresholds of 8:10 
and 9:10 were assessed. Multivariate statistics were used to identify the 
presence of collinearity between independent variables, to determine the 
presence of interactions between variables, and to assess the association 
between type of reg imen prescribed and medication possession, controlling for 
other potential confounding variables. Collinearity diagnostics were performed 
using the PROC REG procedure for multiple regression as suggested by 
Allison (42). Collinearity between independent variables was assessed 
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separately for MPR thresholds of 8:10 and 9:10. The presence of collinearity 
was determined using thresholds for condition index and proportion of shared 
variance as described by Tabachnick and Fidell (43). 
The likelihood ratio test was used to test for interaction between variables in 
multivariate logistic models , using the chunk test as described by Kleinbaum 
(44 ). For this procedure, we calculated the difference in the -21og statistic 
between full and reduced models. Full models included all possible interaction 
and single terms; reduced models included single terms only. The difference 
in -21og statistic between full and reduced models was tested for significance 
using the chi-square distribution with alpha .05, and with degrees of freedom 
equal to the difference in terms between the two models. A difference in -21og 
value that was less than the chi-square statistic was considered sufficient 
evidence that the model could not be better fit by including interaction between 
variables. 
Various multivariate models were assessed. Initial models contained all 
independent variables: non-significant terms were removed to create several 
other models. When non-significant terms were removed from models, we 
examined the magnitude of change in the parameter estimate beta and 
confidence interval for the variable regimen type (dual or monotherapy). The 
association between regimen type and medication possession is presented in 
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a summary table that presents the parameter estimate, standard error, odds 
ratio, and 95% confidence interval obtained for each model. 
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RESULTS 
A total of 1537 patients were identified as receiving dispensings for either a 
sulfonylurea, metformin, or both. Of these three types of hypoglycemic drug 
regimens, a majority of patients were classified as users of sulfonylurea only 
(n = 967; 63%). A total of 404 patients (26%) were determined to be users of 
both sulfonylurea and metformin. A lesser number of patients were classified 
as users of metformin only (n =166; 11 %). 
Table 2 presents the frequency and percentage of several characteristics the 
population, and within each regimen type. For all categories of drug therapy, 
patients were most frequently male and between the ages of 50-64. 
Approximately half of patients in each of the three regimen categories were 
between the ages of 50 and 64. More than half of patients in each among 
each regimen type were identified as having insurance plan B. Insurance 
types plan A and plan B accounted for 87-89% of all subjects. 
Patients dispensed only sulfonylureas were least frequently dispensed a 
medication for an anti-depressant (11 %), as compared to those receiving 
monotherapy with metformin (13%) or dual therapy with sulfonylurea plus 
metformin (16%). Of all patients studied , 13% received a dispensing for one 
of the antidepressant medications presented in figure 1. 
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The frequency and percent of patients possessing medication for at least 80% 
and 90% of days is presented in Table 3. Patients receiving dispensings for 
only a sulfonylurea were most frequently determined to have medication 
possession ratios greater then 8: 10 and 9: 10 (77% and 69% respectively) . 
Patients receiving dispensings for only metformin were less frequently 
identified as having an MPR above 0.80 and 0.90 (71 % and 57%). Patients 
dispensed both sulfonylurea and metformin were least frequently identified as 
having an MPR greater than 8:10 (57%) or 9:10 (43%). Overall, 71 % of 
patients possessed enough medication for 8 of 10 days, and 60% of patients 
possessed a quantity of medication sufficient to be able to adhere to therapy 
at least 90% of days. 
The relationship between medication possession and other potential 
confounding variables is presented in Tables 4a and 4b. For both users of 
only sulfonylureas and among the total sample, patients under 50 years of age 
were most frequently identified as having an MPR less than 8:10 or 9:10 (p < 
0.01 ). Among those dispensed both a sulfonylurea and metformin, those 
under 50 years of age were also more frequently categorized as having MPR 
less than 8:10 or 9:10, though this result was statistically significant only for 
the MPR threshold of less than 8:10 (p < 0.05). Subjects 65 years of age or 
older were least frequently identified as having an MPR less than 8:10 or 9:10 
(p < 0.01 ). The percentage of males and females having an MPR < 0.80 or 
0.90 did not differ significantly for any of the regimen types or overall. 
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Likewise, type of insurance did not differ significantly between groups for 
either MPR threshold. 
Patients receiving greater than 15 total dispensings were least frequently 
categorized as having an MPR less than 8:10 or 9:10, and those dispensed 
less than 5 prescriptions were most frequently categorized as not possessing 
a sufficient quantity of medication using either MPR threshold. These 
differences were statistically significant overall , and among the group of 
patients receiving dispensings for sulfonylurea only (p < 0.01 for each). The 
lesser number of patients in the metformin only and in the metformin plus 
sulfonylurea regimen categories likely affected the ability to detect a statically 
significant difference for these groups. 
Among patients dispensed sulfonylureas, those who received a dispensing for 
a medication for depression more frequently had an MPR less than 8:10 or 
9:10 (p < 0.05). The percentage of patients who were prescribed an anti-
depressant did not differ in statistical significance for other regimen categories 
or overall. 
To determine the appropriate form for inclusion into logistic models , the 
parametric form of the continuous variables age and number of dispensings 
was assessed. Age was relatively linearly related to the MPR, with the 
likelihood of being categorized as having an MPR less than 8:10 or 9:10 
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decreasing with advancing age. Age categories used for analyses were based 
upon the frequency distribution of ages and for ease in presentation and 
interpretation. We did not find the presence of a strong linear trend between 
the total number of dispensings and the MPR. However, patients receiving 12 
or more dispensings were less likely to be classified as having an MPR less 
than 8:10 or 9:10, while a total of less than 12 dispensings did not prove to be 
associated with the MPR. Thus, for use in logistic models, we dichotomized 
the total number of dispensings at 12 prescriptions. 
Tables 5a and 5b present the results of bivariate logistic models for each 
independent variable using MPR thresholds of 8:10 and 9:10. As compared 
with patients receiving dispensings for either a sulfonylurea or metformin only, 
those receiving dispensings for both drugs were more likely to be classified as 
having and MPR less than 8:10 (OR 2.4; 95% Cl 1.9 - 3.1) or less than 9:10 
(OR 2.49; 95% Cl 1.97 - 3.14 ). Age was also significantly associated with 
medication possession. As compared with patients less than 50 years of age, 
patients who were 50-65 years of age and 65 years or older were less likely to 
be classified with an MPR less than 8:10 (age 50-65 OR 0.55: 95% Cl 0.42 -
0.71; age 65 or older OR 0.48: 95% Cl 0.35 - 0.65), and less likely to be 
classified as having an MPR less than 9:10 (age 50-65 OR 0.60: 95% Cl 0.46 
- 0.76; age 65 or older OR 0.58: 95% Cl 0.44 - 0.76). The total number of 
dispensings was also associated with medication possession, as those 
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receiving 12 or more dispensings were less likely to have an MPR less than 
8:10 (OR 0.56: 95% Cl 0.45 - 0.71) or 9:10 (OR 0.57: 95% Cl 0.47 - 0.70). 
Receiving a dispensing for an anti-depressant medication increased the 
likelihood of being classified as having an MPR less than 8:10 or 9:10, though 
the association was not statistically significant (MPR < 8:10 OR 1.27: 95% Cl 
0.92 - 1.75; MPR < 9:10 OR 1.21 : 95% Cl 0.89 - 1.64). Gender and type of 
insurance did not appear to influence the likelihood of being classified as 
having an MPR less than 8:10 or 9:10 in bivariate logistic models. 
Multivariate logistic analyses were performed to control for potential 
confounding factors while assessing the association between type of regimen 
(one drug or two) and medication possession. The results of a multivariate 
model including all independent variables are presented in Table 7a (MPR 
less than 8:10) and Table 7b (MPR less than 9:10). Compared to those 
receiving dispensings for only a sulfonylurea or metformin, patients receiving 
dispensings for both a sulfonylurea and metformin (dual therapy) were more 
than three times as likely to be classified as having an MPR less than 8:10 
(MPR < 8: 10: OR 3.12, 95% Cl 2.40 - 4.06; MPR < 9: 10 OR 3.20 , 95% Cl 
2.49 - 4.12). In these models, age and more than 12 total dispensings were 
also shown to be associated with medication possession . Receiving a 
dispensing for an anti-depressant was a non-significant contributor to this 
model (MPR < 8:10: OR 1.36, 95% Cl 0.96 - 1.92; MPR < 9:10: OR 1.31, 95% 
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Cl 0.94 - 1.82). Gender and insurance type were not found to be associated 
with medication possession using either the 8:10 or 9:10 thresholds. 
Tables 8a and 8b present the results of multivariate models containing only 
the significant terms: regimen type, age category and total number of 
dispensings. Removing the non-significant variables (gender, insurance type, 
and received anti-depressant medication) resulted in little change in the 
likelihood of being categorized as having an MPR less than 8: 10 or 9:10 
among those prescribed dual therapy. It this model , patients who received 
dispensings for both a sulfonylurea and metformin remained more than 3 
times more likely to be classified as having an MPR less than 8:10 or 9:10. 
(MPR < 8:10: OR 3.14, 95% Cl 2.42 - 4.08; MPR < 9:10: OR 3.20, 95% Cl 
2.49 - 4.11 ). To assess the influence of the total number of dispensings, we 
included only the terms for regimen type and age category in another logistic 
model (Tables 9a and 9b). Without controlling for the number of prescriptions 
dispensed, patients receiving dispensings for both a sulfonylurea and 
metformin remained less likely to possess medication, though the effect was 
lessened as compared to models that included this factor (MPR < 8:10: OR 
2.47, 95% Cl 1.93-3.14; MPR < 9:10 OR 2.51, 95% Cl 1.99-3.18). In the 
models including only regimen type and age category, the effect of regimen 
type on medication possession was similar to what was found for the bivariate 
analyses presented in tables 5a and 5b. Parameter estimates (beta) for the 
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( regimen type and associated standard errors and 95% confidence intervals for 
each of the models described above are presented in tables 1 Oa and 1 Ob. 
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DISCUSSION 
Medication possession was highest among patients that were dispensed only 
sulfonylureas, with 77% and 67% of such patients possessing medication for 
at least 80% and 90% of days, respectively. Medication possession was next 
highest among patients dispensed only metformin, with 71 % of such patients 
possessing medication for at least 8of10 days, and 57% of patients 
possessing mediation for 9of10 days. Patients that received dispensings for 
both drugs were less frequently in possession of medication. Only 57% of 
such patients possessed enough medication to be adherence 80% of days, 
and less than half of patients prescribed both drugs (43%) possessed enough 
medication to cover 90% of days in the period . Overall , 71 % of all patients 
possessed medication for at least 8of10 days, and only 60% of patients 
possessed medication for 9of10 days. In all models, dual therapy with a 
sulfonylurea plus metformin was associated with an increased likelihood of 
non-adherence as defined as medication possession , as compared with 
monotherapy with either a sulfonylurea or metformin. 
These results provide evidence that the self-management of diabetes is far 
from ideal for many patients. Clearly, patients who are not in possession of 
medication cannot be achieving the 'tight control ' of blood glucose that has 
been demonstrated to reduce the incidence of many types of diabetes 
complications. Unfortunately, the finding that many diabetic patients do not 
strictly adhere to prescribed hypoglycemic drug regimens is not unexpected. 
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Other researchers have provided evidence that adherence to hypoglycemic 
therapy is often sub-optimal. Venturini et al (45) reported a mean medication 
possession percentage of 83% of days among HMO patients prescribed a 
sulfonylurea . In a study using Medicaid claims data, Sclar et al (46) found that 
only 39.4% of newly treated diabetics receiving a second-generation 
sulfonylurea obtained at least 6 months supply of medication during a 12-
month period . In an assessment of hypoglycemic drug possession among 
nearly 3,000 Scottish diabetics, Morris et al (47) found that roughly one-third of 
patients prescribed sulfonylureas received enough medication to cover 90% of 
days. Poor adherence to prescribed therapies among diabetic patients has 
been described by several researchers (48-53). 
The primary aim of this study was to determine if adherence to prescribed 
drug regimens was poorer among patients prescribed dual therapy with a 
sulfonylurea plus metformin as compared with patients receiving only one 
medication as monotherapy. Indeed, patients prescribed the two 
hypoglycemic drugs together were less likely to possess medication. In 
addition , the difference in adherence was pronounced. As compared with 
patients receiving dispensings for only a sulfonylurea or metformin, the 
percentage of patients having a medication possession ratio less than 8:10 or 
9:10 was significantly greater for patients receiving both drugs. Logistic 
models provided an estimate of influence, with the odds of non-adherence as 
measured in terms of medication possession ranging from 2.4 to 3.1 times 
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greater for those prescribed both medications as compared with patients 
receiving monotherapy, depending upon inclusion of other factors in the 
model. 
Morris et al (47) reported similar findings when comparing medication 
possession rates among Scottish diabetics who received dispensings for 
either sulfonylurea, metformin, or both . During a period of up to three-years, 
only 31% of patients using a sulfonylurea, and 34% of patients using 
metformin possessed enough medication to achieve adequate adherence, 
defined as possessing medication for 90% of days during the period. 
An influence of the number of medications prescribed on adherence has also 
been described. Sellars and Hayes (54) note that in general the probability of 
non-adherence can be expected to increase with the number of medications 
prescribed. Treatment complexity has been shown to be a barrier to 
adherence in diabetic patients (55). In other health conditions, the number of 
medications prescribed has been shown to be an influence of drug utilization. 
For example, persistence with a single-pill combination of two anti-
hypertensive agents was found to be superior to persistence rates when the 
same agents were prescribed as separate pills (56). Additionally, treatment 
complexity is a recognized feature of adherence to drug therapies for human 
immunodeficiency virus (57, 58). 
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The age of the patient was also found to be associated with medication 
possession. In th is study, bivariate analyses revealed that patients 50 years of 
age or older were less likely to be categorized as non-adherent. This finding is 
consistent with research by Sclar, who also found older diabetic patients to be 
more likely to obtain oral hypoglycemic medication regularly (46). This finding 
is explainable using the health beliefs model as described by Becker (59). 
According to this model , patients that perceive their disease to pose a threat to 
health will be more likely to adhere to therapies that they perceive will lessen 
the risk of illness. Thus, in this study, perhaps younger diabetic patients were 
poorly adherent to drug therapy due to a lessened concern about poor longer-
term outcomes resulting from persistent uncontrolled blood glucose. 
Conversely, older patients may be more concerned about impending ill health, 
and thus be more likely to adhere to therapy. 
Patients receiving 12 or more dispensings were 55% percent less likely to be 
non-adherent for MPR thresholds of 8:10 and 9:10 days. However, our 
calculations of total dispensings do not equate to the total number of 
medications prescribed, since non-adherence and differing days supply of 
medications may be responsible for some portion of the difference in the 
number of dispensings. Nevertheless, patients that received less than 12 
dispensings were more likely to be identified as having an MPR below 8:10 
and 9:10 days. A possible explanation for this finding is that patients receiving 
less than 12 dispensings during the four-month period were less ill, and 
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perhaps less adherent for reasons related to the health bel iefs model as 
previously described. Also, it is likely that patients receiving 12 or more 
dispensings were afflicted with other co-morbid conditions and thus more 
vigilant in their adherence to therapy in an effort to stave off ill health . 
Removing the term for the total number of prescriptions from multivariate 
models resulted in a decrease in the odds of non-adherence among patients 
dispensed both a sulfonylurea and metformin. Thus, controlling for the 
number of prescriptions dispensed resulted in an increase in the odds for non-
adherence among those prescribed both drugs. Such effect was lacking for all 
other independent variables except age. Gender and insurance type were not 
found to be significant influences of medication possession . 
Depression was identified as a risk factor for non-adherence by Di Matteo (34 ). 
In an attempt to control for the presence of depression, we identified patients 
that received a dispensing for one of several anti-depressant medications. 
For such patients, the risk of nonadherence to drug therapy was greater. 
However, the 95% confidence interval did not exclude the possibility that no 
effect was present (MPR < 8:10: 95% Cl 0.92 - 1.75; MPR < 9:10: 95% Cl 
0.89 - 1.64 ). Additionally, dispensing of an anti-depressant was not found to 
be a significant influence of medication possession in multivariate models that 
included all potential confounding variables. Thus, in this study, patients who 
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received one or more selected antidepressant medications were not more 
likely to be nonadherent to hypoglycemic drug therapy. 
An important limitation of the study relates to the use of medication possession 
as a measure of adherence. Certainly the possession of medication is only an 
initial step in the process of adhering to prescribed therapy. Patients in 
possession of medication may skip dosages when feeling well, or otherwise 
consume medication in a manner that differs from the instructions of the 
prescriber. Despite this limitation, possession of medication has been 
considered a useful 'first-order' measure of adherence (60), since patients 
must first possess medication before they can adhere to therapy. 
Another limitation relates to the duration of time used to assess medication 
possession. The four-month period used in this study is shorter than what was 
used to assess adherence to hypoglycemic drug regimens for some other 
studies. For example, Morris used a three-year period to investigate 
hypoglycemic drug dispensings (47), while both Skaer at al (53) and Sclar at al 
(46) assessed refill dispensings over a 12-month period. Beta-Brown et al 
(61) investigated hypoglycemic drug use over a ten-year period. In our study, 
use of a longer period of time for assessing adherence would have likely 
resulted in a greater number of patients identified as non-adherent. It cannot 
be assumed that such patients would have been similarly distributed in terms 
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of regimen type and medication possession . Thus, a longer period of time 
used to assess medication possession may have resulted in different findings. 
Additionally, patients receiving dual therapy may have initially failed 
monotherapy due to poor adherence. Thus, the group of patients using two 
hypoglycemic medications may inherently be more likely to be nonadherent. 
Importantly, this study did not include many important factors known to be 
associated with adherence to prescribed drug regimens. Though we 
assessed the influence of gender and age, other patient-related factors may 
have been important to include. For example, race may have been an 
influence on adherence with sulfonylurea treatment, as found by Sclar et al 
(46). More notably, other complex behavioral factors may have been 
responsible for the differences in medication possession observed . For 
example, a patient's self-efficacy in adhering to prescribed regimens has been 
associated with superior adherence (29). Add itionally, a patient's stage of 
readiness to adhere to a prescribed regimen may prove explanatory (62 , 63). 
In this study, the identification and incorporation of factors related to 
perception and beliefs may have influenced the association between drug 
regimen type and medication possession . 
Additionally, important factors related to the characteristics of the disease 
were not included in this analysis. It is possible , for example, that some 
142 
patients classified as non-adherent in fact no longer required medication. 
perhaps from adherence to recommended diet or exercise programs. Also, a 
percentage of patients classified as non-adherent may have been hospitalized 
during the assessment period. Additionally, the severity of disease may have 
also been important to assess. as highly symptomatic patients may have been 
more likely to adhere to therapy. Severity of disease may partly explain the 
finding of increased medication possession among older patients. 
Other potentially important confounding factors relate to obtaining medication. 
Information related to prescription co-payment was not provided , thus the 
influence of out-of-pocket expenditure on medication possession cannot be 
assessed . Additionally, though patients were required to obtain prescriptions 
at designated pharmacies for reimbursement. it is possible that some patients 
filled prescriptions at other locations by using other insurances or by paying 
cash. A last potentially important factor related to the drug regimen not 
included in this analysis relates to the type of drug therapies studied. Though 
sulfonylureas and metformin remain popular therapies in the treatment of type 
2 diabetes. newer hypoglycemic agents have become increasingly utilized 
during the past several years. Though dual therapy with a sulfonylurea plus 
metformin was found to be associated with an increased likelihood of non-
adherence. the association between other hypoglycemic drug combinations 
and medication possession is uncertain . One must not assume that 
adherence to therapy would also be lesser for combination therapies that 
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include, for example, a thiazoladinedionne, meglitinde, or alpha glucosidase 
inhibitor. 
Finally, it is important to note that dose frequency was not included as an 
influence on medication possession . Both metformin and sulfonylureas may 
be prescribed as one or two daily doses; depending upon the agent prescribed 
for the latter. (64 ). A sustained release preparation of metformin was not 
available during the period of study. 
Despite these limitations, we found that patients receiving dispensings for both 
a sulfonylurea and metformin possessed medication for a lesser number of 
days as compared with patients who were dispensed only a sulfonylurea or 
metformin. This effect was strongest when controlling for the age of the 
patients and the total number of prescription dispensings. In this model , 
patients who received dispensings for both drugs were 3.14 times more likely 
to be non-adherent as defined as possessing medication for less than 8 of 10 
days in the measurement period . Such patients were also 3.20 times more 
likely to be non-adherent using an MPR threshold of 9 in 10 days. The 
association between dual therapy with sulfonylurea plus metformin and an 
MPR of less than 8:1 O or 9: 1 O was also significant in bivariate analyses. 
Adherence with drug therapy was found to be sub-optimal among all patients, 
regardless of regimen type. Greater than one in four of all patients did not 
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possess a sufficient quantify of medication to adhere to prescribed therapy at 
least 80% of days; and roughly two in five patients did not possess enough 
medication to adhere to therapy at least 90% of days. Additionally, these 
estimates likely underestimate the true rate of adherence, since possessing 
medication is but one step in the process of adherence. 
Despite the limitations described, this research should add to evidence 
demonstrating that adherence to hypoglycemic drug therapy is a fundamental 
problem, and potentially the greatest influence on the development of diabetic 
complications. Accordingly, adherence to drug therapy for patients with 
diabetes deserves at least as much attention as other components of diabetes 
management, such as preventative exams and monitoring of blood pressure 
and lipid levels. 
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CONCLUSION 
As compared with monotherapy with a sulfonylurea or metformin, dual therapy 
with a sulfonylurea plus metformin is associated with a greater than three fold 
increase in the likelihood of non-adherence, controlling for the age of the 
patient and total number of medications dispensed. Patients receiving 
monotherapy with sulfonylurea were most frequently adherent, with 77% of 
patients possessing medication for at least 8of10 days in the study period , 
and 67% receiving at least enough medication to cover 9 of 10 days. Of those 
receiving monotherapy with metformin, 77% possessed enough medication to 
adhere 8 of 10 days, and 57% of patients possessed enough medication to 
adhere 9 of 10 days. The lowest rate of adherence was among patients 
receiving dispensings for a sulfonylurea and metformin. Among patients 
receiving both drugs, 57% received enough medication to adhere 8 of 10 
days, while only 43% of patients possessed at least enough medication for 9 
of 10 days. 
In this population many patients did not adhere to drug therapy to the extent 
considered necessary to achieve tight glycemic control. Such patients can be 
expected to be at increased risk for several types of diabetic complications. 
Thus, components of diabetes management must include the assessment of 
adherence with prescribed hypoglycemic drug regimens, and the application of 
interventions known to be effective in improving adherence. Additionally, the 
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complexity of the drug regimen should be considered as a potential barrier to 
optimal adherence. 
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Table 1. Medications Used to Identify Patients as Having Received an 
Anti-Depressant Medication. 
SSRI 
Citalopram 
Fluoxetine 
Paroxetine 
Sertraline 
Other 
Bupropion 
Mirzatapine 
Nefazodone 
Trazodone 
Venlafaxine 
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Table 2. Characteristics of Patients Receiving Hypoglycemic Therapy 
with a Sulfonylurea and/or Metformin 
Sulfonylurea Metformin Sulfonylurea + Total 
(N = 967; (N = 166; Metformin Population 
62.9%) 10.8%) (N = 404; 26.3%) (N = 1537) 
n % n % n % n % 
Gender 
Male 572 59.15 85 51.20 215 53.22 872 56.73 
Female 395 40.85 81 48.80 189 46.78 665 43.27 
Age 
under 50 229 23.68 55 33.13 104 25.74 388 25.24 
50-64 442 45.71 81 48.80 202 50.00 725 47.17 
65 + 296 30.61 30 18.07 98 24.26 424 27.59 
Insurance 
Plan A 315 32.57 53 31.93 114 28.22 482 31.36 
Plan B 527 54.50 95 57 .23 246 60.89 868 56.47 
Other 125 12.93 18 10.84 44 10.89 187 12.17 
#of Dis-
pensings 
under 5 151 15.62 31 18.67 3 0.74 185 12.04 
5-15 550 56.88 95 57.23 213 52.72 858 55.82 
over 15 266 27.51 40 24.10 188 46.53 494 32.14 
Rx for 
Depression 105 10.86 22 13.25 66 16.34 193 12.56 
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Table 3. Medication Possession : Patients Receiving Dispensings for 
Sulfonylurea and/or Metformin, and Total Population 
Sulfonylurea Metformin Sulfonylurea Total 
(n = 967) (n = 166) + Metformin Population 
(n = 404) (N = 1537) 
n % n % % n % 
Medication 
Possession 
Ratio (MPR) 
>= 8:10 747 77.2 118 71 .1 230 56.93 1095 71 .24 
>= 9:10 646 66.8 94 56.6 174 43.07 914 59.47 
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Table 4a: Bivariate Analyses: Medication Possession Ratio (MPR) and 
Gender, Age Category, Insurance Type, Number of Prescriptions 
Dispensed, and Rx for Depression 
MPR < 8:10 
Sulfonylurea n Metformin Sulfonylurea plus Total 
= 967 n = 166 Metformin n = population 
404 n = 1537 
% % % % 
All Subjects 22.75 28.92 43.07 28 .76 
Regimen type 
sfu or Met 23 .65 .. 
sfu +Met 43 .07 .. 
Gender 
Male 22.72 29.41 44.65 28 .78 
Female 22.78 28.40 41.27 28 .72 
Age 
Under 50 33.19 .. 36.36 53.85. 39.18 .. 
50-64 19.46 .. 27.16 40.59. 26 .21 .. 
65 or older 19.59 .. 20.00 36.73. 23.58 .. 
Insurance 
Plan A 24 .80 33.33 40 .35 26 .76 
Plan B 20 .95 32.08 43.90 29.49 
Other 23 .34 26.32 45.45 30.48 
#of Dis-
pensings 
<5 41 .72 .. 45.16 43.24 .. 
5-15 22 .00 .. 26 .32 53.99 30.42 .. 
> 15 13.53 .. 22 .50 29 .79t 20.45 .. 
Rx for 
depression 
Yes 30.48. 31 .82 37.89 33.16 
No 21 .81 · 28.47 44.08 28.13 
• p < 0.05 
•• p < 0.01 
tNot reportable; one cell with less then 5 subjects 
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Table 4b: Bivariate Analyses: Medication Possession Ratio (MPR) and 
Gender, Age Category, Insurance Type, Number of Prescriptions 
Dispensed, and Rx for Depression 
MPR < 9:10 
Sulfonylurea n Metformin Sulfonylurea plus Total 
= 967 n = 166 Metformin n = population 
404 n = 1537 
% % % % 
All subjects 33.2 43.4 56.93 59.47 
Regimen type 
sfu or Met 34.69 •• 
sfu +Met 56.93 .. 
Gender 
Male 33.57 44.71 59.07 40.94 
Female 32.66 41 .98 54 .50 40.00 
Age 
Under 50 43 .23 .. 52 .73 64.42 50.26 .. 
50-64 29 .19 .. 39.51 54.95 37.52 .. 
65 or older 31.42 .. 36.67 53.06 36.79 .. 
Insurance 
Plan A 32.06 43.40 54.39 38.59 
Plan B 32.64 41 .05 56.50 40.32 
Other 38.40 55.56 65.91 46 .52 
#of Dis-
pensings 
<5 54.97 .. 61.29 56.76 .. 
5-15 34.00 .. 41 .05 67.61 43 .13 .. 
> 15 19.17 .. 35.00 44 .15t 29.96 .. 
Rx for 
depression 
Yes 41.90. 40 .91 50.00 44.56 
No 32.13• 43 .75 58.28 39.96 
* p < 0.05 
p < 0.01 
tNot reportable; one cell with less then 5 subjects 
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Table Sa. Bivariate Logistic Regression Models: Independent Variables 
and MPR < 8:10 
95% 95% 
r.. se OR Cl low Cl high 
Dispensed 
sulfonylurea plus 0.8929 0.0699 2.442 1.921 3.104 
metformint 
Age 
Under 50* 1.0 
50-65 -0.5955 0.1340 0.551 0.424 0.717 
65 + -0.7357 0.1546 0.479 0.354 0.649 
Male gender 0.0031 0.1138 1.003 0.810 1.254 
Number of 
dispensings 
12 + -0 .5731 0.1142 0.564 0.451 0.705 
Insurance 
Plan A 1.0 
Plan B 0.1351 0.1270 1.145 0.892 1.468 
Other insurance 0.1822 0.1893 1.2 0.828 1.739 
Rx for anti-depressant 0.2374 0.1645 1.268 0.918 1.750 
t versus monotherapy 
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Table Sb. Bivariate Logistic Regression Models: Independent Variables 
and MPR < 9:10 
95% 95% 
r.. se OR Cl low Cl high 
Dispensed sulfonylurea 
plus metformint 0.9118 0.1183 2.489 1.974 3.138 
Age 
Under 50* 1.0 
50-65 -0.5204 0.1273 0.594 0.463 0.763 
65 + -0.5514 0.1430 0.576 0.435 0.763 
Male gender 0.0390 0.1049 1.040 0.847 1.277 
Number of dispensings 
12 + -0.5562 0.1049 0.573 0.467 0.704 
Insurance 
Plan A 1.0 
Plan B 0.0726 0.1164 1.075 0.856 1.351 
Other insurance 0.3254 0.1739 1.385 0.985 1.947 
Rx for anti-depressant 0.1888 0.1552 1.208 0.891 1.637 
t versus monotherapy 
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Table 6. Likelihood Ratio Test for 2-Way Interactions 
-21og -21og x2 dt=2s: 
DV statistic difference 40.11 
MPR < 8:10 EV+ V's* 1693.107 
V's* 1720.317 27.21 NS 
MPR< 9:10 EV+ V's* 1912.485 
V's* 1941.272 28.79 NS 
*EV= Interaction terms; V =Single terms (independent variables) 
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Table 7a. Multivariate Logistic Model, All Independent Variables 
MPR < 8:10 
95% 95% 
Beta se OR Cl low Cl High 
Dispensed 
sulfonylurea 
plus metformint 1.1382 0.1 339 3.121 2.401 4.058 
Age 
under50 1.00 
50-64 -0 .5226 0.1398 0.593 0.451 0.780 
65+ -0.5557 0.1616 0.574 0.418 0.787 
Male Gender -0.0405 0.1205 0.960 0.758 1.216 
Insurance 
Plan A 1.00 
Plan B 0.0107 0.1331 1.011 0.779 1.312 
Other 0.0759 0.1970 1.079 0.733 1.587 
#of Dis-
pensings 
12 + -0 .8309 0.1297 0.436 0.338 0.562 
Rx for Anti-
depressant 0.3040 0.1778 1.355 0.956 1.920 
t versus monotherapy 
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Table 7b. Multivariate Logistic Model, All Independent Variables 
MPR < 9:10 
95% 95% 
Beta se OR Cl low Cl High 
Dispensed 
sulfonylurea 
plus 
metformint 1.1634 0.1284 3.201 2.489 4.117 
Age 
under50 1.00 
50-64 -0.4463 0.1331 0.640 0.493 0.831 
65+ -0.3721 0.1503 0.689 0.513 0.925 
Male Gender 0.00125 0.1112 1.001 0.811 1.245 
Insurance 
Plan A 1.00 
Plan B -0.0393 0.1221 0.962 0.757 1.222 
Other 0.2328 0.1813 1.262 0.885 1.801 
#of Dis-
pen sings 
12 + -0 .8108 0.1186 0.445 0.352 0.561 
Rx for Anti-
depressant 0.2697 0.1674 1.310 0.943 1.818 
t versus monotherapy 
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Table Ba. Multivariate Logistic Model: Type of Drug Therapy, Age 
Category, and Number of Dispensings 
MPR < 8:10 
95% 95% 
Beta se OR Cl low Cl High 
Dispensed 
sulfonylurea 
plus 
metformint 1.1442 0.1334 3.140 2.417 4.078 
Age 
under50 1.000 
50-64 -0 .5392 0.1392 0.583 0.444 0.766 
65+ -0.5679 0.1609 0.567 0.413 0.777 
#of Dis-
pen sings 
12 + -0.7937 0.1266 0.452 0.353 0.580 
t versus monotherapy 
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Table Sb.Multivariate Logistic Model: Type of Drug Therapy, Age 
category, and Number of Dispensings 
MPR < 9:10 
95% 95% 
Beta se OR Cl low Cl High 
Dispensed 
sulfonylurea 
plus metformint 1.1621 0.1279 3.197 2.488 4.108 
Age 
under50 1.000 
50-64 -0.4586 0.1325 0.632 0.488 0.820 
65+ -0.3743 0.1496 0.688 0.513 0.922 
#of Dis-
pen sings 
12 + -0.7886 0.1159 0.454 0.362 0.570 
t versus monotherapy 
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Table 9a.Multivariate Logistic Model: Type of Drug Therapy and Age 
Category 
MPR < 8:10 
95% 95% 
Beta se OR Cl low Cl High 
Dispensed 
sulfonylurea 
plus 
metformint 9:1021 0.1239 2.465 1.933 3.142 
Age 
under50 1.000 
50-64 -0 .6293 0.1369 0.533 0.408 0.697 
65+ -0 .7266 0.1574 0.484 0.355 0.658 
t versus monotherapy 
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Table 9b.Multivariate Logistic Model: Type of Drug Therapy and Age 
category 
MPR < 9:10 
95% 95% 
Beta se OR Cl low Cl High 
Dispensed 
sulfonylurea 
plus 
metformint 0.9215 0.1193 2.513 1.989 3.175 
Age 
under50 1.000 
50-64 -0.5528 0.1301 0.575 0.446 0.742 
65+ -0 .5383 0.1458 0.584 0.439 0.777 
t versus monotherapy 
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Table 10a. Association Between Dual Therapy With a Sulfonylurea Plus 
Metformint and Medication Possession: Comparison of Logistic Models 
MPR < 8:10 
Model 
1 
2 
3 
4 
Model 1 
Model 2 
Model 3 
Model 4 
95% 95% 
Beta se OR Cl low Cl High 
1.1382 0.1339 3.121 2.104 4.058 
1.1442 0.1334 3.140 2.417 4.078 
9:1021 0.1239 2.465 1.933 3.142 
0.8929 0.0699 2.442 1.921 3.104 
Additional Variables 
All independent variables (from Table 7a) 
Age category and number of dispensings (from Table Ba) 
Age category only (from Table 9a) 
No additional variables: bivariate relationship (from Table 5a) 
t versus monotherapy 
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Table 10b. Association Between Dual Therapy With a Sulfonylurea Plus 
Metformint and Medication Possession: Comparison of Logistic Models 
MPR < 9:10 
Model 
1 
2 
3 
4 
Model 1 
Model 2 
Model 3 
Model 4 
Beta se OR Cl low Cl High 
1.1634 0.1284 3.201 2.489 4.117 
1.1621 0.1279 3.197 2.488 4.108 
0.9215 0.1193 2.513 1.989 3.175 
0.9118 0.1183 2.489 1.974 3.138 
Additional Variables 
All independent variables (from Table 7b) 
Age category and number of dispensings (from Table 8b) 
Age category only (from Table 9b) 
Bivariate relationship (from Table 5b) 
t versus monotherapy 
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PART2 
Part 2 includes the following appendices: 
Appendix A. Background and Review of the Problem 
Appendix B. Details of the Methods 
Appendix C. Overview of Major Findings 
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Appendix A. Background and Review of the Problem 
Diabetes is a major public health problem. According to data from the Third 
National Health and Nutrition Examination Survey (NHANES Ill ), the 
prevalence of diabetes in 1988-1994 was estimated to be slightly greater than 
five percent for Americans 20 years of age or older (1 ). The prevalence of 
diabetes was also found to be greater for certain races, with the condition 
being increasingly prevalent among Mexican-Americans (5.6%) and non-
Hispanic blacks (6.9%). Additionally, applying criteria developed by the 
American Diabetes Association to NHANES Ill data, another 2.7% of the U.S. 
population have diabetes yet are undiagnosed (2). 
The prevalence of diabetes has increased during the past three decades, and 
this trend is projected to continue (3). Major factors contributing to the 
increase in diabetes prevalence include the aging of the U.S. population and 
an increased prevalence rate of diabetes among older Americans (4, 5). 
Additionally, diabetes-related deaths have decreased during past several 
decades, likely resulting from advances in knowledge and related 
improvements in diabetes care (1 ). Poor diet and sedentary lifestyles have 
also contributed to the increase in diabetes prevalence, with obesity and lack 
of exercise often present as characteristics of the diabetic patient (6). 
Diabetes will likely continue to be a significant epidemiologic problem in 
coming years, as the number of older Americans continues to increase. 
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Further, a growing number of Americans are obese (7), work environments 
increasingly involve prolonged sedentary activity, and burdensome demands 
associated with current lifestyles can make it difficult to incorporate healthy 
nutrition and exercise into one's daily routine. 
Though diabetes has emerged as an important public health problem, strides 
in treatment have resulted in reduced morbidity. The Diabetes Control and 
Complications Trial (DCCT) (8) demonstrated that intensive therapy in type 1 
diabetes can reduce the incidence of retinopathy, neuropathy, and 
nephropathy. In this trial, intensive therapy was defined as three or more daily 
insulin injections guided by frequent blood glucose monitoring. The DCCT 
demonstrated for the first time that aggressive management can reduce the 
risk of some types of diabetic complications (9). Five years later, similar 
results were reported from a large trial investigating the effect of intensive 
glucose control among British patients with type 2 diabetes. The United 
Kingdom Prospective Diabetes Study Group (10) assessed the effects of tight 
control of blood glucose, using an intensive drug regimen aimed at achieving a 
fasting plasma glucose concentration of a less than 6 mmol/L. As compared 
to patients who received a regimen consisting of conventional care, those 
receiving intensive therapy were 25% less likely to be diagnosed with a 
microvascular complication , and 12% less likely to suffer any diabetes-related 
endpoint. The DCCT and UKPDS studies were important in demonstrating 
that several types of diabetic complications can be averted through tight 
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control of blood glucose. Additional trials have since reported similar findings . 
Examples include the Kumamoto Study in Japan (11) and the Veteran's Affairs 
Cooperative Study on Glycemic Control and Complications (12), which both 
reported reductions in risk for selected microvascular diseases among patients 
receiving intensive therapy. 
Intensive therapy has not been shown to significantly reduce the incidence of 
macrovascular diseases such as myocardial infarction or stoke. Though a 
trend for a reduction in these endpoints was observed among those receiving 
intensive therapy in the UKPDS, the frequency of such events was 
substantially greater than the frequency of microvascular complications (13). 
Thus, though the UKPDS trial was sufficiently powered to detect a statistically 
significant reduction in macrovascular complications, no such reduction was 
observed . Additional information regarding the association between regimens 
of tight control and macrovascular disease will be provided from the ongoing 
Veteran 's Affairs Diabetes Trial (14), which is assessing the effect of intensive 
blood glucose control on cardiovascular compl ications in patients with type 2 
disease. Meanwhile, current evidence suggests that control of blood glucose 
alone is not sufficient to significantly reduce the incidence of heart attack, 
stroke, or diabetes-related death. Aggressive management of other 
cardiovascular risk factors is essential , including reduction of LDL-C 
cholesterol and blood pressure to below target levels (15). 
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Strategies for achieving tight glycemic control include hypoglycemic drug 
therapy, though no single class of oral hypoglycemic medication has 
demonstrated superior ability in achieving tight control. In the UKPDS trial , 
patients assigned to intensive therapy with oral medication initially received 
either a first or second-generation sulfonylurea. Patients failing sulfonylurea 
monotherapy received insulin injections, or metformin if overweight (16). No 
single agent or class of agents was associated with superior outcomes. All 
hypoglycemic medications utilized were efficacious in reducing blood glucose, 
yet the specific agent used to achieve this reduction was not of importance. 
Current treatment guidelines of the American Diabetes Association describe 
the goal HbA 1 c to be achieved , yet do not recommend specific agents for 
achieving this goal (17). 
During the past several years, three new classes of oral hypoglycemic drugs 
have become available for use. None of these newer classes of hypoglycemic 
agents has been proven superior in reducing the incidence of microvascular or 
macrovascular diabetic complications. However, the availability of newer 
classes of hypoglycemic drugs has created a panoply of choices for achieving 
euglycemia. Currently, prescribers can chose from over 25 different agents 
representing five different classes of oral hypoglycemic drugs (18). Some of 
these agents can be utilized as monotherapy (19, 20); most have been 
approved for use in combination with other hypoglycemic medications (19-25). 
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The first objective of this research project was to describe hypoglycemic drug 
utilization in a diabetic population. In this descriptive study, we sought to 
identify which mediations were utilized and how frequently they were 
dispensed both alone and in combination. We also identified patients that 
switched hypoglycemic regimens during a 12-month period, and identified to 
which regimens patients were switching. We also compared utilization by age, 
gender, and insurance type, including a comparison of the costs associated 
with hypoglycemic drug utilization. This study will be of particular interest to 
those seeking details of 'real-world ' patterns of hypoglycemic drug utilization, 
and how drug utilization varies among sub-populations. 
Recognizing the reductions in several types of diabetic complications 
observed among patients receiving intensive therapy in the DCCT and UKPDS 
trials, we also explored the relationship between adherence to prescribed 
regimens and changes in drugs dispensed . Specifically, we hypothesized that 
patients that did not consistently receive dispensings for prescribed 
hypoglycemic medications would be more likely to receive a higher dose of 
hypoglycemic medication or a dispensing for a different (new) hypoglycemic 
medication in subsequent months. Thus, we attempted to demonstrate that in 
patients who were nonadherent to prescribed regimens, prescribers might 
have responded to resulting poor control of blood glucose by prescribing 
additional medication. This action may potentially provoke dangerous 
hypoglycemia. Further, it fails to address the behavior of nonadherence to 
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prescribed hypoglycemic therapy, which may ultimately result in diabetic 
complications that could have been avoided. 
A third study involved assessing adherence with drug therapy among patients 
prescribed monotherapy with a sulfonylurea or metformin, and among patients 
prescribed dual therapy with both agents. We hypothesized that patients 
prescribed dual therapy would be less adherent that those prescribed 
monotherapy, and that adherence to hypoglycemic drug regimens would be 
less than optimal overall. This hypothesis was based upon the findings of 
other researchers who have reported poor adherence with therapies for 
chronic diseases (26-31 ). Adherence with prescribed drug therapy in diabetes 
is an acknowledged problem, and many have reported adherence rates that 
would seem to fail to be consistent with requirements for tight control of blood 
glucose (32-34). Morris et al (35) specifically examined the difference in 
adherence between patients receiving monotherapy with a sulfonylurea or 
metformin as compared with patients rece iving dual therapy with both agents. 
In a presentation at the American Diabetes Association 's 601h Annual Scientific 
Session , Morris reported that a significant difference in adherence was 
observed among those prescribed both a sulfonylurea and metformin, and that 
a far less than optimal rate of adherence existed among those receiving 
hypoglycemic monotherapy. In third study presented here, we assessed 
adherence among regimen types, focusing on the likelihood of nonadherence 
among patients receiving dual therapy. 
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Appendix B Details of the Methods 
Data source 
Data for research were provided by Consumer Value Stores (CVS), Inc to the 
department of Applied Pharmaceutical Sciences at the University of Rhode 
Island . The data consisted of a population of enrollees in a comprehensive 
management program for diabetic patients sponsored by either of two area 
health insurance providers . The initial data set included 288,174 medication 
dispensings to 5056 patients between April 27, 1997 and May 16, 1999. The 
data included the following 16 variables: 
ID: Patient Identification number; a unique integer from 1 to 5056. 
BDATE: Patient date of birth; in mmldd/yyyy format. 
GENDER: Male or Female, included as 'M' or 'F'. 
AGENCYNM: Describes the type of payment associated with the medication 
dispensing. For a majority of patients, this variable was one of two health 
plans participating in the diabetes management program. Other insurance 
types used for prescription reimbursement and cash payments were described 
by this variable. 
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AGENCYJD: Numeric descriptor for above 
RX_NBR: Unique number assigned by the dispensing pharmacy for each 
new prescription dispensed and associated refills . 
FILL_NBR: Identifies the refill number 
NOC: National Drug Code identifier; a unique identification number used for 
identifying the product dispensed. 
LABELNM: Name of the product dispensed, including strength and dosage 
from. 
QTY: The quantity of medication dispensed 
DAYSSUPP: The days supply of medication dispensed 
AWPPRICE: The average wholesale price of the quantity of product 
dispensed on the date of dispensing. 
POSTXNDT: The date on which the medication was dispensed to the patient 
or his/her agent 
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AVAILFIL: The number of refills remaining on the prescription 
STORENO: The store number, a unique identifier for the pharmacy 
dispensing the medication 
DEA: A unique identification number assigned to providers and institutions 
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Data cleaning and preparation 
Data was provided in comma-delimited form . From this file, a SAS data set 
was created using SAS for microcomputers versions 6.2 and 8.01 . SAS 
procedures such as PROC FREQ and PROC UNIVARIATE were used to 
screen for missing and spurious data. Five duplicate records were deleted. 
The resulting data set described 288, 171 medication dispensings. Missing 
values for the date of dispensing (POSTXNDT) were present for 5470 of these 
observations (1.9%), and were considered to represent prescriptions held 'on-
file ' in the computer system. Such observations were deleted, further reducing 
the number of dispensings to 282,701. 
A next step was to create a date set that included only dispensings for 
hypoglycemic medications. The PROC FREQ procedure was used to identify 
all medications dispensed. Using this output, text strings describing 
hypoglycemic products were identified and incorporated into a SAS program 
that deleted dispensings for drugs not used for blood glucose control. A total 
of 671 patients did not receive a dispensing for a hypoglycemic medication 
(13 .3%): these patients were eliminated from the sample. The resulting data 
set included only patients that received dispensings for a hypoglycemic 
medication (N = 4385), and included only dispensings for hypoglycemic 
medications (n = 78,960). 
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The variable LABLENM was used to create two new variables for describing 
categories of hypoglycemic medication dispensed. The first such variable, 
RXCODE, consisted of the first four letters of the chemical name of the 
product dispensed plus the medication strength. For example, a label name of 
'GLYBURIDE 5MG TABLET' was converted to 'glyb5'. Similarly, a dispensing 
for Dia beta® brand of glyburide 5mg was also coded as 'glyb5'. The use of 
the RXCODE variable facilitated categorization of dispensings by therapeutic 
class. The RXCODE drug categorization system was also useful in that a 
change in manufacturer of a product dispensed would not be categorized as a 
change in type of medication dispensed. Table 2 presents the description for 
variable LABLENM for all hypoglycemic drugs identified, and associated 
created variable RXCODE. A second variable, STRENGTH, was created to 
describe the strength of medication dispensed. An additional variable BRAND 
described the type of sulfonylurea dispensed as either brand or generic. 
Variables RXCODE, STRENGTH, and BRAND were created using if-then 
statements for each of 48 different descriptions of oral drugs described by 
variable LABELNM. All insulin products were coded as RXCODE 'ins' and 
STRENGTH '99999'. 
Data was transposed to create a data set containing one record per patient, 
using the PROC TRANSPOSE procedure. The resulting data set included 
4385 observations (subjects) and 772 variables. 
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To provide a standard for comparison , we included only patients that received 
dispensings of hypoglycemic medication for at least a 12-month period . This 
was accomplished by comparing the date of the first dispensing of 
hypoglycemic medication with the last date of dispensing. Patients with at 
least 365 days between first and last were included in the sample. The 
resulting data set included 2901 patients, representing 57.4% of the original 
5056 subjects. 
Categorization of age, insurance type, and number of dispensings 
Using the variable BDATE, we created three age categories: under 50 , 50-64, 
and greater than 65 years of age. These categories were established to 
compare drug utilization by younger, middle-aged, and senior diabetics. Such 
patients represented 35.54%, 43.40%, and 22.06% of the population 
respectively. Jn an effort to focus on patients with type 2 disease, we removed 
patients under 40 years of age from some analyses (age under 40: n = 386, 
13.62% of total population). 
For most patients (87 .18%), the insurance type associated with hypoglycemic 
drug dispensings was one of two health plans. Of the remaining patients, 
8.62% received dispensings that were reimbursed by one of over 50 other 
types of health insurance provider. Cash payment for dispensings was the 
sole insurance type associated with dispensings for 4.2% of subjects. In 
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comparisons of the drug regimen utilized, four categories of insurance type 
were identified: health plan A, health plan B, other insurance, and cash. For 
other bivariate and multivariate analyses, the insurance type categories of 
'other insurance' and 'cash ' were combined into a single category, since we 
were primarily interested in assessing differences between the two main 
health plans. 
The total number of dispensings was a factor that included dispensings for any 
type of medication. The original data of all pharmacy dispensings was used to 
obtain values of this variable. To derive this variable, we first identified the 
earliest date of dispensing of a hypoglycemic medication. Next, we 
determined the number of dispensings for which the dispensing date was later 
than but no more than four months (122 days) following the first dispensing of 
a hypoglycemic medication. Univariate analysis of this variable was 
performed to obtain quartiles of the frequency distribution. The lowest, 
highest, and inner quartiles of frequency distribution were used to create the 
following three categories: under 5 dispensings; 5-15 dispensings, and greater 
than 15 dispensings. 
Creation of drug regimen categories 
The frequency of dispensing of hypoglycemic medications was assessed 
using the PROC FREQ procedure. Regimen categories were defined based 
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on dispensing frequencies and with a priori awareness of regimens of interest; 
such as users of sulfonylurea only and users of sulfonylurea plus metformin. 
To minimize misclassification resulting from changes in regimen during the 12-
month period, we based drug regimen classification on the first three months 
of the 12-month period . Using the regimen categories presented in Figure 1, 
98.3% of patients were classified as receiving one of nine types of 
hypoglycemic drugs regimen , with 1.72% of patients classified as receiving an 
'other regimen' . The variable REGVAR was created , representing regimen 
categories 1-10. To assess changes in drug regimen during the 12-month 
period, we also categorized patients based upon the last three months of the 
12-month period, using the same regimen classification strategy. The ten 
levels of variable ENDVAR represented the regimen category utilized during 
the last three months of the 12-month period . 
Identifying changes in regimen category and dose 
Changes in drug regimen utilized between the first and last three months of 
the 12-month period were identified by comparing values for variables 
REGVAR and ENDVAR. We also determined which regimens patients were 
switching to, presenting both the frequency and percentage of change. 
We also identified changes in the dose of medication utilized. Two aspects of 
dispensings were assessed to determine if a change in dose had occurred . 
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First, a change in the variable RXCODE that did not result in a change in 
regimen category was considered to represent a change in medication dose. 
For example, a dispensing of glyburide 5mg tabs (RXCODE 'glyb5') was 
considered to represent a change in dose if previous dispensings were for 
glyburide 2.5mg tabs (RXCODE 'glyb2.5'). Second, we assessed the dose 
dispensed by comparing the number of doses per day. This was 
accomplished by dividing the quantity of medication dispensed by the days 
supply received. For example, a dispensing of 60 tablets for a supply of 30 
days would be identified as a daily dose of 2. A difference in this value 
between dispensings of the same medication was considered to indicate a 
dose change. For analyses involving medication possession , patients were 
eliminated if either the drug dispensed or the daily dose differed during the first 
four months of the 12-month period . 
Determining the medication possession ratio 
The assessment of medication possession was based upon the first four 
months of the 12-month period . We calculated the total days supply of 
medication received for all dispensings preceding the last dispensing during 
the four-month period ; and determined the total number of days between the 
first and last dispensing. The medication possession ratio (MPR) was defined 
as the total days supply of medication received compared with the total 
number of days between the first and last dispensing. Patients were 
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considered to be nonadherent if the MPR was less than 8:10, or less than 9:10 
for some analyses. Patients who received only one dispensing during the 
four-month period but who received medication in subsequent months were 
classified as non-adherent. 
Analyses 
All analyses were performed using the variables described above, and using 
SAS for microcomputers version 8.01 . The coding of variables and description 
of variable types is presented in Table 3. A summary of all analyses 
performed is presented in Tables 4a (univariate), 4b {bivariate), and 4c 
(multivariate). 
Programming details were obtained from the SAS Procedures Guide (1) and 
the SAS Language and Procedures usage manual (2) . Fundamentals of SAS 
coding were learned using SAS Programming by Example by Cody and Pass 
(3). Interpretation of statistical procedures was aided by Hatcher and 
Stepanski's A Step-by-Step Approach to Using the SAS System for Univariate 
and Multivariate Statistics (4) and Allison 's Logistic Regression Using the SAS 
System (5). 
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Table 1. Drug Regimen Categories 
Re imen 
1 Insulin only 
2 Insulin + Troglitazone 
3 Insulin + non-troglitazone agent 
4 Sulfonylurea mono-therapy 
5 Sulfonylurea + metformin 
6 Sulfonylurea + non-metformin 
7 Troglitazone mono-therapy 
8 Glimepramide mono-therapy 
9 Metformin mono-therapy 
10 Other regimen not classified 
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Table 2. Variable LABELNM and Derived Variable RXCODE 
LABELNM RX CODE 
AMARYL 1MG TABLET glim1 
AMARYL 2MG TABLET glim2 
AMARYL 4MG TABLET glim4 
CHLORPROPAMIDE 100MG TABLET chlo100 
DIABETA 1.25MG TABLET glyb1 .2 
DIABETA 2.5MG TABLET glyb2.5 
DIABETA 5MG TABLET glyb5 
DIABINESE 100MG TABLET chlo100 
DIABINESE 250MG TABLET chlo250 
GLIPIZIDE 10MG TABLET glip10 
GLIPIZIDE 5MG TABLET glip5 
GLUCOPHAGE 1000MG TABLET gluc100 
GLUCOPHAGE 500MG TABLET gluc500 
GLUCOPHAGE 850MG TABLET gluc850 
GLUCOTROL 10MG TABLET glip10 
GLUCOTROL 5MG TABLET glip5 
GLUCOTROL XL 10MG TABLET SA glipxl1 
GLUCOTROL XL 5MG TABLET SA glipxl5 
GL YBURIDE 1.25MG TABLET glyb1 .2 
GL YBURIDE 2.5MG TABLET glyb2.5 
GL YBURIDE 5MG TABLET glyb5 
GL YBURIDE MICRO 1.5MG TAB glyb1.5 
GL YBURIDE MICRO 3MG TABLET glyb1 .5 
GLYBURIDE MICRO 6MG TABLET glyb6 
GL YNASE 1.5MG PREST AB glyb1.5 
GL YNASE 3MG PRESTAB glyb3 
GL YNASE 6MG PRESTAB glyb6 
GL YSET 25MG TABLET migl25 
GL YSET 50MG TABLET migl50 
HUMALOG 100U/ML CARTRIDGE ins 
HUMALOG 100U/ML PEN ins 
HUMALOG 100U/ML VIAL ins 
HUMULIN 50/50 VIAL ins 
HUMULIN 70/30 CARTRIDGE ins 
HUMULIN 70/30 PEN ins 
HUMULIN 70/30 VIAL ins 
HUMULIN L 100U/ML VIAL ins 
HUMULIN N 100U/ML CARTRIDGE ins 
HUMULIN N 100U/ML PEN ins 
HUMULIN N 100U/ML VIAL ins 
HUMULIN R 100U/ML CARTRIDGE ins 
HUMULIN R 100U/ML VIAL ins 
HUMULIN R 500U/ML VIAL ins 
HUMULIN U 100U/ML VIAL ins 
MICRONASE 1.25MG TABLET glyb1 .2 
MICRONASE 2.5MG TABLET glyb2.5 
MICRONASE 5MG TABLET glyb5 
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Table 2 (continued). Variable LABLENM and Derived Variable RXCODE 
LABLENM 
NOVOLIN 70/30 100U/ML VIAL 
NOVOLIN 70/30 150U/1.5ML PREFL 
NOVOLIN 70/30 U100 CARTRIDG 
NOVOLIN L 100U/ML VIAL 
NOVOLIN N 100U/ML CARTRIDGE 
NOVOLIN N 100U/ML SYRINGE 
NOVOLIN N 100U/ML VIAL 
NOVOLIN R 100U/ML CARTRIDGE 
NOVOLIN R 100U/ML SYRINGE 
NOVOLIN R 100U/ML VIAL 
NOVOPEN 1.5 INSULIN DEVICE 
NOVOPEN 3 INSULIN DEVICE 
ORINASE 500MG TABLET 
PRANDIN 0.5MG TABLET 
PRANDIN 1MG TABLET 
PRANDIN 2MG TABLET 
PRECOSE 100MG TABLET 
PRECOSE 25MG TABLET 
PRECOSE 50MG TABLET 
REZULIN 200MG TABLET 
REZULIN 300MG TABLET 
REZULIN 400MG TABLET 
TOLAZAMIDE 100MG TABLET 
TOLAZAMIDE 250MG TABLET 
TOLAZAMIDE 500MG TABLET 
TOLBUTAMIDE 500MG TABLET 
TOLINASE 100MG TABLET 
TOLINASE 250MG TABLET 
RXCODE 
193 
ins 
ins 
ins 
ins 
ins 
ins 
ins 
ins 
ins 
ins 
ins 
ins 
tolb500 
pran0.5 
pran1 
pran2 
prec100 
prec25 
prec50 
rezu200 
rezu300 
rezu400 
tola100 
tola250 
tola500 
tolb500 
tola100 
tola250 
Table 3. Coding of Variables Used in Analyses 
Variable Description (codified as) Variable type 
AGECAT Under 50 (1 ); 50-64 (2); 65 or older (3) categorical 
AGECAT1 Under 40 (1 ); 40-49 (2); 50-64 (3); 65 or older categorical 
(4) 
AGENCYNM Insurer name (char) character 
string 
ANYCHANGE Change in medication or dose or drug dichotomous 
dispensed during the 12-month period (1 ); 
else (0) 
AWP10 The average wholesale price of the number 
medication dispensed minus ten percent 
(num) 
BDATE Date of birth as SAS date (num) continuous 
BRAND If brand product dispensed (1 ); generic (0) dichotomous 
CASH Cash payment (1); else (0) dichotomous 
(dummy) 
COST12 The 12 month cost of all hypoglycemic number 
medication dispensed; calculated as AWP -
10% (num) 
DAYSSUP The days supply of medication dispensed integer 
(num) 
DE PRES Received Rx for antidepressant (1 ); else (0) dichotomous 
DOSE The quantity dispensed divided by the days number 
supply (num) 
DOSECHANGE Change in dose of drug dispensed during the dichotomous 
12-month period (1); else (0) 
ENDVAR Category of drug regimen utilized (1-10) , discrete 
based on the last three months of 
dispensings; see Figure1, manuscript 1. 
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( 
FIRSTDT Date of the earliest dispensing of a SAS date 
hypoglycemic medication (num) 
GEN1 First generation sulfonylurea (1 ); else (0) dichotomous 
GENDER Male (M) or female (F) dichotomous 
INSCAT Insurance category: planA (1 ); planB (2); categorical 
LASTDT 
other insurance (3); cash (4) 
Date of the latest dispensing of a 
hypoglycemic medication (num) 
SAS date 
MALE Male (1 ); else (0) dichotomous 
(dummy) 
MEDCHANGE Change in medication during the 12-month dichotomous 
period (1 ); else (0) 
MPR Medication Possession Ratio; calculated by Continuous 
dividing quantity of medication dispensed by 
number of days between dispensings (num) 
MPR80 If MPR < 0.80 then (1 ); else (0). 
MPR90 If MPR < 0.90 then (1); else (0). 
OTHERINS Other insurance (1); else (0) 
OTHINSCA Other insurance or cash (1 ); else (0) 
OVER11 Greater than 11 dispensings during first four 
months (1 ); else (0) 
OVER15 Over 15 dispensings during first four months 
(1); else (0) 
OVER4LESS16 Between 5 and 15 dispensings during first 
four months (1 ); else (0) 
OVER50UNDER6 Age between 50-64 years (1 ); else (0) 
5 
OVER65 Age 65 years or older (1 ); else (0) 
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dichotomous 
dichotomous 
dichotomous 
{dummy) 
dichotomous 
{dummy) 
dichotomous 
(dummy) 
dichotomous 
(dummy) 
dichotomous 
(dummy) 
dichotomous 
{dummy) 
dichotomous 
(dummy) 
PLANA 
PLANS 
POSTXNDT 
QTY 
REGVAR 
RX CODE 
STRENGTH 
TOTALRX 
TROGLIT 
TXTYPE 
UNDER5 
UNDER50 
Plan A (1); else (0) dichotomous 
(dummy) 
Plan B (1); else (0) dichotomous 
(dummy) 
Date of dispensing (num) SAS date 
The quantity of medication dispensed (num) integer 
Category of drug regimen utilized (1-10), discrete 
based on the first three months of 
dispensings; see Figure1 . manuscript 1. 
Used to identify class and strength of 
hypoglycemic medication dispensed (char) 
Strength of medication dispensed; 9999 for 
insulin products (num) 
Total number of dispensings during first four 
months (num) 
Troglitazone dispensed (1 ); else (0) 
Dual therapy with both a sulfonylurea and 
metformin (1) or monotherapy with either 
agent (0) 
Less than 5 dispensings during first four 
months (1); else (0) 
Age under 50 years (1 ); else (0) 
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character 
string 
number 
continuous 
(integer) 
dichotomous 
dichotomous 
dichotomous 
(dummy) 
dichotomous 
(dummy) 
Table 4a. Summary of Univariate Analyses Performed 
IV = Independent Variable 
DV = Dependent Variable 
MPR = Medication Possession Ratio 
Po~ulation Descri~tion 
All patients Frequency and percent of patients 
receiving for each age category 
dispensing 
s of hypo- Frequency and percent of patients 
glycemic for gender 
drugs 
Frequency and percent of patients 
for each category of insurance type 
Patients Frequency and percent of patients 
receiving receiving insulin or oral 
sulfonylure hypoglycemic agents 
a only 
Frequency and percent of patients 
for each age category 
Frequency and percent of patients 
for gender 
Frequency and percent of patients 
for each category of insurance type 
Frequency and percent of patients 
for each category of number of 
dispensings 
Frequency and percent of patients 
receiving an anti-depressant 
medication 
Mean medication possession ratio 
(MPR) < 8:10, < 9:10 
Frequency and percent of patients 
having a medication possession ratio 
(MPR) < 8:10 or< 9:10 
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Procedure 
PROC 
FREQ 
PROC 
FREQ 
PROC 
FREQ 
PROC 
FREQ 
PROC 
FREQ 
PROC 
FREQ 
PROC 
FREQ 
PROC 
FREQ 
PROC 
FREQ 
PROC 
FREQ 
PROC 
FREQ 
Table#; 
(manuscri~t #) 
Table 1 (1) 
Table 1 (1) 
Table 1 (1) 
Table 1 (2) 
Table 1 (2) 
Table 1 (2) 
Table 1 (2) 
Table 1 (2) 
Table 1 (3) 
Table 2 (2) 
Table 2 (2) 
Patients Frequency and percent of patients for each PROC Table 1 
receiving age category FREQ (2) 
metformin 
only Frequency and percent of patients for PROC Table 1 
gender FREQ (2) 
Frequency and percent of patients for each PROC Table 1 
category of insurance type FREQ (2) 
Frequency and percent of patients for each PROC Table 1 
category of number of dispensings FREQ (2) 
Frequency and percent of patients receiving PROC Table 1 
an anti-depressant medication FREQ (3) 
Mean medication possession ratio (MPR) < PROC Table 2 
8:10, < 9:10 FREQ (2) 
Frequency and percent of patients having a PROC Table 2 
medication possession ratio (MPR) < 8:10 FREQ (2) 
or< 9:10 
Patients Frequency and percent of patients for each PROC Table 1 
receiving age category FREQ (3) 
both 
sulfonylurea Frequency and percent of patients for PROC Table 1 
and gender FREQ (3) 
metformin 
Frequency and percent of patients for each PROC Table 1 
category of insurance type FREQ (3) 
Frequency and percent of patients for each PROC Table 1 
category of number of dispensings FREQ (3) 
Frequency and percent of patients receiving PROC Table 1 
an anti-depressant medication FREQ (3) 
Patients Frequency and percent of patients having a PROC Table 2 
receiving medication possession ratio (MPR) < 8:10 FREQ (2) 
sulfonylurea or<9:10 
only or met-
formin only 
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All patients Frequency and percent of patients for each PROC Table 1 
receiving age category FREQ (3) 
sulfonylurea 
only or Frequency and percent of patients for PROC Table 1 
metformin gender FREQ (3) 
only, or 
receiving Frequency and percent of patients for each PROC Table 1 
both drugs category of insurance type FREQ (3) 
Frequency and percent of patients for each PROC Table 1 
category of number of dispensings FREQ (3) 
Frequency and percent of patients receiving PROC Table 1 
an anti-depressant medication FREQ (3) 
Frequency and percent of patients having a PROC Table 2 
medication possession ratio (MPR) < 8:10 FREQ (2) 
Or< 9:10 
Frequency and percent of patients having a PROC Table 2 
medication possession ratio (MPR) >= 8:10 FREQ (3) 
Or>= 9:10 
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Table 4b. Summary of Bivariate Analyses Performed 
Table#; 
Po~ulation Descri~tion Procedure (manuscri~t #) 
All patients Drug regimen and Gender Chi- Table 4 (1) 
receiving Square 
dispensings 
of hypo- Drug regimen and age Chi- Table 5a (1) 
glycemic Square 
drugs Drug regimen and insurance type Chi- Table 6 (1) 
(N = Square 
29,001) 
Cost of medications dispensed and ANOVA, Table 9 (1) 
Age Tu key's 
test 
Cost of medications dispensed and Student's Table 9 (1) 
Gender I-test 
Cost of medications dispensed and ANOVA, Table 9 (1) 
Insurance type Tukey's 
test 
Above, if Drug regimen and Age Chi- Table 5b (1) 
patient>= Square 
40 years of Troglitazone dispensings and Age Chi- Table 8 (1) 
age Square 
Patients Brand name sulfonylurea and age Chi- Table 7 (1) 
receiving Square 
sulfonylurea 
only Brand name sulfonylurea and gender Chi- Table 7 (1) 
Square 
Brand name sulfonylurea and Chi- Table 7 (1) 
insurance type Square 
Medication possession ratio(< 8:10) Chi- Table 3 (2) 
and age Square 
Medication possession ratio(< 8:10) Chi- Table 3 (2) 
and gender Square 
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Medication possession ratio{< 8:10) Chi- Table 3 (2) 
and insurance type Square 
Medication possession ratio (< 8:10) Chi- Table 3 (2) 
and number of dispensings Square 
Medication possession ratio {< 8:10) Chi- Table3a (3) 
and dual drug therapy Square 
Medication possession ratio{< 8:10) Chi- Table3a (3) 
and Rx for depression Square 
Medication possession ratio{< 9:10) Chi- Table 3b (3) 
and age Square 
Medication possession ratio(< 9:10) Chi- Table 3b (3) 
and gender Square 
Medication possession ratio(< 9:10) Chi- Table 3b (3) 
and insurance type Square 
Medication possession ratio(< 9:10) Chi- Table 3b (3) 
and number of dispensings Square 
Medication possession ratio (< 9:10) Chi- Table 3b (3) 
and dual drug therapy Square 
Medication possession ratio(< 9:10) Chi- Table 3b (3) 
and Rx for depression Square 
Change in dose and Age Chi- Table 4a (2) 
Square 
Change in dose and Gender Chi- Table 4a (2) 
Square 
Change in dose and Insurance Type Chi- Table 4a (2) 
Square 
Change in dose and Number of Chi- Table 4a (2) 
Dispensings Square 
Change in dose and Medication Chi- Table 4a (2) 
Possession Ratio Square 
Change in drug and Age Chi- Table 4a (2) 
Square 
Change in drug and Gender Chi- Table 4a (2) 
Square 
Change in drug and Insurance Type Chi- Table 4a (2) 
Square 
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Change in drug and Number of Chi- Table 4a (2) 
Dispensings Square 
Change in drug and Medication Chi- Table 4a (2) 
Possession Ratio Square 
Change in dose or drug and Age Chi- Table 4a (2) 
Square 
Change in dose or drug Gender Chi- Table 4a (2) 
Square 
Change in dose or drug Insurance Chi- Table 4a (2) 
Type Square 
Change in dose or drug and Number Chi- Table 4a (2) 
of Dispensings Square 
Change in dose or drug and Chi- Table 4a (2) 
Medication Possession Ratio Square 
Medication possession and DV Dose PROC Table 5a (2) 
change LOGISTIC 
Age and DV Dose change PROC Table 5a (2) 
LOGISTIC 
Gender and DV Dose change PROC Table 5a (2) 
LOGISTIC 
Number of dispensings and DV Dose PROC Table 5a (2) 
change LOGISTIC 
Insurance type and DV Dose change PROC Table 5a (2) 
LOGISTIC 
Medication possession and DV PROC Table 6a (2) 
Change in drug dispensed LOGISTIC 
Age and DV Change in drug PROC Table 6a (2) 
dispensed LOGISTIC 
Gender and DV Change in drug PROC Table 6a (2) 
dispensed LOGISTIC 
Number of dispensings and DV PROC Table 6a (2) 
Change in drug dispensed (DV) LOGISTIC 
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Insurance type and DV Change in PROC Table 6a (2) 
drug dispensed LOGISTIC 
Patients Medication possession ratio(< 8:10) Chi- Table 3 (2) 
receiving and age Square 
metformin 
only Medication possession ratio(< 8:10) Chi- Table 3 (2) 
and gender Square 
Medication possession ratio(< 8:10) Chi- Table 3 (2) 
and insurance type Square 
Medication possession ratio(< 8:10) Chi- Table 3 (2) 
and number of dispensings Square 
Medication possession ratio(< 8:10) Chi- Table3a (3) 
and dual drug therapy Square 
Medication possession ratio (< 8:10) Chi- Table3a (3) 
and Rx for depression Square 
Medication possession ratio(< 9:10) Chi- Table 3b (3) 
and age Square 
Medication possession ratio{< 9:10) Chi- Table 3b (3) 
and gender Square 
Medication possession ratio{< 9:10) Chi- Table 3b (3) 
and insurance type Square 
Medication possession ratio{< 9:10) Chi- Table 3b (3) 
and number of dispensings Square 
Medication possession ratio(< 9:10) Chi- Table 3b (3) 
and dual drug therapy Square 
Medication possession ratio(< 9:10) Chi- Table 3b (3) 
and Rx for depression Square 
Change in dose and Age Chi- Table 4b (2) 
Square 
Change in dose and Gender Chi- Table 4b (2) 
Square 
Change in dose and Insurance Type Chi- Table 4b (2) 
Square 
Change in dose and Number of Chi- Table 4b (2) 
Dispensings Square 
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Change in dose and Medication Chi- Table 4b (2) 
Possession Ratio Square 
Change in drug and Age Chi- Table 4b (2) 
Square 
Change in drug and Gender Chi- Table 4b (2) 
Square 
Change in drug and Insurance Type Chi- Table 4b (2) 
Square 
Change in drug and Number of Chi- Table 4b (2) 
Dispensings Square 
Change in drug and Medication Chi- Table 4b (2) 
Possession Ratio Square 
Change in dose or drug and Age Chi- Table 4b (2) 
Square 
Change in dose or drug Gender Chi- Table 4b (2) 
Square 
Change in dose or drug Insurance Chi- Table 4b (2) 
Type Square 
Change in dose or drug and Number Chi- Table 4b (2) 
of Dispensings Square 
Change in dose or drug and Chi- Table 4b (2) 
Medication Possession Ratio Square 
Medication possession and DV Dose PROC Table 5b (2) 
change (DV**) LOGISTIC 
Age and DV Dose change PROC Table 5b (2) 
LOGISTIC 
Gender and DV Dose change PROC Table 5b (2) 
LOGISTIC 
Number of dispensings and DV Dose PROC Table 5b (2) 
change LOGISTIC 
Insurance type and DV Dose change PROC Table 5b (2) 
LOGISTIC 
Medication possession and DV PROC Table 6b (2) 
Change in drug dispensed LOGISTIC 
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Age and DV Change in drug PROC Table 6b (2) 
dispensed LOGISTIC 
Gender and DV Change in drug PROC Table 6b (2) 
dispensed LOGISTIC 
Number of dispensings and DV PROC Table 6b (2) 
Change in drug dispensed LOGISTIC 
Insurance type and DV Change in PROC Table 6b (2) 
drug dispensed LOGISTIC 
Medication possession and DV PROC Table 6b (2) 
Change in drug dispensed LOGISTIC 
Age and DV Change in drug PROC Table 6b (2) 
dispensed LOGISTIC 
Gender and DV Change in drug PROC Table 6b (2) 
dispensed LOGISTIC 
Number of dispensings and DV PROC Table 6b (2) 
Change in drug dispensed LOGISTIC 
Insurance type and DV Change in PROC Table 6b (2) 
drug dispensed LOGISTIC 
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I 
Patients Medication possession ratio(< 8:10) and Chi- Table 3 (2) 
receiving age Square 
both 
sulfonylurea Medication possession ratio{< 8:10) and Table 3 (2) 
and gender Chi-
metformin Square 
Medication possession ratio{< 8:10) and Chi- Table 3 (2) 
insurance type Square 
Medication possession ratio {< 8:10) and Chi- Table 3 (2) 
number of dispensings Square 
Medication possession ratio{< 8:10) and Chi- Table3a (3) 
dual drug therapy Square 
Medication possession ratio(< 8:10) and Chi- Table3a (3) 
Rx for depression Square 
Medication possession ratio(< 9:10) and Chi- Table 3b 
age Square (3) 
Medication possession ratio{< 9:10) and Chi- Table 3b 
gender Square (3) 
Medication possession ratio{< 9:10) and Chi- Table 3b 
insurance type Square (3) 
Medication possession ratio(< 9:10) and Chi- Table 3b 
number of dispensings Square (3) 
Medication possession ratio{< 9:10) and Chi- Table 3b 
dual drug therapy Square (3) 
Medication possession ratio(< 9:10) and Chi- Table 3b 
Rx for depression Square (3) 
Chi- Table 3 (2) 
Patients Medication possession ratio(< 8:10) and Square 
receiving age 
sulfonylurea 
only, Medication possession ratio{< 8:10) and Chi- Table 3 (2) 
metformin gender Square 
only, or 
both drugs Medication possession ratio{< 8:10) and Chi- Table 3 (2) 
insurance type Square 
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Medication possession ratio(< 8:10) and Chi- Table 3 (2) 
number of dispensings Square 
Medication possession ratio(< 8:10) and Chi- Table3a (3) 
dual drug therapy Square 
Medication possession ratio(< 8:10) and Chi- Table3a (3) 
Rx for depression Square 
Medication possession ratio(< 9:10) and Chi- Table 3b 
age Square (3) 
Medication possession ratio(< 9:10) and Chi- Table 3b 
gender Square (3) 
Medication possession ratio(< 9:10) and Chi- Table 3b 
insurance type Square (3) 
Medication possession ratio(< 9:10) and Chi- Table 3b 
number of dispensings Square (3) 
Medication possession ratio(< 9:10) and Chi- Table 3b 
dual drug therapy Square (3) 
Medication possession ratio(< 9:10) and Chi- Table 3b 
Rx for depression Square (3) 
Mono versus dual therapy and DV PROC Table 4a 
Medication possession ratio(< 8:10) LOGIS (3) 
TIC 
Age category and DV Medication PROC Table 4a 
possession ratio(< 8:10) LOGIS (3) 
TIC 
Gender and DV Medication possession PROC Table 4a 
ratio LOGIS (3) 
(< 8:10) TIC 
Number of dispensings and DV PROC Table 4a 
Medication possession ratio(< 8:10) LOGIS (3) 
TIC 
Insurance type and DV Medication PROC Table 4a 
possession LOGIS (3) 
Ratio(< 8:10) TIC 
Rx for anti-depressant and DV PROC Table 4a 
Medication possession ratio(< 8:10) LOGIS (3) 
TIC 
Mono versus dual therapy and DV PROC Table 4b 
Medication possession ratio(< 9:10) LOGIS (3) 
TIC 
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Age category and DV Medication PROC Table 4b 
possession ratio (< 9: 10) LOGIS (3) 
TIC 
Gender and DV Medication possession PROC Table 4b 
ratio LOGIS (3) 
(<9:10) TIC 
Number of dispensings and DV PROC Table 4b 
Medication possession ratio(< 9:10) LOGIS (3) 
TIC 
Insurance type and DV Medication PROC Table 4b 
possession LOGIS (3) 
Ratio(< 9:10) TIC 
Rx for anti-depressant and DV PROC Table 4b 
Medication possession ratio(< 9:10) LOGIS (3) 
TIC 
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Table 4c. Summary of Multivariate Analyses Performed 
Table#; 
Po12ulation Descri12tion Procedure (manuscri12t #) 
Patients Assessment of Colinearity between PROC n/a 
receiving independent variables : DV = Dose REG / 
sulfonylurea change COLLIN 
only 
Assessment of Colinearity between PROC n/a 
independent variables: DV = Drug REG / 
change COLLIN 
Assessment of Colinearity between PROC n/a 
independent variables : DV = Dose or REG / 
Drug change COLLIN 
Likelihood ratio test for interactions PROC Table 7 (2) 
between independent variables (- LOGISTIC 
21og statistic): 
DV = Dose change 
Likelihood ratio test for interactions PROC Table 7 (2) 
between independent variables (- LOGISTIC 
21og statistic): 
DV = Drug change 
Likelihood ratio test for interactions PROC Table 7 (2) 
between independent variables (- LOGISTIC 
21og statistic): 
DV = Dose or Drug change 
All independent variables and DV PROC Table Ba (2) 
Dose change LOGISTIC 
lvs MPR and AGE category and DV PROC Table Ba (2) 
Dose change LOGISTIC 
All independent variables and DV PROC Table Bb (2) 
Drug change LOGISTIC 
IV AGE category and DV Drug PROC Table Bb (2) 
change LOGISTIC 
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All independent variables and DV 
Drug or Dose change 
IV AGE category and DV Drug or 
Dose change 
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PROC Table Be (2) 
LOGISTIC 
PROC Table Be (2) 
LOGISTIC 
Patients Assessment of Colinearity between PROC n/a 
receiving independent variables: DV = Dose change REG / 
metformin COLLIN 
only 
Assessment of Colinearity between PROC n/a 
independent variables: DV = Drug change REG / 
COLLIN 
Assessment of Colinearity between PROC n/a 
independent variables: DV = Dose or Drug REG / 
change COLLIN 
Likelihood ratio test for interactions PROC Table 7 
between independent variables (-21og LOGISTIC (2) 
statistic): 
DV = Dose change 
Likelihood ratio test for interactions PROC Table 7 
between independent variables (-21og LOGISTIC (2) 
statistic): 
DV = Drug change 
Likelihood ratio test for interactions PROC Table 7 
between independent variables (-21og LOGISTIC (2) 
statistic): 
DV = Dose or Drug change 
Patients Assessment of Colinearity between PROC n/a 
receiving independent variables: DV = Dose change REG / 
sulfonylurea COLLIN 
only or 
metformin Assessment of Colinearity between PROC n/a 
only independent variables: DV = Drug change REG / 
COLLIN 
Assessment of Colinearity between PROC n/a 
independent variables: DV = Dose or Drug REG / 
change COLLIN 
Likelihood ratio test for interactions PROC Table 7 
between independent variables (-21og LOGISTIC (2) 
statistic): 
DV = Dose change 
Likelihood ratio test for interactions PROC Table 7 
between independent variables (-21og LOGISTIC (2) 
statistic) : 
DV = Drug change 
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Likelihood ratio test for interactions PROC Table 7 
between independent variables (-21og LOGISTIC (2) 
statistic): 
DV = Dose or Drug change 
All independent variables and DV Dose PROC Table 9a 
change LOGISTIC (2) 
All independent variables and DV Drug PROC Table 9b 
change LOGISTIC (2) 
All independent variables and DV Drug or PROC Table 9c 
Dose change LOGISTIC (2) 
All independent variables and DV Dose PROC Table 
change LOGISTIC 10a (2) 
lvs MPR and AGE category and DV Dose PROC Table 
change LOGISTIC 10a (2) 
All independent variables and DV Drug PROC Table 
change LOGISTIC 10b (2) 
IV AGE category and DV Drug change PROC Table 
LOGISTIC 10b (2) 
All independent variables and DV Drug or PROC Table 
Dose change LOGISTIC 10c (2) 
lvs MPR and AGE category and DV Drug PROC Table 
or Dose change LOGISTIC 10c (2) 
All patients Likelihood ratio test for interactions PROC Table 5 
receiving between independent variables (-21og REG / (3) 
sulfonylurea, statistic): COLLIN 
metformin, DV = MPR < 8:10 
or both Likelihood ratio test for interactions PROC Table 5 
between independent variables (-21og REG / (3) 
statistic) : COLLIN 
DV = MPR < 9:10 
All independent variables and DV MPR < PROC Table 6a 
8:10 LOGISTIC (3) 
All independent variables and DV MPR < PROC Table 6a 
9:10 LOGISTIC (3) 
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lvs Mono versus dual therapy, Age PROC Table 7a 
category, and Number of dispensings and LOGISTIC (3) 
DV MPR < 8:10 
lvs Mono versus dual therapy, Age PROC Table 7b 
category, and Number of dispensings and LOGISTIC (3) 
DV MPR < 9:10 
lvs Mono versus dual therapy and Age PROC Table 8a 
category and DV MPR < 8:10 LOGISTIC (3) 
lvs Mono versus dual therapy and Age PROC Table 8b 
category DV MPR < 9:10 LOGISTIC (3) 
( 
( 
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Appendix C. Overview of Major Findings 
The objective of the analyses described in manuscript 1 was to assess 
hypoglycemic drug utilization; and specifically, to identify which hypoglycemic 
agents were most frequently utilized and what differences in utilization and 
direct costs may exist between age categories, genders, or insurance types. 
Sulfonylureas were the most frequently prescribed class of hypoglycemic 
medication. Greater than half of all patients (56.8%) and greater than three-
quarters of patients receiving oral therapy (75.7%) received a dispensing for a 
sulfonylurea. Metformin was the next most frequently prescribed oral agent: 
20.9% of all patients and 27.6% of patients receiving oral therapy received at 
least one dispensing for metformin. Troglitazone was the third most frequently 
utilized oral medication. During the 12-month period, 16.04% of all patients 
received a dispensing for troglitazone. The use of this agent was most 
frequent among younger diabetics: 20.3% of patients age 40 - 49 years 
received a dispensing for troglitazone; only 10.2% of seniors received a 
dispensing for this agent. Of the other newer hypoglycemic medications, 
glimepramide, repaglinide, and acarbose were each dispensed to less than 
5% of all patients. 
During the 12-month period, patients frequently experienced a change in 
hypoglycemic medication(s) dispensed. The most frequently observed change 
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in drug regimen was for patients dispensed sulfonylurea only. The percentage 
of patients categorized as receiving only a sulfonylurea decreased by 8.76%, 
the largest percent change for any drug regimen category. Changes in drug 
regimen utilized were also frequent. Of patients categorized as receiving only 
a sulfonylurea during the first 90 days of the 12-month period, 74% remained 
using the same regimen during the last 90 days of the 12-month period . For 
patients initially categorized as receiving both a sulfonylurea and metformin, 
70% were similarly classified based upon dispensings during the last there 
months. Thus, 26% and 30% of patients receiving sulfonylurea or sulfonylurea 
plus metformin respectively changed regimen during the 12-month period . 
Similar magnitude changes were observed for the other less frequently utilized 
regimens, and ranged from a low of 18% for patients receiving insulin only to a 
high of 70% among patients receiving insulin plus an oral agent other than 
troglitazone. Based on these results , it was concluded that the diabetic 
patients in this population frequently changed medication regimen, possibly as 
a result of worsening glucose control, inconsistent refill patterns 
(nonadherence), or desire to utilize new therapies. 
Patients 65 years of age or older were less frequently dispensed troglitazone 
or metformin as monotherapy, and more frequently received dispensings for 
sulfonylureas. The less frequent use of troglitazone and metformin in older 
patients may reflect an increased prevalence of contraindicating co-
morbidities. Increased duration of disease may be a potential explanation for 
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the greater utilization of sulfonylureas in older patients. Such patients may 
have been more likely to have initiated treatment in earlier years, when 
sulfonylureas were the primary oral therapeutic option. 
Differences in the 12-month cost of hypoglycemic medication utilized reflect 
the differing patterns of drug use among age groups. Drug utilization costs 
were lowest among older patients, who more frequently received dispensings 
for lesser-cost sulfonylurea products. The total 12-month cost of medication 
dispensed was not significantly different among patients under 50 years of age 
and between 50 and 64 years of age. 
The analyses described in manuscript 2 provided insight into the relationship 
between adherence to therapy and changes in the drug regimen . It was 
hypothesized poor glucose control would result from failure to possess a 
sufficient quantity of medication necessary to be adherent. The proxy for poor 
glucose control used in these analyses was a change in dose of hypoglycemic 
medication dispensed or a change in the class of hypoglycemic drug 
dispensed. 
A change in dose of sulfonylurea or metformin was more than twice as 
frequently observed than a change in type of hypoglycemic medication 
dispensed for both users of sulfonylureas (change in dose: 58.53%, change in 
drug 26.78%) and metformin (change in dose: 48.19%, change in drug 
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18.07%). Among all patients dispensed either a sulfonylurea or metformin 
only, 57% received medication at different dosages during the 12-month 
period; 58.5% of patients receiving a su lfonylurea and 48.2% of patients 
receiving metformin did not receive the same dose of medication throughout 
the 12-month period. 
In both bivariate and multivariate analyses of patients receiving dispensings 
for sulfonylurea only, possession of medication for less than 8 of 10 days was 
associated with an increased likelihood of a change in dose of medication 
dispensed in subsequent months. A similar effect was observed among 
patients in the combined sample of patients receiving a sulfonylurea or 
metformin. Based upon the results of multivariate analyses, such patients 
were 36% more likely to receive a dispensing for a different strength of drug 
(OR 1.36, 95% Cl 1.02 - 1.83). A statistically significant association between 
possession of metformin and change in dose dispensed was not observed, 
possibly due to a lack of power to detect such an effect based on the lesser 
number of such patients. 
Among users of sulfonylureas, medication possession was associated with the 
combined outcome of change in medication dose or change in type of 
hypoglycemic medication dispensed. This association was also observed in 
analyses based upon the combined sample of patients receiving dispensings 
for sulfonylurea or metformin only. Such an association was not observed 
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among patients receiving dispensings for metformin only. Additionally, 
medication possession was not found to be associated with the sole outcome 
of change of type of hypoglycemic medication dispensed for the sulfonylurea 
only, metformin only, and combined samples. 
Age was associated with medication possession. Patients under 50 years of 
age were most frequently categorized as not possessing a quantity of 
medication sufficient to cover eight of ten days in the assessment period . This 
difference was only statistically significant for users of sulfonylurea 
monotherapy. This sample included nearly six times as many patients as the 
metformin sample (sulfonylurea: n = 967; metformin: n = 166). Age was also 
found to be significant in multivariate analyses assessing the association 
between medication possession and change in regimen utilized or dose 
dispensed. As compared with younger patients, sulfonylurea users 65 years 
of age or older were 43% less likely to receive a different dose of 
hypoglycemic medication during the 12-month period (OR 0.57, 95% Cl 0.40 -
0.81 ). Such patients were also 48.5% less likely to receive a medication other 
than a sulfonylurea during the 12 months (OR 0.52 , 95% Cl 0.34 - 0.78). 
These relationships were not found to be significant for analyses based upon 
the smaller sample of patients who received dispensings for metformin only. 
Among patients dispensed either sulfonylureas or metformin, those dispensed 
a greater number of prescriptions for any health condition were less frequently 
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categorized as failing to possess medication for less than 80% of days. The 
outcomes of change in dose or change in class of medication dispensed were 
not found to be significantly influenced by differences in the medication 
possession ratio. 
The aims of the analyses described in manuscript 3 were to assess adherence 
with hypoglycemic medication via the medication possession ratio and to 
compare medication possession among patients dispensed either 
monotherapy with sulfonylurea or metformin with patients receiving dual 
therapy with both medications. Additionally, we examined the association 
between medication possession and age, gender, insurance plan, the total 
number of dispensings, and the dispensing of a medication typically used to 
treat depression. 
Based upon medication possession, adherence to any hypoglycemic drug 
regimen was frequently sub-optimal. Greater than one in four of all patients 
studied (28.8%) did not receive a quantity of medication sufficient to cover 8 of 
10 days in the period. Only 59.5% of all patients possessed medication at a 
ratio equal to or exceeding 9: 10. Medication possession was highest among 
patients who received dispensings for sulfonylureas only (MPR >= 8:10: 
77.2%, MPR >= 9:10: 66.8%). Patients receiving dispensings for metformin 
only were less adherent, with 71.1 % and 56.6% of patients possessing 
medication for at least eight of ten or nine of ten days in the assessment 
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period , respectively. The least adherent sub-population was patients receiving 
dispensings for both metformin and sulfonylureas . Less than half of such 
patients possessed medication for at least nine of ten days (43 .1 %), while 
56.9% of patients received at least enough medication to cover eight of ten 
days. 
In both bivariate and multivariate logistic models, dual therapy with a 
sulfonylurea and metformin was associated with an increased likelihood of 
failure to possess medication for at least eight of ten and nine of ten days. In 
bivariate logistic analyses, patients were nearly 2.5 times more likely to be 
classified as nonadherent if they received dispensings for both drugs (MPR < 
8: 10: OR 2.44, 95% Cl 1.92 - 3.1 O; MPR < 9:10: OR 2.49, 95% Cl 1.97 -
3.14 ). Multivariate analyses controlling for the influence of age and the total 
number of dispensings were also conducted . Based upon these analyses, 
and as compared with a one drug regimen, the use of dual therapy was 
associated with a greater than three-fold increase in the likelihood of being 
classified as nonadherent for both the 8: 10 and 9: 10 MPR thresholds (MPR < 
8: 10: OR 3.14, 95% Cl 2.42 - 4.08; MPR < 9:10: OR 3.20, 95% Cl 2.49 -
4.118). 
Of the five potential confounding variables examined , only age and the total 
number of dispensings were significant influences on medication possession. 
Based upon bivariate logistic regression analyses, patents 65 years of age or 
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older were 52.1 % less likely to be classified as nonadherent as compared with 
patients of younger age, using an MPR threshold of less than 8:10 (OR 0.48, 
95% Cl 0.35 - 0.65). Seniors were 42.4 % less likely to be classified as 
nonadherent based upon the MPR threshold of less than 9:10 (OR 0.58, 95% 
Cl 0.44 - 0.76). Patients receiving 12 or more dispensings for any type of 
medication were 44.6% less likely to be classified as nonadherent based upon 
the 8:10 MPR threshold (OR 0.56, 95% Cl 0.35 - 0.65), and 42.3% less likely 
based upon the 9:10 MPR threshold (OR 0.57, 95% Cl 0.47 - 0.70). Three 
other potential confounding variables were examined: gender, insurance type 
and receiving a dispensing for an antidepressant. None of these variables 
were found to be a significant influence on medication possession. 
In sum, the hypoglycemic drug utilization patterns of diabetic patients and 
various sub-populations can be characterized as frequently changing, and 
differing substantially between age categories. Older patients in this 
population more frequently received dispensings for sulfonylureas only, less 
frequently received dispensings for troglitazone or metformin as monotherapy, 
and more likely to refill prescriptions when due. Additionally, the 12-month 
total cost of all hypoglycemic medication dispensed was lowest among 
patients 65 years of age and older. Gender and insurance type were not 
found to be significantly associated with medication possession, or with 
change in medication dose or type of medication dispensed. Medication 
possession was found to be associated with an increase in the likelihood of 
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receiving a dispensing for a different strength of hypoglycemic medication 
among sulfonylurea users, and among a combined sample of patients 
receiving dispensings for with sulfonylurea or metformin only. Medication 
possession was often sub-optimal for what would be deemed sufficient for 
achieving tight glucose control. Patients were found to be least likely to 
possess medication when both a sulfonylurea and metformin were used as 
dual therapy, as compared with patients receiving either agent as 
monotherapy. 
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